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During acute altitude exposure, humans maintain higher skin temperature
and lower core body temperature. However, the role of cutaneous vascular
regulation in these thermoregulatory differences is unclear. Therefore, the
purpose of these studies was to investigate the impact of altitude exposure on
reflex control of skin blood flow and core temperature during cold exposure. In
Chapter IV, the effects of hypoxia and hypocapnia on cutaneous vasoconstriction
during mild cold exposure were investigated. We found that hypoxia stimulates
cutaneous vasodilation in men whereas skin blood flow is unaltered in women.
However, during whole body cooling skin blood flow is upward shifted in both
sexes. The development of hypocapnia does not affect the vascular response to
vhypoxia in either sex, but reduces the magnitude of cutaneous vasoconstriction
during cold exposure by 50% in women. In Chapter V, we studied the
timecourse of a-adrenergic blockade by yohimbine in the cutaneous circulation
and how the duration of cold exposure modulates cotransmitter-mediated
vasoconstriction during cold stress. We found that yohimbine produces
functional a-adrenergic blockade within 30 minutes of initial delivery and
completely abolishes reflex cutaneous vasoconstriction during mild cold stress.
This latter finding was surprising, and an additional protocol demonstrated that
cotransmitter-mediated vasoconstriction only participates in the vascular
response to cold stress when the exposure is more prolonged. In Chapter VI, the
effects of hypoxia on cutaneous vasoconstrictor mechanisms and core cooling
rate were tested during more prolonged and severe cold stress. In contrast to
our findings during brief cold exposure, we showed that cutaneous
vasoconstriction during prolonged cold stress is potentiated by hypoxia and
abolishes hypoxic vasodilation. Moreover, increased cotransmitter-mediated
vasoconstriction appears to account for this response. Hypoxia had no effect on
core cooling rate during severe cold exposure. The selective potentiation of
cotransmitter-mediated vasoconstriction observed during hypoxia in Chapter VI
provided the basis for Chapter VII. This study was designed to test the effect of
hypoxia on cutaneous vascular responsiveness to peripherally stimulated
sympathetic vasoconstriction. The results demonstrated that a-adrenergic
vasoconstrictor transduction is not affected by hypoxia, and that stimulation of
adrenergic nerves with tyramine does not elicit cotransmitter-mediated
vasoconstriction in skin.
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1CHAPTER I
INTRODUCTION
Background
In thermoneutral or cool environments, maintenance of thermal balance in
humans is dependent on two primary temperature gradients: a gradient between
the core and skin and a gradient between the skin and ambient environment.
Metabolic heat produced within the core tissues (- 37.5°C) circulates in the blood
down a temperature gradient to the skin (- 33.0°C), and heat transferred to the
skin is dissipated to the ambient environment « 33.0°C). Thus, control of the
circulation through the skin represents the primary physiological mechanism for
thermoregulation in humans in neutral or cool environments.
When environmental temperature falls, skin blood flow is reduced in order
to decrease heat transfer from the core to the periphery, thereby promoting heat
conservation (Toner & McArdle, 1988). This thermoregulatory adjustment also
decreases skin temperature, which narrows the gradient for cutaneous heat loss
and is vital to the prevention of hypothermia in cold environments. The reduction
in skin blood flow upon body cooling is regulated by cutaneous sympathetic
adrenergic nerves, which contain both norepinephrine and other sympathetic
cotransmitters (Kellogg ef al., 1989; Lundberg, 1996). As ambient temperature
decreases, the activity of cutaneous adrenergic nerves increases, releasing
2norepinephrine onto post junctional a-receptors (predominantly a2-receptors).
The binding of norepinephrine to post junctional a-receptors causes
vasoconstriction, and this mechanism is responsible for approximately 60% of
the reduction in skin blood flow during cold stress (Thompson & Kenney, 2004).
The remaining - 40% of the cold induced vasoconstriction is mediated by
adrenergic nerve cotransmission (Stephens et al., 2001; Thompson & Kenney,
2004). The primary peptide thought to mediate sympathetic cotransmission in
this setting is neuropeptide Y, which causes cutaneous vasoconstriction via post
junctional neuropeptide Y1-receptors (Stephens et al., 2004).
When humans encounter cold temperatures at high altitude, lower oxygen
levels and cold temperatures may have competing effects on skin blood flow.
For example, hypoxia per se elicits a cutaneous hyperemia that is mediated at
the tissue level (Anderson et al., 1991; Simmons et al., 2007). In this setting, the
rate of core cooling is accelerated, and lower core temperatures are reached
during cold exposure compared to sea level conditions (Cipriano & Goldman,
1975; Johnston et al., 1996). While core temperature falls faster at altitude, skin
temperature remains higher throughout cold exposure compared to sea levels
conditions (Cipriano & Goldman, 1975; Blatteis & Lutherer, 1976). Taken·
together, these results indicate a less effective reduction incore-to-skin heat
transfer during cold exposure at altitude. Such impairment in heat conservation
could reflect an acute alteration in output from the thermoregulatory controller
during hypoxia (central mechanism). Conversely, the mechanism responsible
could be peripheral, affecting some aspect of cutaneous vascular regulation by
3sympathetic adrenergic nerves. A peripheral impairment in cutaneous vascular
control during cold stress could result from two different scenarios: first, the
maintenance of higher skin temperature (and probably higher skin blood flow)
could represent the summation of two environmental stimuli affecting the
cutaneous circulation through completely separate mechanisms. In this
scenario, the higher skin blood flow during cold stress (at altitude) would
represent hypoxic vasodilation superimposed on reflex vasoconstriction. The
second possibility is that low tissue oxygen tension could impair the transduction
of sympathetic vasoconstrictor outflow into vascular resistance. In this scenario,
hypoxic vasodilation would still be superimposed on cutaneous vasoconstriction,
but the vasoconstriction would also be less effective. Therefore, in addition to
the simple summation of two environmental stimuli, the cutaneous vascular
response may also reflect the interaction of hypoxia and cold thermoregulatory
effector mechanisms.
Statement of the problem
High altitude environments are characterized by reduced barometric
pressure and inadequate oxygen supply. In this setting, a variety of species
selectively regulate a lower body temperature, presumably favoring a protective
reduction in metabolism. Some evidence suggests that humans exhibit a similar
response in hypoxic environments, as discussed above. However, existing data
can not adequately explain the mechanisms underlying changes in human·
thermoregulation at high altitude. For example, exposure of humans to
hypobaric hypoxia reduces core temperature measured during 4 hours of cold
4exposure, indicating more rapid heat loss to the environment. However. it is
unclear from these observations whether augmented core cooling was caused by
the reduction in barometric pressure or the maintenance of greater heat flow from
the core to the skin. Barometric pressure per se is capable of altering the
coefficient for heat transfer across the skin, which could increase cutaneous heat
loss solely through biophysical mechanisms. Conversely, the cutaneous
vasodilation induced by low oxygen levels in thermoneutral conditions could
persist during cold exposure. This would counter the reduction in heat transfer
away, from the core, and would impact heat loss through hemodynamic
mechanisms. Importantly, there are no reports in the literature of cutaneous
perfusion measurements (in non-acral skin) during combined altitude and cold
stress.
Therefore, the purpose of these experiments was to investigate the
regulation of skin blood flow and core body temperature during combined
hypoxia and cold exposure. The investigation described in Chapter IV had two
main goals. First, we sought to study whether the magnitude of cutaneous
vasodilation during hypoxia is affected by changes in blood carbon dioxide levels.
Second, we sought to determine if cutaneous vasodilation persists during whole
body cooling in a hypoxic environment. In Chapter V, we tested the timecourse
over which two pharmacological agents affect the cutaneous vasculature in
human skin. A second protocol in Chapter V tested the relationship between
mean skin temperature and sympathetic cotransmitter-mediated (non-
noradrenergic) vasoconstriction during prolong cold exposure. In Chapter VI we
5first sought to study the function of both noradrenergic and non-noradrenergic
cutaneous vasoconstriction during combined cold exposure and hypoxia.
Second, we sought to determine if the persistent vasodilation observed during
combined hypoxia and cold stress could explain the increased rate of core
cooling in this setting described by others. Finally, the investigation in Chapter
VII was designed to test post-junctional responsiveness to sympathetic
vasoconstrictor stimuli during hypoxia in human skin.
Hypotheses
The series of studies contained in this dissertation were designed to test
the following hypotheses:
1. In Chapter IV we hypothesized that cutaneous vasodilation during hypoxia
is greater in magnitude when accompanied by hypercapnia, and that
cutaneous vasodilation persists during mild whole body cooling regardless
of carbon dioxide levels. Furthermore, we hypothesized that rapid
exposure to hypoxia produces a greater cutaneous vascular response
than slower, progressive hypoxic exposure.
2. In Chapter V we hypothesized that selective blockade of a-adrenergic and
neuropeptide Y-Y1 receptors in different skin sites reduces, but does not
completely abolish, reflex cutaneous vasoconstriction during whole body
cooling. We further hypothesized that these effects increase over time
once drug delivery is begun. Lastly, we hypothesized that sympathetic
non-noradrenergic vasoconstriction is selectively activated at lower skin
temperatures during prolonged cold stress.
63. In Chapter VI we hypothesized that the upward shift in skin blood flow
during whole body cooling is mediated through noradrenergic
mechanisms, and that a tight relationship exists between the degree of
upward shift in skin blood flow and the increase in core cooling rate during
severe cold exposure in hypoxic conditions.
4. In Chapter VII we hypothesized that non-noradrenergic, but not
noradrenergic cutaneous vasoconstrictor responsiveness is increased
during systemic hypoxia in resting humans.
Significance
Environmental hypoxia and cold temperatures interact in some way to
make the sojourner unusually susceptible to a decline in core body temperature
(Cipriano & Goldman, 1975; Johnston et al., 1996). Historically, military
personnel have had the greatest risk of encountering cold temperatures and high
altitude conditions simultaneously (Hamlet, 1988). However, as mountaineering
has moved into the mainstream this risk has increased in civilian populations.
Numerous skilled athletes die each year when attempting to summit high altitude
peaks in cold temperatures. In view of the potentially lethal effects of
simultaneous altitude and cold exposure, well controlled laboratory studies are
needed to probe thermoregulatory adjustments to this unique environmental
extreme.
7CHAPTER II
REVIEW OF THE LITERATURE
Introduction
This review of the literature is organized into four sections that provide the
background and context from which to understand the impetus for and design of
these studies. The first section gives a brief introduction into differential
vasomotor control mechanisms which influence acral (non-hairy) and non-acral
(hairy) skin blood flow in humans. This section is not part of the formal literature
review, but is necessary in order to understand how seemingly disparate
observations made in different portions of the integument can be reconciled into
a coherent control scheme. The second section begins the literature review by
addressing cutaneous vascular responses to changes in blood oxygen and
carbon dioxide levels. The third section reviews the work leading up to our
current understanding of cutaneous vascular regulation in humans during cold
exposure. The fourth and final section examines a body of literature leading to
our current understanding of how high altitude hypoxia affects sympathetic
vasoconstriction in human limbs.
Differential autonomic control of cutaneous blood vessels
Cutaneous vascular innervation by the sympathetic nervous system is
variable across the integument, with nerve activity directed to acral and non-acral
8portions responding differently during a variety of environmental stresses {e.g.,
chemoreceptor stimulation, thermal stress). The circulation to the acral skin of
the hands, ears, nose, feet, etc., is innervated only by the adrenergic branch of
the sympathetic nervous system. These are vasoconstrictor nerves, releasing
norepinephrine (and sympathetic cotransmitters) from their varicosities which
bind vascular alpha receptors, causing vasoconstriction (Fox & Edholm, 1963).
These nerves increase their activity during cold stress (vasoconstriction) and
decrease activity during body warming (passive vasodilation). The non-acral skin
of the arms, legs, etc., possesses both the adrenergic vasoconstrictor system as
well as a non-adrenergic active vasodilator system (Roddie et al., 1957; Fox &
Edholm, 1963). The non-adrenergic system mediates both sweating and active
vasodilation via cholinergic nerve co-transmission (Kellogg et al., 1995). Both
sets of nerves are sympathetic in origin; however, each is activated in separate
circumstances during thermal stress. In summary, cutaneous vascular regulation
by the autonomic nervous system is different in acral and non-acral areas of the
skin. Thus, responses to environmental stimuli in these two portions of the
integument may be different.
Cutaneous vascular responses to changes in blood gas levels
Acral skin and oxygen
Around the start of the first world war, Schneider and Sisco (1914)
published the first observations on the blood flow to the human hand during
acute high altitude exposure. These investigators exposed 5 men to an altitude
of 14,000 feet by transporting them from Colorado Springs, CO to Pike's Peak
9(elevation: 14,109 ft). Their measurements were made using calorimetry, and
therefore estimations of blood flow were based on the amount of heat transferred
from the subject's hand to a water bath in which it was fully immersed. It was
shown that exposure to high altitude caused a 30 to 76 % increase in hand blood
flow, and this effect was partially reversed by the administration of supplemental
oxygen. The authors concluded that low oxygen per se was responsible for
these changes in hand blood flow because oxygen administration partially
reversed the response. However, the possibility that low blood carbon dioxide
levels (hypocapnia) or alkalosis may have mediated part or all of this response,
secondary to increased alveolar ventilation at altitude, was not considered. The
hypocapnia and alkalosis associated with hypoxic hyperpnea would also abate
with the administration of supplemental oxygen, which would reduce alveolar
ventilation by decreasing the firing of peripheral chemoreceptors. l\Jevertheless,
these early observations established the possibility that some aspect of high
altitude exposure is capable of increasing blood flow in the extremities of
humans.
In a later study, Durand et a/. (1969) measured blood flow in the hand over
a range of local temperatures at both high altitude and sea level. Three sea level
natives were studied at three different altitudes: sea level, 3,750 meters (12,300
ft), and 4,800 meters (15,750 ft). Blood flow to the hand was measured by the
method of venous occlusion plethysmography with a water filled plethysmograph,
and local temperature of the hand was affected by adjusting the temperature of
the water filling this device. The results showed that hand blood flow was not
10
altered when local skin temperature was in the normal range (i.e., 33°C or
below). However, as skin temperature was increased over a range of local
temperatures reaching 43°C, blood flow was lower at higher altitudes, and this
effect was scaled to the elevation of exposure such that it was most pronounced
at 4,800 meters (Durand et al., 1969). Because the hand circulation is directed
mostly to skin and consists of relatively little muscle tissue, the authors·
concluded that high altitude causes cutaneous vasoconstriction. However, at
least two issues related to this data set warrant mention. First, while this study
included data from 38 subjects, some of them lowlanders and others native of
rngh altitude, only 3 sea level natives participated in blood flow studies at each of
the three altitudes. Therefore, the authors conclusions about cutaneous
vasoconstriction during hypoxia are based on a sample of only 3 subjects.
Second and perhaps related to the first issue, the authors failed to demonstrate
an effect of local temperature on hand blood flow when water temperature was
reduced below 33°C (in sea level conditions). Resting blood flow measured at
thermoneutral skin temperature was low, and no further decrease was seen as
local temperature was decreased to re. This is contrary to the vasoconstrictor
response expected during local cold exposure, and raises questions about
whether relatively small but physiologically significant changes in perfusion could
be detected in this study. For example, if exposure of the hand to a locally
applied cold stimulus typically decreases local skin blood flow by 50% of the
resting value (Johnson et a/., 2005), the failure to detect a difference in this study
suggests that a cutaneous vascular response of equal magnitude (but possibly
11
opposite direction) could have occurred upon exposure to high altitude, and
these changes would have been missed in this investigation. In summary, the
combination of small sample size and the failure to demonstrate a decrease in
hand blood flow during severe local cooling raise the possibility that a type II
statistical error was made (i.e., no difference was detected in a situation where
one does exist). Nevertheless, in view of the downward shift in hand blood flow
observed with increasing altitude (at higher local temperatures), these data
suggest there may be an interaction between local blood flow and altitude
exposure in determining the cutaneous vascular response to high altitude in acral
skin.
In 1983, the first simultaneous measurements of skin sympathetic
vasoconstrictor nerve activity and skin blood flow were made in humans exposed
to hypoxia (Kollai, 1983). This study evaluated the relationship between skin
sympathetic nerve activity, recorded from the median nerve at the wrist, and
finger pulse wave amplitude as measured by photoplethysmography. While
hypoxic exposures were transient (90 seconds), the results demonstrated that
peripheral chemoreceptor stimulation is capable of increasing sympathetic
outflow directed to the skin, and that this neural activity has a measurable impact
on the hand circulation. However, as noted by the author, it is unclear from these
photoplethysmographic measurements which vascular segments (resistance vs.
capacitance vessels) were affected by the increase in sympathetic nerve activity
during hypoxia, and the 90 second exposure was too short to obtain an
estimation of the net vascular response to steady state hypoxia. Nevertheless,
12
while these data did not address the steady state vascular response to hypoxia in
the hand circulation, they demonstrated that hypoxia activates sympathetic nerve
activity to the hand circulation, and that this produces vasoconstriction at some
level of the vasculature.
It is important to note that the observations described above (Kollai, 1983)
were made during hypoxia which also produced hypocapnia. Therefore, the
possibility exists that the sympathetic or vascular responses (or both) measured
were caused by the fall in blood carbon dioxide levels. Along these lines,
sympathetic stimulation of forearm veins during mild hypoxia is abolished if the
associated hypocapnia is corrected with supplemental C02 (Wei! ef a/., 1971).
Inasmuch as forearm venoconstriction is confined solely to the cutaneous
circulation, and is absent during a variety of stresses when the skin circulation is
arrested (Zelis & Mason, 1969), these data would suggest that the hypocapnia
associated with transient hypoxic exposure contributed to the increase in
sympathetic nerve activity directed to the hand circulation.
The first study to address whether skin blood flow responses are different
in acral vs. non-acral skin during hypoxia was performed in 1986 (Sagawa ef a/.).
These investigators elegantly showed that changes in cutaneous blood flow
during altitude exposure depend on the type of skin circulation being
investigated, with finger blood flow (measured with venous occlusion
plethysmography) and vascular conductance unchanged by 60 minutes at a
simulated altitude of 5,600 meters (- 18,400 tt). As discussed below, non-acral
cutaneous vascular responses were divergent from those measured in the hand,
13
indicating that cutaneous vascular regulation during altitude exposure may vary
across different portions of the integument (Sagawa et al., 1986).
In 1998, a paper was published in Clinical Science in which the variability
of cutaneous pulse wave amplitude was assessed at high altitude (16,300 ft) and
at sea level by power spectral analysis of a photoplethysmographic signal
obtained from the right index finger (Bernardi et al., 1998). As with previous field
studies (see above), no attempt was made to control for changes in CO2 , but
these investigators controlled breathing frequency in hopes of clamping minute
ventilation at altitude. Unfortunately, increases in minute ventilation occur almost
exclusively via increases in tidal volume in this setting (Simmons et al., 2007).
Nevertheless, the results showed a reduction in "global variability" of skin blood
flow, which the authors interpreted as evidence of marked cutaneous
vasoconstriction at high altitude.
In summary, investigations of the acral skin vascular response to hypoxia
over the past century have varied widely in both techniques used to quantify
blood flow and chosen units in which to expresses vascular changes (blood flow
vs. vascular conductance). None of these investigations have adequately
addressed the role of hypoxic hyperpnea in measured vascular responses, nor
has any attempted to account for changes in blood carbon dioxide levels as a
potential mediator of these responses (none has regulated C02 levels). As
mentioned above, increases in skin sympathetic nerve activity in the median
nerve during hypoxia may indicate venoconstrictor or arteriolar vasoconstrictor
signals. Furthermore, voluntary hyperventilation elicits a robust reduction in skin
14
blood flow of both the hands and feet, but it is unclear whether this response is
mediated by low carbon dioxide levels, increased lung stretch, or elevated
oxygen levels (Anderson et al., 1991; Barker et al., 1991). Nevertheless, the lack
of evidence for sustained vasoconstriction in the hand during hypoxia may
indicate that hypoxia per se opposes the pro-constrictive actions of either
hypocapnia or hyperpnea (or both) in this circulation.
Non-acral skin and oxygen
It has been shown that the rise in blood flow to the human forearm, during
either passive whole body heating or lower body dynamic exercise, is confined to
the non-acral skin circulation (Detry et al., 1972; Johnson & Rowell, 1975).
Therefore, Rowell et al. (1982) measured the effect of simulated exposure to
4,500 meters on forearm vascular responses to upright cycle exercise in order to
determine whether sympathetic vasoconstrictor outflow was activated toward the
non-acral skin circulation. These authors hypothesized that if cutaneous
vasoconstriction occurred during hypoxia, the rise in forearm blood flow during
exercise would be blunted, and the forearm blood flow-esophageal temperature
relationship would be rightward shifted with respect to internal temperature. The
results from the 4 subjects tested in that study (protocol 1) did not indicate that
any shift occurred in the forearm blood flow-esophageal temperature relationship
during exercise. Therefore, these authors concluded that hypoxia had no
appreciable effect on the cutaneous circulation. However, as discussed by the
authors, any effect of hypoxia on the skeletal muscle circulation would have also
affected forearm blood flow in this investigation, but this possibility was dismissed
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because hypoxia was not thought to produce any net vascular response in
human muscle. While the reasoning of Rowell ef al. (1982) with respect to the
influence of muscle blood flow on their data was sound, the data in support of
their contention (that muscle blood flow is not increased during hypoxia) were
equivocal at the time. It is now recognized that exposure to simulated high
altitude elicits skeletal muscle vasodilation, although a portion of the response is
masked by increased muscle sympathetic nerve activity and vasoconstriction
(Leuenberger ef al., 1991; Weisbrod ef al., 2001; Moradkhan ef al., 2007). In
addition, as discussed below, hypoxia also increases skin blood flow in the
forearm, though this response is difficult to detect if small numbers of subjects
are tested (Weisbrod ef al., 2001). Nevertheless, this response, together with
hypoxic vasodilation in muscle, would further increase forearm blood flow during
hypoxia, a response not observed by Rowell ef al. (1982). Thus, it may be that
exercise per se, or the> 20% increase in relative work rate caused by the
simulated altitude of 4,500 meters, might have dominated the control of
sympathetic effector responses in this investigation. With these additional factors
affecting the circulation, added to the fact that responses of the study were
negative, no definitive conclusions can be drawn from this investigation about
regulation of non-acral skin blood flow at rest in humans.
As discussed above, Sagawa ef al. (1986) were the first to address the
concept of differential regional control of skin blood flow during hypoxia. These
investigators simulated an altitude of 5,600 meters by inducing hypobaric hypoxia
at an ambient temperature of 28°C. During both sea level and altitude exposure
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blood flow was evaluated in the finger and the forearm (by venous occlusion
plethysmography) over a range of ambient temperatures from 28°C to 38°C.
These authors also addressed biophysical mechanisms of heat transfer between
their subjects and the ambient environment, and this enabled estimation of the
mean heat transfer coefficient between the skin and ambient for each subject
both at altitude and sea level. Their results showed that forearm blood flow was
upward shifted for any given change in forearm skin temperature at simulated
high altitude, a response probably reflecting changes in blood flow to both
skeletal muscle and non-acral skin. However, because the mean heat transfer
coefficient was increased in hypobaric hypoxia, and this value was calculated
using changes in skin temperature of the non-acral skin, the authors concluded
that part of the forearm vasodilation represented an increase in non-acral skin
blood flow. Coupled with their findings of unchanged finger vascular
conductance (see above), these data provided the first demonstration that
cutaneous vascular responses to hypoxia can vary across the integument.
The effects of hypobaric hypoxia were further studied by Kolka et al.
(1987). These investigators studied the relationship between forearm blood flow
and core temperature during 35 minutes of cycle exercise at 60% of the altitude
specific peak V02. Three altitudes were tested (sea level, 2,596 meters, and
4,575 meters), and the highest altitude was associated with a reduction in the
esophageal temperature-forearm blood flow relationship. These results
disagreed with the findings of Rowell et al. (1982), and the hypobaric
environment was suggested as a possible cause. Hypobaria per se increases
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evaporative heat loss across the skin, and this effect probably played a major
role in reducing skin temperature because subjects performed exercise which
increased core temperature by - 0.60°C. Therefore, the reduced forearm blood
flow for a given workload was likely mediated in part by the reduction in skin
temperature during hypobaric hypoxia (Wenger et ai, 1985).
The first investigation of the non-acral cutaneous vascular response to
hypoxia in resting humans came in 1991. Two studies published in different
journals (and with very different study aims) applied the laser Doppler flowmetry
technique to investigate cutaneous microcirculatory responses during systemic
hypoxia. Leuenberger et a/. (1991) studied forearm and cutaneous vascular
responses during 30 minutes of normobaric hypoxia producing a mean arterial
oxygen saturation of 74%. During hypoxia, forearm blood flow rose (and
vascular resistance fell) as did skin blood flow. The increase in skin blood flow
was on the order of 20%, but this change failed to reach statistical significance
likely due to sample size limitations (see below). Anderson et a/. (1991) studied
cutaneous vascular responses to a range of barometric pressures from 0.12 to
2.5 atmospheres absolute. Cutaneous vascular responses were studied in the
skin of the calf, and an inverse relationship between ambient pressure and skin
blood flow was observed. This study was important because it confirmed that
cutaneous vasodilation during hypoxia is also present during hypobaria,
indicating that the use of exercise and the associated high rates of evaporative
heat loss probably contributed to reductions in skin temperature and blood flow
observed previously during hypobaric hypoxia (Kolka et a/., 1987). In addition,
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this study provided evidence in the leg that non-acral cutaneous blood flow varies
inversely with the partial pressure of oxygen, and this observation was later
confirmed in the human forearm skin (Yamazaki et a/., 2007).
The results of Leuenberger et a/. (1991) were extended when Weisbrod et
a/. (2001) studied sympathetic vascular regulation during hypoxia using intra-
arterial phentolamine to produce post-synaptic blockade of a-adrenergic
receptors (thus inhibiting sympathetic vasoconstriction). During hypoxia, the
area of skin pretreated with phentolamine displayed a greater vasodilation than
the skin with intact adrenergic control (Weisbrod et a/., 2001). Based on these
results, the authors concluded that sympathetic vasoconstriction masked a
portion of hypoxic vasodilation in the cutaneous circulation as is the case in the
skeletal muscle vasculature. However, Simmons et a/. (2007) later showed that
pretreatment of the skin with bretylium tosylate (for presynaptic inhibition of
adrenergic nerves) did not affect the magnitude of hypoxic vasodilation,
indicating that increases in sympathetic vasoconstrictor nerve activity do not
oppose hypoxic vasodilation in the skin. The combined results from these two
studies indicated the following: in the skin, blockade of sympathetic adrenergic
nerves does not affect hypoxic vasodilation, but blockade of a-adrenergic
receptors unmasks greater hypoxic vasodilation.
These seemingly disparate observations appear to be reconciled by
consideration of the different loci at which phentolamine and bretylium block
sympathetic vasoconstriction. For instance, phentolamine blocks postsynaptic
a1- and a2- adrenergic receptors (Hoffman, 2001) while bretylium tosylate blocks
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adrenergic nerve transmission presynaptically (Haeusler et al., 1969). Blockade
of a1- and a2- adrenergic receptors interferes with both humoral and neural
adrenergic vasoconstriction, whereas only neural vasoconstriction is blocked by
inhibition of sympathetic adrenergic fibers. Thus the results indicating that
cutaneous vasodilation is unmasked by a-receptor blockade may indicate that
humoral (adrenergic) vasoconstriction is present in the skin during hypoxia. This
vasoconstriction would be sensitive to a-receptor blockade but not to presynaptic
inhibition by bretylium. A likely candidate for such a circulating mediator of
adrenergic vasoconstriction is epinephrine, which is present in the blood at
higher concentrations during acute hypoxia (Weisbrod et al., 2001). Epinephrine
has been shown to cause cutaneous vasoconstriction when administered intra-
arterially, intravenously, by subcutaneous injection, or by iontophoresis (Barcroft
et al., 1955; Cooper et al., 1955; Roddie, 1983; Hoffman, 2001). Taken together,
the combined observations of Weisbrod et al. (2001) and Simmons et al. (2007)
suggest that adrenergic vasoconstriction of humoral origin (possibly epinephrine)
may mask some of the cutaneous vasodilation during hypoxia, and adrenergic
vasoconstriction of neural origin (I.e., sympathetic vasoconstrictor nerves) does
not affect hypoxic vasodilation in human skin.
Acral skin and carbon dioxide
Diji (1959) first described the effect of carbon dioxide on hand blood flow
in humans. Blood flow was measured by calorimetry while the hand was
immersed in a water bath. When carbon dioxide was mixed into the bath, heat
elimination to the water bath (index of blood -now) increased by an average of
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40%. Because subjects breathed normal air and were therefore without
chemoreceptor stimulation by CO2, the effects on hand blood flow were assumed
to be local in origin. Subsequent investigations probed the forearm vascular
response to local administration of CO2 as well as systemic effects mediated by
central and peripheral chemoreflexes (Richardson et a/., 1961; Kontos et a/.,
1967). However, in each of these investigations blood flow to the hand was
occluded by inflation of a wrist cuff to suprasystolic pressure, and therefore it
remains unknown if a competition exists between chemoreflex-mediated
vasoconstrictor and locally-mediated vasodilator influences in the hand
circulation during hypercapnia.
Non-acral skin and carbon dioxide
Carbon dioxide baths were in use for the treatment of peripheral vascular
disease dating back to the late 1800s. However, the evidence for- a beneficial
effect caused by the direct action of CO2 on the skin microcirculation was not
demonstrated until 1942. In a simple study, Stein and Weinstein (1942) showed
that the diffusion of CO2 into the cutaneous microcirculation produced a limb
hyperemia which ranged up to 150% of baseline blood flow. These results were
obtained in the lower leg, and the data were the first to demonstrate that the
beneficial effects of carbon dioxide bath treatment are due in part to a locally-
mediated vasodilation in the skin microcirculation.
The results of Stein and Weinstein (1942) were later extended to the
forearm circulation by Diji and Greenfield (1960). These authors administered
subcutaneous injections of gas containing carbon dioxide concentrations ranging
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from 12.5% to 100%. The results showed that skin temperature in the region of
subcutaneous injection was elevated versus the temperature measured at a
control site, and this response was present beginning with the lowest carbon
dioxide concentrations used. After confirming that these responses were not an
effect of subcutaneous gas administration, the authors concluded that the local
action of carbon dioxide on the resistance vessels in the skin was responsible for
local increases in blood flow. Importantly, these data were the first to
demonstrate that physiological concentrations of carbon dioxide, approximated
by the lowest dose of CO2 administered (Thompson & Brown, 1960), could
stimulate vasodilation in the forearm cutaneous circulation.
In order to investigate the degree to which sympathetically-mediated
chemoreflex responses can oppose the local action of CO2 on skin blood vessels
during hypercapnia, Simmons et a/. (2007) exposed 13 subjects to mild and
moderate systemic hypercapnia elevating end-tidal PC02 by 5 and 9 torr,
respectively. Cutaneous vascular responses were studied in the forearm in an
area with intact vasoconstrictor control and an area in which adrenergic
vasoconstriction was abolished by treatment with bretylium tosylate. The results
demonstrated that both mild and moderate hypercapnia caused cutaneous
vasodilation, but the mechanisms behind this response were not entirely clear.
During mild hypercapnia, withdrawal of sympathetic vasoconstriction appeared to
mediate most of the vasodilator response, whereas no effect of vasoconstrictor
tone was observed in the moderate hypercapnia condition. Neither response
was reproduced by voluntary hyperventilation when breathing frequency and
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volume were matched to hypercapnic values. Thus, it appears that modest
levels of arterial hypercapnia cause a slight increase in skin blood flow, and this
hyperemia is mediated in part by withdrawal of sympathetic vasoconstriction.
Also, a local effect of CO2 may be present if the degree of hypercapnia is more
severe, but this issue remains unclear.
In summary, current data support the notion that high concentrations of
carbon dioxide administered locally to either acral or non-acral skin cause a
substantial increase in cutaneous blood flow (Stein & Weinstein, 1942; Diji, 1959;
Diji & Greenfield, 1960). Interestingly, it would appear that systemic induction of
hypercapnia results in withdrawal of cutaneous sympathetic vasoconstrictor tone
instead of the opposite response observed in the skeletal muscle circulation
(Richardson et a/., 1961). During acute exposure to systemic hypercapnia in
humans, sympathetic withdrawal appears to mediate the cutaneous vascular
response to lower levels of hypercapnia, while a local effect emerges as the
stress becomes more severe (see discussion in Simmons et a/., 2007).
Cutaneous vascular regulation during whole body cold stress
In response to whole body cold stress, skin blood flow is reduced by
activation of sympathetic adrenergic nerves directed to cutaneous arterioles.
The adrenergic nature of these nerves is demonstrated by the abolition of the
response after pretreatment with bretylium (Kellogg et a/., 1989). For many
years it was thought that only norepinephrine was released from cutaneous
sympathetic adrenergic nerves, and that this norepinephrine mediated the whole
of the vasoconstrictor response during cold stress by binding to post-synaptic a-
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adrenergic receptors (Fox & Edholm, 1963; Kellogg, 2006). However, this
dogma was slowly changed with the publication of numerous studies which
together suggest that cutaneous vasoconstriction is mediated partly through
sympathetic cotransmitter-mediated (non-noradrenergic) mechanisms.
In the 1980s, Ekblad et al. (1984) and Pernow et al. (1987) demonstrated
that another putative neurotransmitter - neuropeptide Y - is commonly
colocalized with norepinephrine in sympathetic perivascular nerves. These
investigators used immunofluorescence to determine that neuropeptide Y is
contained in the neuronal terminals of sympathetic perivascular nerves. These
authors suggested that neuropeptide Y may be released with norepinephrine and
playa role in regulation of local blood flow. This idea was later confirmed by the
combined results of Eckberg et al. (1988) and Pernow et al. (1989a). Eckberg et
al. (1988) demonstrated that release of neuropeptide Y into the plasma was
strongly correlated (r =0.87) with directly measured sympathetic nerve activity
over a range of blood pressures. Next, Pernow et al. (1989a) showed that intra-
arterial infusion of neuropeptide Y into the human forearm causes a robust
vasoconstrictor response. Taken together, these combined studies
demonstrated that neuropeptide Y is present in sympathetic perivascular
neurons, is released by sympathetic nerves when they are activated by the
autonomic nervous system, and causes vasoconstriction in the human limb
circulation (Ekblad et al., 1984; Pernow et al., 1987; Eckberg et al., 1988; Pernow
et al., 1989a).
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In 2001, Stephens et al. first demonstrated that cutaneous
vasoconstriction during cold stress involves a sympathetic nerve cotransmission
component. These investigators administered yohimbine via intradermal
injection to produce post-synaptic blockade of alpha-adrenergic receptors in the
forearm skin of seven men. A separate area of forearm skin received saline and
served as a control. Although yohimbine is classically thought of as an a2
receptor antagonist, previous work has shown that it functions as a non-specific
a-blocker when administered at high concentrations, and numerous studies have
recently used yohimbine in the 5mM range to block both a1- and a2- adrenergic
receptors in the cutaneous microcirculation (Stephens et al., 2001; Stephens et
al., 2002; Stephens et al., 2004; Thompson & Kenney, 2004). After sites on the
skin were pretreated with either yohimbine or saline, subjects were exposed to
whole body cold stress for 15 minutes while blood flow was measured over both
sites using laser Doppler flowmetry. The results showed that cutaneous
vasoconstriction persists in the presence of post-synaptic a-blockade, with - 40%
of the response apparently mediated by sympathetic cotransmission (Stephens
et al., 2001). These same authors later showed that cotransmitter-mediated
vasoconstriction was also present in women taking oral contraceptives, but only
during the high hormone phase of contraceptive use (Stephens et al., 2002).
In 2004, the possibility that sympathetic cotransmitter-mediated
vasoconstriction involves the binding of post-synaptic neuropeptide-Y receptors
was tested. Stephens et al. (2004) repeated the protocol in which cotransmitter-
mediated vasoconstriction was demonstrated by blocking adrenergic
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vasoconstriction with yohimbine. This time another skin site was included in
which both adrenergic receptors as well as neuropeptide Y receptors were
blocked. The authors used BIBP-3226 to selectively block neuropeptide Y-Y1
receptors (Doods ef al., 1996) because this receptor subtype was previously
shown to mediate vasoconstriction in the splenic and renal vascular bed of the
swine (Modin ef al., 1991) and the mesenteric artery of the rat (Zukowska-Grojec
ef al., 1996). The skin blood flow responses during cold stress were further
blunted in the presence of neuropeptide Y receptor antagonism, and this
abolished virtually all of the cotransrnitter-mediated vasoconstrictor response.
In summary, the dogma which held that cutaneous vasoconstriction is
mediated solely through adrenergic vasoconstriction has been revised over the
past decade. It is now understood that approximately 40% of the vasoconstrictor
response is non-adrenergic in origin, but appears to be sensitive to blockade of
neuropeptide Y receptors. Thus, both norepinephrine and neuropeptide Yare
released from sympathetic adrenergic nerves during cold stress. Norepinephrine
causes cutaneous vasoconstriction through 01- and 02- receptors, while
neuropeptide Y affects vasoconstriction via neuropeptide Y-Y1 receptors.
Hypoxia and sympathetic vasoconstriction
Long standing interest has centered on the possibility that tissue hypoxia,
through effects on the chemical milieu within the muscle, can alter the
transduction of sympathetic vasoconstrictor outflow into vascular resistance
(Dinenno, 2003). While the focus of this review is on the cutaneous -circulation,
vasoconstrictor transduction during hypoxia is relatively under investigated in the
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skin compared to the skeletal muscle circulation. Therefore, pivotal studies from
this body of research will be cited here in order to provide a base from which to
understand the discussion of cutaneous vasoconstrictor responses in this
dissertation, and how these responses might be altered by hypoxia.
A number of complex issues have obscured a clear understanding of
sympathetic vasoconstrictor transduction for many decades. For example, the
measured variable in most studies of vasoconstrictor transduction is either a
change in blood flow, vascular resistance, or vascular conductance. However,
when the environmental stress being considered (hypoxia) alters baseline blood
How, the expression of vasoconstrictor responses can be obscured by presenting
values as a percentage of baseline parameters (i.e., the law of initial values).
Furthermore, vascular resistance and conductance are inversely related such
that when blood flow is high, a considerable change in vascular conductance
produces only a small change in vascular resistance. Therefore, complications
as simple as how to express data have impeded progress in this area over the
years.
In addition to methodological complications, the' central versus peripheral
actions of hypoxia have made experimental results difficult to interpret with
respect to vasoconstrictor transduction. For example, hypoxia is known to
impact sensory integration within the central nervous system (Steiner et al.,
2002). However, the peripheral vascular effects of hypoxia can also result in
functional hemodynamic changes (Heistad &Abboud, 1980). Therefore, a
common limitation to some experiments in this area is that the central and
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peripheral effects of hypoxia can not be disassociated from one another.
Fortunately, some experimental models have controlled for this issue, and select
studies from this body of literature are presented below.
In 1970, Heistad and Wheeler published the first report addressing
sympathetic vasoconstrictor function during hypoxia in humans. These authors
tested forearm vascular responses to a variety of sympathoexcitatory stimuli as
well as intra-arterial infusions of vasoconstrictor substances. In this
comprehensive approach, vasoconstrictor responses were first tested during
physiologic excitation of the sympathetic nervous system and subsequently
retested during infusions of exogenous norepinephrine. Lower body negative
pressure and the application of ice to the forehead were used to activate centrally
integrated sympathetic vasoconstrictor responses. The results demonstrated
that vasoconstrictor responses to lower body negative pressure as well as ice on
the forehead were reduced when subject breathed a 12% oxygen mixture. In
addition, forearm vascular responses to intra-arterial infusions of norepinephrine
were reduced during hypoxia, indicating that a peripheral effect of hypoxia may
playa role in these altered vasoconstrictor responses (Heistad & Wheeler, 1970).
Therefore, the authors concluded that sympathetic vasoconstriction is blunted in
the forearm circulation during hypoxia, and a peripheral effect on vasoconstrictor
transduction is a least partly responsible for this phenomenon. These authors
also tested the role of hypocapnia in these responses and demonstrated that
hypoxia was the primary culprit responsible for their findings.
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These same authors later tested both forearm and hand vascular
responses to the same sympathoexcitatory stimuli (not intra-arterial infusions)
during carbon monoxide breathing. This experimental approach induces tissue
hypoxia without affecting arterial oxygen tension, and so peripheral chemoreflex
activation is absent or minimal with this approach. The results confirmed the
author's previous findings that sympathetic vasoconstriction is reduced in the
forearm, and demonstrated that similar effects are seen in the hand circulation
(Le., acral skin). These data demonstrated that reduced vasoconstriction in the
limbs during hypoxia is not the result of central interactions between the
peripheral chemoreflex and other major homeostatic reflexes (Le., baroreflexes,
thermoregulatory reflexes, etc), and showed that vasoconstrictor transduction in
the skin circulation is also affected by hypoxia (Heistad & Wheeler, 1972).
Importantly, while a role for central reflex interactions was ruled out by these
experimental results, the effects of hypoxia on central integration of afferent and
efferent stimuli within the major reflexes (e.g., thermoregulatory reflexes) wa.s not
addressed by this study (see paragraph above).
In 1990, Rowell and Seals measured forearm vascular responses to
graded lower body negative pressure during both normoxia and hypoxia. During
hypoxia, absolute changes in vascular resistance were smaller at every level of
lower body negative pressure, but the percent change from baseline was the
same owing to a decrease in resting vascular resistance (Rowell & Seals, 1990).
These results highlight the problems with interpreting results as a percentage of
baseline values when resting hemodynamics is altered. However, a comparison
-------------------
29
of these results with those obtained by Heistad and Wheeler (1970) allows some
tentative conclusions to be drawn. For example, when Heistad and Wheeler
(1970) exposed subjects to hypoxia they observed no change in resting forearm
vascular resistance. Therefore, the data from that study represent an opportunity
to compare vascular responses during hypoxia without the confounding effects of
a change in baseline blood flow. Because the percent changes in forearm
vascular resistance measured by Heistad and Wheeler (1970) were diminished
by hypoxia, and the absolute values measured by Rowell and Seals (1990) were
similarly diminished, it appears that hypoxia is capable of decreasing sympathetic
vasoconstrictor responses, at least during the application of lower body suction.
As described above, Heistad and Wheeler (1970) showed that the
reduction in sympathetic vasoconstriction during hypoxia is at least partly
explained by blunted vascular transduction, as indicated by reduced
vasoconstrictor responses to exogenous norepinephrine. However, Dinenno et
al. (2003) recently demonstrated that forearm vascular responses to intra-arterial
infusion of tyramine were not altered by three different levels of hypoxia. In
contrast to intra-arterial infusion of norepinephrine, tyramine causes endogenous
release of norepinephrine from sympathetic terminals. Therefore, the
discrepancy between peripheral vascular responses noted by Heistad and
Wheeler (1970) and Dinenno et al. (2003) may relate to the exogenous versus
endogenous nature of the adrenergic stimulus. For example, norepinephrine
clearance is increased by hypoxia, an effect that may be mediated by enhanced
axonal norepinephrine reuptake (Leuenberger et al., 1991). Therefore, one
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possible explanation for differing responses to exogenous and endogenous
norepinephrine is that infused norepinephrine is cleared and metabolized faster
during hypoxia, thus reducing the amount of catecholamine to reaches post-
junctional a-adrenergic receptors. However, the mechanisms which stimulate
increased clearance of norepinephrine during hypoxia are poorly understood,
and the degree to which intraluminal and extraluminal (abluminal) norepinephrine
are affected is unknown.
In contrast to human studies, experiments in rats consistently report
blunted sympathetic vasoconstriction during hypoxia in skeletal muscle \Coney &
Marshall, 2003, 2007). These studies have yielded important information
because it is possible to electrically stimulate post-ganglionic sympathetic nerves
in animal preparations, thereby overcoming the limitations of central integration
of afferent stimuli during reflex activation. Results from these studies indicate
that a-adrenergic receptors are sensitive to inhibition by hypoxia, whereas
neuropeptide Y receptors are resistant to this effect (Coney & Marshall, 2007).
This recent finding has significant implications for previous research in humans,
and raises the possibility that discrepant findings from past studies may be
explained by differential contributions from cotransmitter-mediated
vasoconstrictor pathways. In support of this possibility are data demonstrating
that neuropeptide Y release into human plasma is correlated with muscle
sympathetic nerve activity during barore'flex-mediated changes in sympathetic
outflow (Eckberg ef al., 1988). Therefore, different degrees of sympathetic
activation in previous human studies, and thus different contributions of
cotransmitter-mediated vasoconstriction, may partially explain some of the
disparate findings regarding vasoconstrictor transduction during hypoxia.
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CHAPTER III
OVERVIEW OF METHODOLOGIES
Subjects
These studies were approved by the institutional review board of the
University of Oregon, and each subject gave written, informed consent before
participation.
Forty seven healthy, nonsmoking, normotensive subjects (25 men, 22
women), age 23 ± 3 yr, participated in this series of studies [height 175 ± 13 (SD)
cm, weight 72.2 ± 15.9 kg, body mass index 23.2 ± 2.8 kg/m2]. Subjects were
taking no medications, except for oral contraceptives, and none had been to
altitude (>1,500 m) within 5 months. Women in Chapters IV, V, and VII were
studied either during the early follicular phase of the menstrual cycle or during
the placebo phase of oral contraceptive use. In Chapter VI, only women who
were using oral contraceptives were studied, and these women were tested
during the high hormone phase of oral contraceptive use (Stephens ef a/., 2002).
All female subjects had a negative urine pregnancy test within 1 hour of
participation.
Instrumentation
In the studies described within Chapters IV, V, and VII, all data 'collection
took place with the subject laying supine with the exception of the drug infusion
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period in the study described in Chapter VII. During the drug infusion period in
that study, subjects sat semi-recumbent with their arm positioned at heart level
and were later moved to the supine position for the last half of the study. Two
body positions were used in that study because the duration of the protocol (7.5
hours) made it difficult for subjects to remain still in the supine position during the
final hours of data collection. In the study described within Chapter VI, all data
was collected with the subject seated in the semi-recumbent position inside of a
custom modified jacuzzi bathtub. As with the other studies contained in this
dissertation, the subject's arms were placed at heart level.
The studies described in Chapters V, VI, and VII made use of the
microdialysis technique as described below. When the subject arrived on the
study day, three microdialysis fibers (model MD 2000, Bioanalytical Systems,
West Lafayette, IN) were placed in the skin of the ventral forearm. The
rnicrodialysis fiber (or probe) consists of a length of fine tubing impermeable to
diffusion except for a 10 mm membrane that allows the diffusion of compounds
no larger than 20 kDa. Fibers were placed by first inserting a 25-gauge need1e
through the dermis of the skin to create a path for insertion. The fiber was then
threaded through the internal lumen of the needle, and the needle was
withdrawn, leaving the membrane in the skin. The fiber was taped in place and
then connected to a syringe via a luer tip connector at the proximal end. The
fiber was then perfused with lactated Ringer's solution at a rate of 4 pI/min with a
microinfusion pump (CMA/102, CMA Microdialysis, Stockholm, Sweden). Sites
were at least 5 cm apart.
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Pharmacological interventions
Each of the study compounds used in this dissertation has either been
approved for human use by the United States Food and Drug Administration or
has been administered to human volunteers previously in the research setting in
the exact format used here. The mechanism of action as well as the theoretical
basis for the use of each compound is described below and throughout the
individual chapters. In addition, specific mixing instructions for target drug
concentrations have been included in the separate appendices.
Yohimbine Hel was used throughout these studies to block both a1- and
a2- adrenergic receptors. Yohimbine is classically thought of as a selective a2-
adrenergic receptor antagonist, and this is the main pharmacological effect when
administered systemically. However, yohimbine can be delivered locally into the
skin via intradermal injection or microdialysis and this method allows the
administration of much higher concentrations of the drug in a small area of skin.
At high local concentrations (5mM), yohimbine acts as a non-selective blocker of
a-adrenergic receptors and abolishes the vasoconstrictor response to both
norepinephrine and phenylephrine (o1-receptor agonist) administration (Stephens
et al., 2001; Stephens et al., 2002; Stephens et al., 2004; Thompson & Kenney,
2004). Therefore, yohimbine has recently been used by numerous investigators
to block the adrenergic vasoconstrictor effects of norepinephrine in the skin
(Stephens et al., 2001; Stephens et al., 2002; Stephens et al., 2004; Thompson
& Kenney, 2004).
35
BIBP-3226 is a neuropeptide V-receptor antagonist selective for the
neuropeptide Y-Y1 receptor. This drug selectively binds the neuropeptide Y-Y1
receptor and displaces the ligand, exerting no intracellular signaling effects (Le.,
competitive inhibition). In vitro, BIBP-3226 significantly displaces the
neuropeptide Y binding curve to the right in both human and animal vascular
tissues. In vivo, intravenous infusion of BIBP-3226 produces a dose dependent
abolition of the pressor response to neuropeptide Y in the rat (Doods et al.,
1996). In conscious humans, BIBP-3226 delivered via intradermal microdialysis
(10.5 IJM) was previously shown to block sympathetic cotransmitter-mediated
(non-noradrenergic) vasoconstriction during whole body cooling (Stephens et al.,
2004). Therefore, a similar dose of BIBP-3226 was used throughout these
studies with the goal of blocking sympathetic vasoconstriction mediated through
neuropeptide Y-Y1 receptors.
Tyramine was used in the study described in Chapter VII to stimulate the
release of neurotransmitters from cutaneous sympathetic adrenergic nerves.
Tyramine is selectively taken up by adrenergic nerve terminals and displaces
intraneuronal transmitters from their storage vesicles, causing a transient release
of neurotransmitter into the extracellular space. Tyramine is considered an
indirect acting sympathomimetic agent insofar as it possesses no direct
vasoconstrictor properties on vascular smooth muscle (Lundberg et al., 1989b;
Hoffman, 2001). Previous research has provided mixed results regarding which
neurotransmitters are released from sympathetic terminals upon stimulation with
tyramine. For example, Lundberg et al. (1989b) showed that tyramine
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stimulation of the pig spleen in vivo caused vasoconstriction that was associated
with an increase in norepinephrine outflow but no change in neuropeptide Y
outflow in the venous effluent draining the isolated organ. Later, Takiyyuddin ef
a/. (1994) demonstrated that intravenous infusion of tyramine caused an increase
in arterial pressure and plasma norepinephrine, while plasma neuropeptide Y
was unaltered. In contrast, Cheng ef a/. (1987) demonstrated that tyramine
releases both norepinephrine and neuropeptide Y from sympathetic terminals of
the rabbit jejunum, but that neuropeptide Y is only released at higher
concentrations of tyramine. In addition, tyramine was shown to cause a dose
dependent rise in neuropeptide Y release from sympathetic terminals of the rat
vas deferens (Cheng & Shen, 1987). Therefore, it appears that tyramine
stimulates the release of neuropeptide Y with norepinephrine in certain tissues,
whereas norepinephrine is released alone in others. Another aspect that may
affect the release of neuropeptide Y by tyramine is the mode of delivery to the
target tissue. For example, the studies which have documented neuropeptide Y
release from sympathetic terminals have delivered tyramine to neuronal tissues
via the extracellular fluid. In contrast, those studies indicating that tyramine does
not stimulate neuropeptide Y release have delivered tyramine through
intraluminal infusion (arterial or venous supply). Therefore, the intraluminal
versus abluminal delivery of tyramine may cause different outcomes regarding
neurotransmitter release from sympathetic terminals, in agreement with studies
on other vasoactive compounds (Marshall, 2007). Tyramine was delivered in
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Chapter VII by microdialysis so as to introduce it directly into the cutaneous
interstitium.
Propranolol was used in Chapters V and VI to block ~-adrenergic
receptors, which have been identified in the skin circulation of humans (Crandall
et al., 1997). Propranolol is a non-selective 13-adrenergic receptor antagonist that
possesses no a-adrenergic blocking properties (Hoffman, 2001).
Environmental stress
Cold exposure
Cold stress was achieved via three different methods in this series of
studies. The three cooling methods were similar insofar as cold stress was
applied to a large portion of the body to induce reflex cutaneous vasoconstriction.
Local cold exposure in the region of blood flow measurement was prevented
either by confining the cold exposure to other regions of the body or by local
heating, or both. The cutaneous vascular response to local cooling of the skin
induces a vasoconstrictor response which is mediated by different mechanisms
than the reflex response initiated when a larger portion of the body is cooled
(Kellogg, 2006). The local cooling response involves an early phase in which
vasoconstriction is mediated through a-adrenergic receptors and dependent on
sympathetic vasoconstrictor nerves, and a latter phase in which vasoconstriction
is non-neural, non-noradrenergic, and appears to be mediated through an effect
of cold temperature on intracellular mechanisms within the vascular smooth
muscle (Kellogg, 2006; Thompson-Torgerson et al., 2008).
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In Chapters IV and part of Chapter V, subjects wore a water-perfused suit
that covered the entire body surface except for the head, hands, feet, and,
forearm where measurement of vascular responses was performed. To induce
cold stress, the water circulating through the whole body suit was cooled either
progressively or in a ramp protocol (see Chapters IV and V). Because the suit
makes contact with the skin surface of the subject, the contribution of conductive
heat transfer away from the skin surface using this technique is relatively high
compared to ambient temperature cooling. In the second protocol contained
within Chapter V, whole body cold stress was induced by progressively
decreasing the temperature of the environmental chamber in which the subject
lay supine (Le., ambient temperature cooling). Because the surface on which the
subject lay was not being directly cooled, and air movement was considerable
within the chamber, the mechanisms through which heat loss were increased
were largely convective and radiative (although conductive heat loss to the bed
likely increased somewhat). In the study described within Chapter VI, cold
exposure was induced by cooling a tub of water in which the subject was
immersed to the sternum. Water was used to cool the subject in Chapter VI
because the goal of the second phase of the study was to induce a decline in
core body temperature. Conscious humans are resistant to changes in core
body temperature owing to robust thermoregulatory reflexes including peripheral
vasoconstriction and shivering. Therefore, the use of water for body cooling is
necessary if a rapid decline in body temperature is desired because water
increases the rate of heat transfer from the skin surface by 20 times (Santee &
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Gonzalez, 1988). The water bathing the subject was cooled by the addition of
ice, and a jacuzzi circulation system maintained the homogeneity of water
temperature within the tub.
Changes in blood gases
To achieve control of respiratory gases, subjects breathed from a custom
built breathing circuit using a scuba mouthpiece and nose clip. The inspiratory
.mixture provided at the mouthpiece originated from 3 gas tanks - air (20.93%
O2), nitrogen (100% N2), and carbon dioxide (100% CO2) - connected to the
inspiratory line by flow regulators. The fraction of inspired oxygen {FI02) and
carbon dioxide (FIC02) were varied by adjusting the flowrate from each of the gas
tanks, and the inspired air was mixed as it filled a 6 liter tube which served as an
inspiratory reservoir. The 6 liter tube connected to the breathing circuit proximal
to the mouthpiece, and its distal end was open to room air. Total flowrate
through the breathing circuit was always greater than the subjects' minute
ventilation, and thus excess gas delivered through the inspiratory line escaped to
the room through the 6 liter tube. The mouthpiece consisted of two one-way
valves (Rudolph) to insure inspiration from the breathing circuit and expiration to
room air, except in the study described in Chapter VI. In that study, expiratory
gases were passed through a mixing chamber integrated with a mass
spectrometry system for the measurement of whole body oxygen consumption.
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Measurements
Heart rate
Heart rate was monitored throughout each protocol using a 3-lead
electrocardiogram (Cardiocap/5, Datex-Ohmeda, Madison, WI).
Arterial pressure
Systolic (SBP) and diastolic (DBP) arterial pressure were measured from
the brachial artery via oscillometry (Cardiocap/5, Datex-Ohmeda, Madison, WI)
throughout each protocol. Mean arterial pressure was calculated as DSP +
((SBP-DBP)/3). In addition, arterial pressure was measured on a beat to beat
basis by photoplethysmography (Finometer, Finapres Medical Systems BV,
Arnhem, the Netherlands) in the study described within Chapter IV. However,
during this study it was determined that this method fails to adequately track
changes in arterial pressure during cold stress, likely due to a reduction in distal
extremity blood flow. Therefore, these measurements were not included in any
of the analyses for Chapter IV.
Arterial oxygen saturation
Arterial O2 saturation was measured during the studies described in
Chapters IV, VI, and VII via pulse oximetry (Cardiocap/5, Datex-Ohmeda,
Madison, WI) on the earlobe.
End-tidal PC02
The partial pressure of carbon dioxide (PC02) in the alveoli was estimated
by measuring end-tidal PC02 via infrared capnography (Cardiocap/5, Datex-
Ohmeda, Madison, WI) or mass spectrometry (Marquette MGA 1100, MA Tech
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Services, St. Louis, MO) throughout these protocols. Infrared capnography
makes use of the fact that CO2absorbs light in the infrared (IR) range, and the
amount of CO2 in a sample is determined relative to the amount of IR light
absorbed when a beam is passed through the sample. Mass spectrometry
measures the mass to charge ratio of molecules ionized and accelerated in a
vacuum. Therefore, C02 in a given sample can be separated and expressed as
a percentage or partial pressure of the total gas sample.
Minute ventilation
Tidal volume was measured throughout these protocols using a turbine
pneumotach (VMM-400, Interface Associates, Laguna Niguel, CA). Peak values
of the inspiratory volume tracing were identified and determined along with their
interval length using CODAS software (WinDaq, Dataq Instruments, Akron, OH).
Minute ventilation was calculated as the product of tidal volume and respiratory
frequency and expressed in liters of inspired volume per minute.
Whole body oxygen consumption
Whole body V02was assessed during normoxia and hypoxia via indirect
open circuit calorimetry using the following equation: V02= VE«1 - (FE0 2 +
FEC02)) / F,N2x F10 2- FE0 2) where V02 is whole body oxygen consumption, VE
is minute ventilation, FE0 2 and FECO2 are the fractions of expired oxygen and
carbon dioxide, and F1N2 and F,02 are the fractions of inspired nitrogen and
oxygen, respectively. VE was measured as described above, FE02 and FeC02
were measured by passing the expired respiratory gases through a mixing
chamber (Parvomedics, Sandy, UT) integrated with a mass spectrometry system
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(Marquette MGA 1100, MA Tech Services, St. Louis, MO), F1N2 is constant, and
F,02 was measured from the peak of the tidal P02 tracing on a minute by minute
basis.
Skin blood flow
Skin blood flow was measured in each of these studies by laser-Doppler
flowmetry on the ventral surface of the forearm. This technique measures skin
blood flow by directing low power light from a monochromatic stable laser at the
skin surface. The emitted light is scattered by moving red blood cells in the
cutaneous microvasculature and photodetected to yield a perfusion unit termed
'flux'. The flux value measured is proportional to the product of the average
speed and number of red blood cells moving through the cutaneous
microvasculature to a depth of approximately 1mm (measured tissue volume - 1
mm3). This value has been validated against measurements of absolute skin
blood flow during thermal stress, and correlations of 0.94 to 0.98 were observed
between the cutaneous vascular response to whole body heating as measured
by laser-Doppler flowmetry and venous occlusion plethysmography (Johnson et
al., 1984). Skin blood flow was divided by mean arterial pressure to calculate
cutaneous vascular conductance, and measurements were scaled to values
recorded during baseline conditions (Thompson & Kenney, 2004).
Skin temperature
Weighted mean skin temperature was measured using copper-constantan
thermocouples on representative areas of the skin (see Chapters V and VI).
Thermocouples measure skin temperature based on the non-linear relationship
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that exists between temperature and the flow of voltage between two wires that
are fastened in contact and insulated (copper and constantan). The signal
obtained from the thermocouples was first linearized and then transferred to the
data acquisition system for recording. The temperature of the water bath in the
study described within Chapter VI was also measured using a thermocouple. All
thermocouples were calibrated prior to the study with a two point calibration
using water baths of known temperature.
Core temperature
Internal body temperature was measured using a CoreTemp (HQlnc,
Palmetto, FL) wireless core body temperature telemetry based monitoring
system. In this method, core temperature is measured by an ingestible pill that is
designed for human use (approved by the FDA) and is accurate to 0.1 °C. The
subjects ingested the pill at least 6 hours before the study, or the night before if
the study began early in the morning. This system allowed for core temperature
to be directly recorded in real time, and this method has been validated against
rectal temperature measurements during interval running trials (Gant et al.,
2006). In validation studies intestinal pill temperature measurements have given
readings - 0.15°C higher than the rectal temperature probe, but changes during
heating and cooling are tracked well by this method.
Data acquisition and analysis
The majority of data collected during these protocols were digitized with
signal-processing software (WinDaq, Dataq Instruments, Akron, OH) and
analyzed off-line. Notable exceptions were core temperature measurements and
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brachial artery blood pressures, which were recorded on paper during the
experiment. Statistical analyses were performed with SAS statistical software
using PROC MIXED (SAS v9.1.3, SAS Institute, Cary, NC). Details of specific
analyses are provided within the individual chapters and depended on the design
of the study. A theme throughout these analyses was the univariate analysis of
variance (ANOVA), performed with one, two, or three factors depending on the
circumstance. The paired t-test was also used for certain analyseswhen
appropriate.
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CHAPTER IV
EFFECT OF CO2 REGULATION ON THE CUTANEOUS VASCULAR
RESPONSE TO HYPOXIA AND MILD COLD STRESS
Introduction
It is well established that low oxygen levels exert a relaxing effect on
peripheral blood vessels in the human limb circulation (Schneider & Sisco, 1914;
Sagawa et al., 1986; Anderson et al., 1991; Leuenberger et al., 1991; Weisbrod
et al., 2001; Simmons et al., 2007). In the skeletal muscle circulation and likely
the circulation to the hand, locally and humorally-mediated hypoxic vasodilation
is opposed by increases in sympathetic vasoconstrictor nerve activity (Kollai,
1983; Saito et al., 1988; Weisbrod et al., 2001). However, we have recently
shown that hypoxic vasodilation in the non-acral skin of the forearm is not
restrained by neurally-mediated sympathetic vasoconstriction (Simmons et al.,
2007). It was suggested that this "unchecked" cutaneous vasodilation may have
important thermoregulatory consequences inasmuch as relatively small changes
in resting skin blood flow can have large impacts on convective heat loss.
During whole body cold stress, skin blood flow is reduced in order to
decrease heat transfer from the core to the periphery, thereby promoting heat
conservation (Hamlet, 1988). This thermoregulatory adjustment is vital to the
prevention of hypothermia in cold environments. However, when cold and
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hypoxia are encountered simultaneously, the rate of core cooling is accelerated,
and lower core temperatures are reached compared to sea level conditions
(Cipriano & Goldman, 1975; Johnston et al., 1996). While core temperature falls
faster at altitude, skin temperature remains higher throughout cold exposure
compared to sea levels conditions (Cipriano & Goldman, 1975; Blatteis &
Lutherer, 1976). Taken together, these results indicate a less effective reduction
in core-to-skin heat transfer during cold exposure at altitude. Importantly, we are
aware of no studies which have directly measured skin blood flow during
combined hypoxia and whole body cold stress.
Previous studies of the cutaneous vascular response to hypoxia have
failed to address the potential role of carbon dioxide in mediating these changes.
The vasodilator action of carbon dioxide on cutaneous blood vessels was first
demonstrated by Stein and Weinstein (1942) who showed that adding carbon
dioxide to a water bath increased blood flow in the immersed calf by 60%. Diji
and Greenfield (1960) later extended these observations to encompass the
peripheral effects of physiological levels of carbon dioxide. More recently, we
have shown that systemic hypercapnia elicits cutaneous vasodilation at levels
commonly encountered in patients with respiratory disease (Simmons et al.,
2007). However, these responses may have been dominated by the systemic
actions of hypercapnia rather than local vascular effects. Conversely, the
hypocapnia associated with hypoxia exposure has been shown to mediate both
arterial dilation and venous constriction in human limbs (Black & Roddie, 1958;
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Weil et a/., 1971). The degree to which hypercapnia or hypocapnia affects the
cutaneous vascular response to hypoxia remains unknown.
With the above information as a background, this study was designed
around three main goals. First, we sought to test the effect of changes in carbon
dioxide on the cutaneous vascular response to hypoxia. We hypothesized that
the magnitude of hypoxic vasodilation is directly related to the blood carbon
dioxide level (Le., hypo vs. hypercapnia). The second study aim was to
determine whether hypoxic vasodilation persists during whole body cooling. We
hypothesized that skin blood flow is upward shifted by hypoxia throughout the
duration of whole body cold exposure. Lastly we sought to determine if the rate
of fall in blood oxygen levels during exposure to hypoxia affects the magnitude of
vascular response in the skin. This last question was stimu~ated by pilot work in
our laboratory, which suggested that a greater vasodilation is obseNed if hypoxia
is induced over a short timecourse (a few minutes) rather than over ten minutes
or more. Therefore, we tested the hypothesis that rapid induction of hypoxia {in <
2 minutes) produces a greater cutaneous vascular response than progressive
hypoxic exposure.
Methods
This study was approved by the institutional review board of the University
of Oregon, and each subject gave written, informed consent before participation.
Subjects
Fourteen healthy, nonsmoking, normotensive subjects (7 men, 7 women),
age 23 ± 3 yr, participated in this study {height 178 ± 12 (SD) em, weight 75.5 ±
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19.5 kg, body mass index 23.6 ± 3.5 kg/m2]. Subjects were taking no
medications, except for oral contraceptives, and none had been to altitude
(>1,500 m) within 5 months. Women were studied either during the early
follicular phase (1-4 days after the onset of menstruation) of the menstrual cycle
or during the placebo phase of oral contraceptive use to minimize the potential
effects of female hormones on these responses. All female subjects had a
negative urine pregnancy test within 1 hour of participation.
Instrumentation and measurements
Experiments were performed in thermoneutral conditions with the subject
supine, wearing a whole body suit perfused with 34°C water, except during cold
stress. The water-perfused suit covered the entire body surface except for the
head, hands, feet, and forearm where measurement of vascular responses was
performed. After donning the water perfused suit, subjects were instrumented for
the measurement of heart rate via electrocardiography (Cardiocap/5, Datex-
Ohmeda, Madison, WI), ventilation via turbine pneumotach (VMM-400, lnterface
Associates, Laguna Niguel, CA), arterial pressure via brachial artery oscillometry
(Cardiocap/5) and photoplethysmography (Finometer, Finapres Medical Systems
BV, Arnhem, the Netherlands), arterial O2 saturation via pulse oximetry
(Cardiocap/5), and end-tidal P02 and PC02 via mass spectrometry (Marquette
MGA 1100, MA Tech Services, St. Louis, MO). lsocapnia/eucapnia was defined
as the mean end-tidal PC02 (nasal cannula) during a 5-minute period of quiet
breathing. To obtain an index of skin blood flow, cutaneous red blood cell flux
was measured on the ventral forearm by laser-Doppler flowmetry {DRT4, Moor
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Instruments, Devon, UK) with integrated laser-Doppler probes fixed to the skin
with adhesive tape. Skin blood flows were expressed as cutaneous vascular
conductance (red blood cell flux/mean arterial pressure) and normalized to
baseline values as described previously (Simmons et al., 2007).
Protocol
After instrumentation, subjects were familiarized with a custom built
breathing circuit equipped with scuba mouthpiece and nose clip. When subjects
were comfortable breathing from the mouthpiece, an initial cold stress was
performed while subjects breathed normoxic gas and isocapnia was maintained.
To induce cold stress, the water circulating. through the whole body suit was
cooled at a rate of 2°C min-1 from 34°C to 14°C during a 10 minute period. This
10 minute cooling period was preceded by 5 minutes of baseline data collection,
and subjects were removed from the breathing apparatus and re-warmed upon
completion of the cold stress. A resting period lasting 20 minutes followed this
initial cold stress. Pilot data was collected in three subjects to insure that the
cutaneous vascular response to 10 minutes of aggressive whole body cooling is
reproducible after 20 minutes. During these pi/at studies, cutaneous vascular
conductance decreased to 66 ± 5.7 % baseline and 69.5 ± 1.7 % baseline before
and after 20 minutes of supine rest (P = 0.563 for pre vs. post supine rest).
Following the first cold stress and 20 minute resting period, subjects were
exposed to systemic hypoxia 4 different times in random order, and each
exposure was separated by another 20 minutes of quiet supine rest. Pilot data
was also collected to insure that the cutaneous vascu~ar response to hypoxia is
50
reproducible after 20 minutes. During these pilot studies, arterial oxygen
saturation decreased to 80.5 ± 0.9 % and 82.7 ± 0.2 % and cutaneous vascular
conductance increased to 127.5 ± 1.7 % baseline and 129.3 ± 2.1 % baseline
before and after 20 minutes of supine rest (n = 2).
One of the 4 hypoxic exposures was designated as "rapid", during which
arterial O2 saturation was decreased to 80% within 2 minutes. This exposure
lasted 10 minutes and was preceded by 5 minutes of baseline data collection.
Carbon dioxide levels were not controlled during the rapid hypoxic exposure {Le.,
poikilocapnia). The other 3 hypoxic exposures were identical to one another with
the exception of how carbon dioxide levels were controlled. During the 3
identical hypoxic exposures, 5 minutes of baseline data was collected initially.
Hypoxia was then induced by decreasing the fraction of inspired oxygen (F102)
progressively over a 10 minute period. The rate of decrease in FI02 was
designed to produce a fall in arterial O2 saturation of - 2% min-1 down to 80%.
After the target level of hypoxia was reached, 5 minutes of steady state data
were recorded before a cold stress lasting 10 minutes was performed exactly like
the first. Subjects were re-warmed and allowed to breathe room air after whole
body cooling was complete. This hypoxic exposure (with cold stress) was
performed once while end-tidal PC02 was allowed to fall during hypoxia
(poikilocapnia), once while end-tidal PC02 was clamped at resting levels
(isocapnia), and once while end-tidal PC02 was elevated by 3 mmHg
(hypercapnia). All values were recorded continuously prior to and throughout
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each simulated environmental stress. The exception was brachial artery blood
pressure which was recorded every 5 minutes.
Control ofbreathing mixture
To achieve control of tidal gases, subjects breathed from a custom built
breathing circuit using a scuba mouthpiece and nose clip. The inspiratory
mixture provided at the mouthpiece originated from 3 gas tanks - air (20.93%
O2), nitrogen (100% N2), and carbon dioxide (100% C02) - connected to the
inspiratory line by flow regulators. The fraction of inspired oxygen (FI02) and
carbon dioxide (FIC02) were varied by adjusting the flowrate from each of the gas
tanks, and the inspired air was mixed as it filled a 6 liter tube which served as an
inspiratory reservoir. The 6 liter tube connected to the breathing circuit proximal
to the mouthpiece, and its distal end was open to room air. Total flowrate
through the breathing circuit was always greater than the subjects' minute
ventilation, and thus excess gas delivered through the inspiratory line escaped to
the room through the 6 liter tube. The mouthpiece consisted of two one-way
valves (Rudolph) to insure inspiration from the breathing circuit and expiration to
room air.
Data acquisition and analysis
Data were digitized with signal-processing software (WinDaq, Dataq
Instruments, Akron, OH) and analyzed off-line. All data (except brachial blood
pressures) were averaged over 2.5 minute intervals and analyzed with SAS
statistical software using PROC MIXED (SAS v9.1.3, SAS Institute, Cary, NC).
Because clear differences were apparent in the responses of males and females
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to hypoxia and cold stress, these two groups were separated for da.ta analysis.
Within sex, results were analyzed with a 2 way ANOVA testing for the effects of
time and condition.
Because changes in baseline skin blood flow can affect interpretation of
cutaneous vascular responses during cold stress (Hodges et al., 2007), we
expressed decreases in cutaneous vascular conductance during whole body
cooling in terms of the "absolute" change as well as the "relative" change. The
"absolute" decrease in cutaneous vascular conductance was defined as the
magnitude of drop during cold stress expressed as a function of normoxic,
isocapnic baseline values (recorded before hypoxic exposure). The "relative"
decrease in cutaneous vascular conductance was defined as the magnitude of
drop during cold stress ~xpressed as a function of steady state hypoxic values
recorded immediately prior to initiation of whole body cooling. In this way, any
effect of a baseline shift in cutaneous vascular conductance (during hypoxia) on
the interpretation of vasoconstrictor responses during cold stress should be
apparent in our results. Differences were considered statistically significant when
P < 0.05. All values are presented as means ± SE unless otherwise indicated.
Results
Effect of CO2 on responses to progressive hypoxia
Figure 1 shows cutaneous vascular and cardiorespiratory responses to
the three progressive hypoxia conditions in male subjects. As planned,
oxyhemoglobin saturation decreased to - 80% with only slight differences in the
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kinetics of this response between conditions (P < 0.001 for condition x time
interaction). End-tidal PC02 rose by - 2 mmHg during hypercapnic hypoxia and
fell by - 5 mmHg during poikilocapnic hypoxia, with only minimal changes from
pre-exposure baseline during isocapnic hypoxia (P < 0.001 for condition x time
interaction). Importantly, small decreases in end-tidal PC02 during isocapnic
hypoxia do not represent a deviation from eucapnic values, but rather from
slightly elevated values at baseline during mouthpiece breathing. Minute
ventilation and heart rate both increased the most during hypercapnic hypoxia,
while minute ventilation did not change during poikilocapnic hypoxia (condition x
time interaction: P < 0.001 for both minute ventilation and heart rate). Cutaneous
vascular conductance increased in all three conditions during progressive
hypoxia, with blood flow most consistently elevated during the isocapnic
condition (P =0.045 for condition main effect, P =0.063 for condition x time
interaction). Mean arterial pressure was increased by hypercapnic (88.6 ± 4.5
vs. 95.3 ± 4.8 mmHg; P =0.020) but unchanged by poikilocapnic (87.4 ± 3.9 vs.
90.9 ± 4.0 mmHg; P =0.150) and isocapnic hypoxia (89.2 ± 3.3 vs. 89.6 ± 4.3
mmHg; P =0.857; P =0.012 for condition x time interaction).
Figure 1. Cutaneous vascular and cardiorespiratory responses to progressive hypoxia in
male subjects. Triangles =poikilocapnic hypoxia, circles =isocapnic hypoxia, squares =
hypercapnic hypoxia. Values are means ± SE; n =7. Horizontal lines indicate time points
significantly different from time a (P < 0.05 for a poikilocapnic, b isocapnic, and C hypercapnic
hypoxia). t P < 0.05 for condition main effect; * P < 0.05 for condition x time interaction effect.
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Figure 2 shows cutaneous vascular and cardiorespiratory responses to
the three progressive hypoxia conditions in female subjects. Cardiorespiratory
responses were similar to those displayed in figure 1. However, cutaneous
vascular conductance was unchanged by progressive hypoxia during any of the
conditions (P =0.178, P =0.624, and P =0.941 vs. baseline for poikilocapnic,
isocapnic, and hypercapnic hypoxia).
Cutaneous vasoconstrictor responses during whole body cooling
Figure 3 shows cutaneous vascular responses to whole body cooling in
males (A) and females (8) during normoxia and poikilocapnic, isocapnic, and
hypercapnic hypoxia. In male subjects, the decline in cutaneous vascular
conductance during whole body cooling was upward shifted across all time points
in the isocapnic hypoxia condition (P < 0.05 vs. normoxia at all time points; P =
0.018 for condition main effect). However, during both poikilocapnic and
hypercapnic hypoxia, cutaneous vascular conductance was not significantly
different vs. normoxia at any point during the cold stress (all P> 0.05). In female
subjects, cutaneous vascular conductance during the cold stress was higher than
the normoxic condition in all three hypoxic conditions between minutes 5 and 7.5
(all P < 0.05), while this trend only remained through the end of the cold stress in
the poikilocapnic condition (P = 0.004 vs. normoxia; P < 0.001 for condition x
time interaction).
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Figure 2. Cutaneous vascular and cardiorespiratory responses to progressive hypoxia in
female subjects. Triangles = poikilocapnic hypoxia, circles = isocapnic hypoxia, squares =
hypercapnic hypoxia. Values are means ± SE; n =7. Horizontal lines indicate time points
significantly different from time a (P < 0.05 for a poikilocapnic, b isocapnic, and C hypercapnic
hypoxia). * P < 0.05 for condition x time interaction effect.
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Figure 3. Cutaneous vascular responses to whole body cooling during normoxia (open
circles) and poikilocapnic (triangles), isocapnic (filled circles), and hypercapnic (squares)
hypoxia. Responses from male subjects (A) are displayed on the top panel and female
responses (B) are displayed on the bottom panel. Values are means ± SE for 7 males and 7
females. Horizontal lines indicate time points significantly different from time 0 (P < 0.05 for a
poikilocapnic hypoxia, b isocapnic hypoxia, C hypercapnic hypoxia, and d normoxia). t P < 0.05
for condition main effect; * P < 0.05 for condition x time interaction effect.
Figure 4 displays the reduction in cutaneous vascular conductance in
response to cold stress during normoxic and hypoxic conditions in male (A) and
female (8) subjects. Responses during hypoxia are contrasted with those during
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normoxia, and are displayed as the "abso!ute" and "relative" change {see
methods). In men, cutaneous vascular conductance was reduced by - 25 - 30%
during cold stress with no differences between conditions (all P> 0.05). In
women, cutaneous vascular conductance was reduced by - 25 - 35% during
cold stress, except in the poikilocapnic condition when the magnitude of
vasoconstriction was reduced by approximately half (P =0.031 and P =0.023 vs.
normoxia for absolute and relative changes, respectively). Cardiorespiratory
responses during whole body cooling in each condition are displayed in table 1.
Rapid vs. progressive hypoxic exposure
Cutaneous vascular responses to rapidly induced poikilocapnic hypoxia
are contrasted with those to progressive poikilocapnic hypoxia in figure 5. The
mean time taken to achieve target oxyhemoglobin saturation (80%) was 105.6
seconds (min: 69 sec, max: 152 sec) during rapid hypoxia and 588.8 seconds
(min: 509 sec, max: 741 sec) during progressive hypoxia. In men, a sustained
elevation in cutaneous vascular conductance was observed after the induction of
rapid hypoxia (P =0.025 vs. baseline). However, the elevation in cutaneous
vascular conductance observed during the induction of progressive hypoxia (see
figure 1) was not sustained through 5 minutes of steady state measurement (P =
0.262 vs. baseline for final time point before cold stress). In women, cutaneous
vascular conductance was not significantly different from baseline after the
induction of rapid or progressive poikilocapnic hypoxia (P =0.934 and P =0.314
vs. baseline for rapid and progressive hypoxia, respectively). While only men
responded to hypoxia with vasodilation, the direction of the trends observed
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Figure 4. Vasoconstrictor responses to whole body cooling during hypoxia expressed as
a function of two different baselines. White bars = normoxia {Le., control), black bars =
poikilocapnic hypoxia, dark grey bars =isocapnic hypoxia, light grey bars =hypercapnic hypoxia.
Responses from male subjects (A) are displayed on the top panel and female responses (B) are
displayed on the bottom panel. Values are means ± SE for 7 males and 7 females. * indicates
significant reduction in eve during whole body cooling (P < 0.05). t P < 0.05 vs. control
response. See methods for definitions of "absolute" and "relative" change in eve.
Table 1. Cardiorespiratory responses to whole body cooling during normoxia and poikilocapnic, isocapnic, and hypercapnic
hypoxia. Values are means ± SE for 7 males and 7 females. * P < 0.05 vs. thermoneutral within sex and condition. a P < 0.05 vs. normoxia
within time and sex. b P < 0.05 VS. poikilocapnic hypoxia within time and sex. C P < 0.05 VS. isocapnic hypoxia within time and sex.
Normoxia Poikilocapnic hypoxia Isocapnic hypoxia Hypercapnic hypoxia
Thermoneutral Cold Thermoneutral Cold Thermoneutral Cold Thermoneutral Cold
End-tidal P02
(mmHg)
Men 101.3 ±0.8 108.7±1.4* 44.5 ±0.5' 46.8 ±0.7*' 45.6 ± 0.4' 46.8 ± 0.4' 47.1±0.4,b 46.7 ± 0.0'
Women 103.8 ± 1.0 108.0 ± 0.7* 47.6 ± 0.4' 48.1 ± 0.5' 47.9 ± 0.5' 48.7 ± 0.4' 51.0 ± 0.8,b 50.0 ± 0.4'
End-tidal Pco2
(mmHg)
38.3 ± O.4,b 38.4 ± O.4bMen 39.8 ± 0.3 39.2 ± 0.4 34.1 ± 0.6' 31.1 ± 1.2' 40.7 ± 0.5be 41.1±0.4,be
Women 38.9 ± 0.3 38.5 ± 0.3 34.3 ± 0.3' 32.9 ± 0.8' 38.6 ± 0.3b 38.9 ± 0.3b 41.5 ± O.4,be 41.6 ± O.4,be
Oxyhemoglobin
saturation (%)
Men 98.2 ± 0.2 98.6 ±0.2 79.4 ± 0.3' 82.3 ± 0.8*' 79.6 ±0.3' 80.7 ± 0.3' 81.1 ± 0.3' 80.6 ± 0.6'
Women 98.5 ± 0.2 98.7 ± 0.2 78.9 ± 0.2" 80.9 ± 0.2*' 79.3 ± 0.2' 80.5 ± 0.2*' 81.9 ± 0.4,be 82.1 ± 0.4'
Ventilation
(Umin)
26.57 ± 2.00,beMen 5.08±0.32 6.38 ± 0.34 7.11 ±0.43 11.47 ± 1.48' 9.90 ±0.95" 11.89 ± 1.15' 30.94 ± 2.1 O,be
Women 4.28 ±0.17 4.92 ± 0.22 5.24 ± 0.18 7.02 ± 0.74' 15.23 ± 1.41,b 19.06 ± 2.21,b 26.52 ± 2.06,be 29.10 ± 2.44,be
Heart rate
(beats/min)
Men 58.2 ± 1.4 54.3 ± 1.5* 66.0 ± 1.3 68.8 ± 1.2' 65.6 ± 2.0' 64.2 ± 1.5' 73.1 ± 1.2' 74.5 ± 1.7,e
Women 65.9 ± 1.8 63.6± 1.9* 77.3 ± 1.7' 75.4 ± 1.7' 85.2 ± 1.5,b 82.3 ± 1.2*' 89.4 ± 2.0,b 85.9± 1.9*'
Mean arterial
pressure (mmHg)
95.3 ±4.8,b 102.0 ± 6.5,beMen 86.3 ±4.4 89.4 ± 5.1 90.9 ± 4.0' 97.4 ± 6.4' 89.6 ±4.3 95.3 ± 6.1'
Women 81.7±2.1 88.3 ±2.5* 89.4 ± 3.0' 93.3 ± 3.0' 90.3 ± 3.3' 94.4 ± 3.6' 93.3 ± 3.1' 99.0 ± 3.4*,be
0>
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within sex between rapid and progressive hypoxic exposure were strikingly
similar (see figure 5). Therefore, data from both sexes were combined in order to
analyze the effect of rate of hypoxic exposure on the cutaneous vascular
response to steady state hypoxia. This analysis provided evidence for an
upward shift in cutaneous vascular conductance when the rate of fall in arterial
oxygen saturation was faster (P =0.059 for eve during rapid vs. progressive
hypoxia).
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Figure 5. Cutaneous vascular responses to rapid vs. progressive poikilocapnic hypoxia.
Values are means ± SE for 7 males and 7 females. * P < 0.05 vs. normoxia within condition and
sex.
Discussion
This study yielded several new findings. First, a change in blood carbon
dioxide does not impact the cutaneous vascular response to hypoxia in
thermoneutral conditions. Second, the magnitude of vasoconstriction elicited by
whole body cooling is not altered by hypoxia per se. An exception to this rule is
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the response in women when hypocapnia is concomitant with hypoxia. In this
group, the hypocapnia secondary to hypoxic hyperventilation reduces the
magnitude of cutaneous vasoconstriction by approximately 50%. The combined
results in both men and women indicate that hypoxic vasodilation generally
persists during whole body cold stress, even in skin that is not dilated by hypoxia
in thermoneutral conditions. Third, a faster reduction in blood oxygen levels
results in higher skin blood flow once steady state hypoxia is achieved. And
finally, men and women may exhibit different cutaneous vascular responses to
acute hypoxia (see below).
We have previously demonstrated that isocapnic hypoxia causes
vasodilation that is not restrained by sympathetically-mediated vasoconstriction
in non-acral skin (Simmons et a/., 2007). However, we are aware of no previous
studies addressing the role of hypocapnia in the cutaneous vascular response to
hypoxia. Therefore, we sought to test the effect of hypocapnia on the magnitude
of cutaneous vasodilation during hypoxia. We found that cutaneous vascular
responses to hypoxia were not altered by changes in carbon dioxide regulation
(poikilocapnic versus isocapnic hypoxia). This provides strong evidence that
cutaneous vascular responses recorded while breathing hypoxic gas mixtures
can be extrapolated to the high altitude setting.
At first glance it seems that the failure of hypercapnia to potentiate hypoxic
vasodilation in this study is at odds with previous research demonstrating the
vasodilator actions of carbon dioxide in the skin circulation (Stein & Weinstein,
1942; Diji & Greenfield, 1960; Simmons et a/., 2007). However, it is important to
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view these data in the context of the degree of hypercapnia imposed (- 2 - 3
mmHg above eucapnia). This hypercapnic stimulus was sufficient to increase
ventilation from 5.2 liters min-1 to 26.5 liters min-1 during equivalent hypoxic
exposures, likely due to the synergistic effect of combined hypoxia and
hypercapnia on peripheral chemoreflex activation (Somers et al., 1989).
However, the sensitivity of cutaneous blood vessels to carbon dioxide is probably
much less than that of peripheral chemoreceptors and therefore a much greater
hypercapni,c stimulus is necessary to affect these vessels. Previous studies
which demonstrated a local effect of carbon dioxide on skin blood flow used
either water baths at high CO2 concentrations (4 g of CO2 lite (1 ) or subcutaneous
injections of 12.5 - 100% CO2 gas (Stein & Weinstein, 1942; Diji & Greenfield,
1960). In addition, our previous work indicating that hypercapnia causes
sympathetically-mediated vasodilation used end-tidal PC02 values of 5 and 9
rnrnHg above eucapnia, and these responses were modest in magnitude
(Simmons et al., 2007). At these levels of hypercapnia, we were not able to
detect a local effect of C02 on cutaneous blood vessels. Taken together, these
data indicate that the lack of effect of hypercapnia on hypoxic cutaneous
vasodilation should not be viewed as evidence against the impact of CO2 on skin
blood flow, but likely resulted from the use of a hypercapnic stimulus too weak to
exert peripheral vascular effects in the cutaneous circulation.
In male subjects, we found that the magnitude of vasoconstriction during
whole body cooling was unaffected by either hypoxia or changes in carbon
dioxide. This resulted in an upward shift in skin blood flow throughout whole
----_.... _-------------
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body cooling during isocapnic hypoxia. However, the magnitude of this shift was
somewhat diminished by any change in carbon dioxide levels (hypercapnia or
hypocapnia). Nevertheless, the data indicate that hypoxia per 5e is responsible
for the upward shift in blood flow during cold stress in men, and this is consistent
with our earlier findings in thermoneutral conditions (Simmons et al., 2007).
These data also provide the first evidence that elevated skin temperature in men
exposed to cold stress at high altitude is the result of increased perfusion of the
skin (Cipriano & Goldman, 1975; Blatteis & Lutherer, 1976). Importantly, the
higher skin temperatures observed during combined hypoxia and cold stress
were associated with a faster fall in core temperature compared to normoxia
(Cipriano & Goldman, 1975). Taken together, these data suggest that hypoxic
vasodilation persists during cold exposure, and that this results in higher core-to-
skin heat transfer and ultimately greater core heat loss.
The cold-induced vasoconstrictor responses in women were different from
those observed in men in two important ways. First, the upward shift in skin
blood flow seen during the late stages of whole body cooling occurred despite a
lack of hypoxic vasodilation in thermoneutral conditions. In this case, differences
in skin blood flow between normoxic and hypoxic conditions only became
apparent during whole body cooling. The mechanism underlying this response
pattern is unclear. It may be that sympathetic vasoconstriction is affected in
some way in females so as to reduce the efficacy of vasoconstrictor transduction
when nerve firing frequency is above tonic levels. This would explain why
vasodilation was only seen once reflex vasoconstriction was stimulated. Along
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these lines, sympathetic vasoconstrictor nerves are known to release additional
neurotransmitters (Le., sympathetic cotransmitters) at higher firing frequencies
(Eckberg et al., 1988). Therefore, it may be that some additional substance
released from sympathetic vasoconstrictor nerves is affected by hypoxia in
women.
The second distinction between male and female vasoconstrictor
responses was that, in females, the development of hypocapnia was associated
with a 50% reduction in the magnitude of vasoconstriction during whole body
cooling. The comparison of this response to that observed during isocapnic
hypoxia suggests that this effect was mediated by hypocapnia. However, the
mechanism by which hypocapnia reduces cutaneous vasoconstriction is unclear.
The preponderance of evidence from animal literature indicates that hyperr;apnia
rather than hypocapnia reduces sympathetic vasoconstriction at the tissue level
(McGillivray-Anderson & Faber, 1990). Therefore, it is unlikely that this blunted
vasoconstrictor response in women is mediated through a peripheral effect of
decreased PC02. Another possibility is that sympathetic vasoconstrictor outflow
in response to cold stress is diminished by hypocapnia in women. During
hypoxia, males and females exrlibit similar activation of the sympathetic nervous
system, however, the effect of hypocapnia on these responses is poorly
understood (Jones et al., 1999). Thus, hypocapnia may selectively impact
central integration of sensory cold stimuli in women. More work in this area is
necessary to uncover the mechanisms responsible for blunted vasoconstriction
during hypocapnia in women.
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The lack of vasodilation in female subjects during hypoxia is seemingly at
odds with a previous study from our lab in which no sex differences were noted in
hypoxic vasodilator responses during isocapnic hypoxia (Simmons et al., 2007).
However, this may be explained by differences in study design and, more
specifically, between the effects examined during statistical analysis. For
example, our previous study was concerned with vascular responses to two
hypoxic conditions (85 and 80% Sa02), and there was a condition effect in the
current study as well (level of CO2). However, the additional effect in this study
(besides sex) in the initial 3 way ANOVA was time. This is contrasted with our
previous study in which drug site (bretylium versus saline) was the additional
effect in the 3 way ANOVA. The inclusion of this drug effect in the ANOVA
dictated that the statistical analysis be run on percent changes from baseline
during each condition, rather than perfusion values with respect to time. We
speculate that these differences in statistical analysis, which were dictated by the
study design, may explain why no sex differences were previously observed in
the cutaneous vascular response to hypoxia. We are aware of no other studies
which have examined this phenomenon.
There exists no standardized protocol for the induction of arterial
hypoxemia in the study of limb vasodilator responses in humans. A number of
laboratories perform such studies, but the method for hypoxic exposure varies.
Some investigators induce hypoxia by immediately switching the inspired gas
from air to 10 - 12% oxygen (Somers et al., 1989; Somers et al., 1991;
Leuenberger et al., 1999), while others gradually reduce the fraction of inspir.ed
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oxygen over 10- 15 minutes or more (Weisbrod et al., 2001; Dinenno et al.,
2003; Wilkins et al., 2006). Our laboratory has employed both of these
techniques in the past, and we have noted some evidence that more rapid
hypoxic exposure induces a greater vascular response. Therefore, in addition to
the three conditions separated by differing carbon dioxide regulation, subjects
were exposed to both rapid and progressive hypoxia in this study (both
poikilocapnic exposures). The results demonstrate that, although vasodilation
was only observed in male subjects during hypoxia, skin blood flow was upward
shifted by the faster rate of decline in 8a02 in both sexes. Combination of these
data sets (males and females) for analysis revealed that more rapid induction of
hypoxemia is associated with greater vasodilator responses.
Exposure to hypoxia alters resting skin blood flow and therefore has the
potential to confound interpretation of cutaneous vasoconstrictor responses when
expressed relative to baseline values (Hodges et al., 2007). To overcome this
potential limitation, we measured cutaneous vascular conductance continuously
throughout the transition between normoxic, hypoxic, and whole body cooling
conditions. Therefore, we were able to use values recorded during normoxia as
pseudo absolute units which were not subject to the effect of hypoxia on baseline
blood flow. When these values are used to express changes occurring during
hypoxia (e.g., during cold stress) they represent absolute units of change, even
though they are expressed as a percentage change (Le., from values measured
before hypoxia). Using this in addition to the conventional method of expressing
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changes during cold stress as a percentage of pre-cooling baseline, we showed
that this issue does not affect the interpretation of results from this study.
A limitation of this study is that arterial/tissue PCOz and pH were not
measured. Therefore, while we document large excursions in end-tidal PC02
during poikilocapnic hypoxia, and would expect subsequent alkalosis, we can
only speculate as to the magnitude of these changes at the tissue level.
In summary, we have shown that the cutaneous vascular response to
hypoxia is not affected by carbon dioxide, but may be affected by sex. A
heterogeneous sample of females studied during the early follicular phase of the
menstrual cycle (not controlled for oral contraceptive use) displayed no
vasodilation during hypoxia in thermoneutral conditions but maintained higher
skin blood flow during whole body cooling. This resulted in a characteristic
upward shift in skin blood flow during whole body cooling that occurred in both
sexes. The magnitude of cutaneous vasoconstriction during brief whole body
cooling was not affected by hypoxia, but was decreased 50% by hypocapnia in
women.
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Chapter IV entitled "Effect of CO2 regulation on the cutaneous vascular
response to hypoxia and mild cold stress" yielded several novel findings, two of
which were particularly germane to the study of thermoregulation at high altitude.
First, acute hypoxia caused an upward shift in skin blood flow during whole body
cooling. Second, hypocapnia reduced the magnitude of cutaneous
vasoconstriction during whole body cooling by 50% in women, while this
response was unaffected in men. Collectively, these data indicated that hypoxic
vasodilation persists during cold stress, and that reflex cutaneous
vasoconstriction may be selectively affected by hypocapnia in women. These
findings provided the basis for the study in Chapter VI. However, two pilot
studies were necessary in order to clarify the timecourse over which study drugs
need to be infused and to better characterize cutaneous non-noradrenergic
vasoconstriction so that the contribution of this alternate pathway to whole body
cooling responses during hypoxia could be studied. Therefore, in Chapter V
entitled "Lack of non-norad renergic cutaneous vasoconstriction during short
duration whole body cooling" we studied the timecourse over which yohimbine
and BIBP-3226 exert pharmacologic action on skin blood vessels and also
investigated the dependence of non-noradrenergic cutaneous vasoconstriction
on the duration of cold stress.
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CHAPTER V
LACK OF NON-NORADRENERGIC CUTANEOUS VASOCONSTRICTION
DURING SHORT DURATION WHOLE BODY COOLING
Introduction
Yohimbine is classically thought of as a selective a2-adrenergic receptor
antagonist, and this is the main pharmacological effect when administered
systemically. However, yohimbine can be delivered locally into the skin via
intradermal injection or microdialysis and this method allows the administration of
much higher concentrations of the drug in a small area of skin. At high local
concentrations (5mM), yohimbine acts as a non-selective blocker of a-adrenergic
receptors and abolishes the vasoconstrictor response to both norepinephrine and
phenylephrine (a1-receptor agonist) administration (Stephens et al., 2001).
Therefore, yohimbine has recently been used by numerous investigators to block
noradrenergic vasoconstriction in the skin (Stephens et al., 2001; Stephens et al.,
2002; Stephens et al., 2004; Thompson & Kenney, 2004).
While yohimbine has become increasingly common for use in studies of
cutaneous vascular regulation, the timecourse of drug delivery varies widely
between studies, ranging from 30 minutes to 75 minutes prior to protocol
initiation. However, some investigators have found that even 60 minutes of
continuous infusion is not sufficient to produce full blockade of sympathetic
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vasoconstriction with other adrenergic blocking agents (Simmons et a/., 2005).
Therefore, we felt it important to test the timecourse over which the antagonistic
properties of yohimbine develop.
BIBP-3226, a neuropeptide Y-Y1 receptor specific antagonist, has been
shown to block the non-noradrenergic component to reflex cutaneous
vasoconstriction during whole body cooling (Stephens et a/., 2004). For this
reason, we used BIBP-3226 in Chapters VI and VII at the same concentrations
used by Stephens et a/. (2004). The cost of this drug, coupled with the
unavailability of a specific neuropeptide Y-Y1 receptor agonist for human use and
the extremely high cost of neuropeptide Y for human use, effectively limited the
amount of pilot work performed with BIBP-3226 throughout these dissertation
studies. However, we included BIBP-3226 in this initial pilot study because only
one previous study used this drug in the skin during whole body cooling, and little
rationale was provided for the timecourse of drug delivery in that study.
The purpose of these pilot protocols was to better understand the
timecourse over which selective blockers of cutaneous vasoconstrictor pathways
exert their influence in the skin. A further goal was to test the hypothesis that
non-noradrenergic cutaneous vasoconstriction is activated at relatively lower skin
temperatures than noradrenergic vasoconstriction during whole body cooling in
humans.
Methods
This study was approved by the institutional review board of the University
of Oregon, and each subject gave written, informed consent before participation.
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Subjects
Nine healthy, nonsmoking, normotensive subjects {6 men, 3 women)
participated in this study. Subjects were taking no medications, except for oral
contraceptives, and none had been to altitude (>1,500 m) within 5 months.
Women were studied either during the early follicular phase of the menstrual
cycle or during the placebo phase of oral contraceptive use to minimize the
potential effects of female hormones on these responses. All female subjects
had a negative urine pregnancy test within 1 hour of participation.
Instrumentation and measurements
Experiments were performed in thermoneutral conditions except for
periods of cold stress, and subjects either wore a whole body water perfused suit
(protocol 1) or rested inside of a purpose built environmental chamber (Tescor,
Inc; protocol 2). When the subject arrived on the study day, three rnicrodialysis
fibers (model MD 2000, Bioanalytical Systems, West Lafayette, IN) with a
membrane length of 10 mm and molecular mass cutoff of 20 kDa «5 IJI dead
space) were placed in the skin of the ventral forearm. Fibers were placed by
inserting a 25-gauge needle through the dermis of the skin while the subject lay
in the supine position. The fiber was then threaded through the internal lumen of
the needle, and the needle was withdrawn, leaving the membrane in place. The
fiber was taped in place and perfused with lactated Ringer's solution at a rate of
4 IJI/min with a microinfusion pump (CMAl102, CMA Microdialysis, Stockholm,
Sweden). Sites were at least 5 cm apart.
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Immediately after microdialysis fiber insertion, subjects rested while the
local hyperemia subsided at each microdialysis site. To obtain an index of skin
blood flow, cutaneous red blood cell flux was measured over the microdialysis
sites by laser-Doppler f10wmetry (MoorLAB, Moor Instruments, Devon, UK) with
integrated laser-Doppler probes fixed to the skin with adhesive tape. Blood
pressure was monitored via brachial artery oscillometry, and skin blood flow was
expressed as cutaneous vascular conductance (red blood cell flux/mean arterial
pressure) and normalized to baseline values as described previously (Simmons
et al., 2007).
Protocol 1
The purpose of this protocol was to test the timecourse over which
yohimbine and BIBP-3226 develop full inhibition of their respective receptor
targets in the skin. The original design of this protocol called for serial infusions
of norepinephrine and [D-Arg25]_NPY to selectively stimulate a-adrenergic
receptors and neuropeptide Y-Y1 receptors, respectively. The hypothesis was
that vasoconstrictor responses to these agents would eventually be abolished
when their receptor blockers (yohimbine and BIBP-3226) built up sufficient local
concentration to competitively inhibit ligand binding. However, as mentioned
above, there is currently no selective neuropeptide Y-Y1 receptor agonist
(including [D-Arg25]-NPY) available for use in humans. Therefore, we tested
cutaneous vascular responses to repeated cold stresses in skin sites treated with
yohimbine and BIBIP-3226. Our rational was that as each drug began to inhibit
the ligand binding of its target receptor(s), the magnitude of vasoconstriction
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would be reduced over time until a plateau was reached, and the timepoint at
which this plateau was reached would represent the amount of time necessary to
administer the drug before full blockade is achieved.
Six subjects participated in protocol 1. After resolution of the local
hyperemia (-1.5 h), skin blood flow was monitored for 5 minutes in resting
conditions. Subjects were supine for the entire protocol. Once baseline skin
blood flow was recorded, one microdialysis site was perfused with 5mM
yohimbine (Sigma, St. Louis, MO) in lactated Ringer's solution for the purpose of
a-adrenergic blockade. A second site was perfused with the neuropeptide Y Y1-
receptor antagonist BIBP-3226 (10.5~M; Sigma, St. Louis, MO) in lactated
Ringer's, and this concentration was based on previous studies (Stephens et a/.,
2004). The third microdialysis fiber received only lactated Ringer's solution and
was designated a control site.
After the initiation of drug infusions, the remainder of the protocol occurred
in continuous 30 minute intervals. During the first 20 minute stage of each
interval (thermoneutral conditions), 34°C water circulated through the water
perfused suit. During the last 10 minutes of each interval, 10°C water was
circulated through the suit to induce cold stress. A total of five 30 minute
intervals were conducted, resulting in each subject being exposed to 5 cold
stresses. Earlier pilot data indicated that cutaneous vascular responses to 10
minutes of cold stress were reproducible after 20 minutes of rest in thermoneutral
conditions (see Chapter IV). The results of protocol 1 indicated that yohimbine
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treatment blocked all of the vasoconstrictor response to whole body cold stress,
and this led to the design of protocol 2.
Protoco/2
Because no vasoconstriction was observed in the skin sites treated with
yohimbine in protocol 1, protocol 2 was designed to (1) confirm that our failure to
demonstrate non-noradrenergic cutaneous vasoconstriction was not due to the
exclusion of propranolol from that protocol, and (2) to test the hypothesis that
non-noradrenergic cutaneous vasoconstriction during whole body cooling is
related to the severity of the cold stimulus.
Three men participated in protocol 2, and each lay supine in a
temperature controlled environmental chamber (28.5°C) wearing only shorts.
After resolution of the local hyperemia associated with microdialysis fiber
insertion (-1.5 h), one site was perfused with 5mM yohimbine in lactated Ringer's
solution for the purpose of a-adrenergic blockade. A second site was perfused
with yohimbine (5mM) and propranolol (1 mM; Sigma, S1. Louis, MO) for the
purpose of combined a- and 13- adrenergic blockade. The third microdialysis fiber
received only lactated Ringer's solution and was designated a control site. Study
drugs were infused for 60-75 minutes prior to beginning the protocol on the basis
of our pilot work with propranolol. During this time, 4 thermocouples were placed
over the skin for the continuous measurement of weighted mean skin
temperature (Sawka & Wenger, 1988).
Once study drugs had been infused for £0-75 minutes, baseline skin blood
flow and skin temperature were recorded for 5 minutes. Subjects were then
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exposed to a progressive cold stress by decreasing the ambient temperature
from 28.5°C to 15°C over 30 minutes. Blood pressure was monitored every 3
minutes during this period, and local skin temperature was clamped at 33°C.
Data acquisition and analysis
Data were digitized with signal-processing software (WinDaq, Dataq
Instruments, Akron, OH) and analyzed off-line. In protocol 1, cutaneous vascular
responses at every site were first analyzed to determine if vasoconstriction
occurred during each cold stress. Next, vasoconstrictor responses were
analyzed with a two way repeated measures ANOVA to test the effects of drug
treatment and time (cold stresses 1 - 5). In protocol 2, means for cutaneous
vascular conductance are presented but these data were not analyzed
statistically because only 3 subjects were tested. Statistical analyses were
performed with SAS statistical software using PROC MIXED (SAS v9.1.3, SAS
Institute, Cary, NC). Differences were considered significant when P < 0.05. All
values are presented as means ± SE, unless otherwise indicated.
Results
Protocol 1
During each whole body cold stress, cutaneous vascular conductance was
consistently reduced in both the control site and the site receiving BIBP-3226 (all
P < 0.05 vs. baseline for both sites), and the magnitude of this reduction was not
different between sites (all P> 0.05). In the yohimbine site, cutaneous vascular
conductance was unchanged by cold stress at any time during the study (all P>
0.05 vs. baseline). In addition, vasoconstrictor response magnitude was
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unchanged by time {i.e., cold stresses 1 - 5) in any of the skin sites (all P> 0.05
within site; P =0.202 for main effect of time). These data have been summarized
in figure 6, with responses averaged over the first and second hour of the
protocol.
Figure 6. Average cutaneous vasoconstrictor responses to 10 minutes of whole body
cooling in skin sites treated with lactated ringers, yohimbine, or BIBP-3226. Averages
represent two vasoconstrictor responses, which were measured every 20 minutes. * P < 0.05 vs.
baseline for vasoconstrictor responses measured during that hour. See text for details; n = 6.
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Protoco/2
In protocol 2 the 30 minute reduction in ambient temperature caused a fall
in weighted mean skin temperature from 32.1 °C to 28.3°C. As a result,
cutaneous vascular conductance fell to 59.6%, 90.5%, and 85.4% of baseline in
control, yohimbine, and combination yohimbine + propranolol treated sites. The
responses in yohimbine and combination yohimbine + propranolol sites were
both reduced in magnitude and shifted to lower skin temperatures compared to
control responses (see figure 7).
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Figure 7. Cutaneous vascular responses to a progressive reduction in ambient
temperature measured in sites treated with yohimbine (5mM), combinded yohimbine
(5mM) + propranolol (1 mM), and lactated ringers (control). Ambient temperature was
reduced from 28.S·C to 1S.5"C over 30 minutes. Data are means from 3 sUbjects.
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Discussion
These pilot studies yielded several new findings. First, the action of
yohimbine on a-adrenergic receptors is very fast when administered at 5mM via
microdialysis (within 30 minutes). Second, there appears to be no residual
vasoconstriction during ten minutes of whole body cooling when a-adrenergic
receptors are blocked. However, when cold stress is prolonged, non-
noradrenergic vasoconstriction is activated and a reduction in skin blood flow is
observed in skin where a-adrenergic receptors are blocked. This response
appears to occur at lower skin temperatures than noradrenergic vasoconstriction.
Finally, any effect of propranolol treatment on cutaneous vasoconstrictor
responses during a-receptor blockade is small and unlikely to explain the lack of
non-noradrenergic cutaneous vasoconstriction observed during ten minutes of
whole body cooling in protocol 1.
Yohimbine (5mM) delivered via cutaneous microdialysis abolished all of
the vasoconstrictor response to whole body cooling in protocol 1. These results
are seemingly at odds with numerous previous studies which demonstrated
persistent vasoconstrictor responses in skin sites treated with comparable
yohimbine concentrations (Stephens et al., 2001; Stephens et al., 2002;
Stephens et al., 2004; Thompson & Kenney, 2004). However, it appears that this
discrepancy can be explained by the length of cold exposure used in these
different studies. In protocol 1, whole body cooling was performed for ten
minutes at a time so that multiple cold exposures could be performed during the
150 minute protocol. Each of these cold exposures was performed by reducing
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the temperature of water circulating through the water perfused suit to 10°C, and
this is similar to the magnitude of cold stress used in other studies. However, the
duration of cold stress used in previous studies was longer, lasting 15 minutes to
45 minutes (Stephens et al., 2001; Thompson & Kenney, 2004). Therefore,
because skin temperature continues to fall when exposed to a constant ambient
temperature below skin temperature (Grant H. Simmons, unpublished
observations), it is likely that the fall in skin temperature in these previous studies
was greater than in protocol 1. This would result in a greater input to the
thermoregulatory centers in the hypothalamus during such a cold stress because
the reflex cutaneous vasoconstriction is driven entirely through changes in skin
temperature (core temperature does not change). Therefore, it is possible that
the lack of non-noradrenergic cutaneous vasoconstriction observed in protocol 1
resulted from the use of a weaker cold stimulus than previous studies.
The mechanism by which non-noradrenergic cutaneous vasoconstriction
is sensitive to the magnitude of cold stress is unclear. However, there is
considerable evidence to suggest that the release of cotransmitters from
sympathetic vasoconstrictor nerves is related to the frequency andlor burst
characteristics when these nerves are activated. For example, Eckberg et a/.
(1988) demonstrated that release of neuropeptide Y into plasma is correlated
with the increase in sympathetic nerve activity during experimental changes in
blood pressure in humans. Importantly, neuropeptide Y is thought to be the most
likely candidate for a sympathetic cotransmitter mediating non-noradrenergic
cutaneous vasoconstriction (Stephens et al., 2004). In the dog gracilis muscle,
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neuropeptide Y is only released into the venous circulation at high rates of
experimental nerve stimulation, whereas norepinephrine is released over a
broader range including low level stimulation (Pernow et al., 1989b). Taken
together, these studies suggest that neuropeptide Y is released from sympathetic
nerves only when the frequency of nerve firing is raised above some threshold
level. Therefore, the observation of non-noradrenergic cutaneous
vasoconstriction in previous studies using a greater magnitude of cold stress
could be explained by the generation of stronger afferent input to the
hypothalamus and a larger subsequent efferent response, manifesting in greater
activation of sympathetic vasoconstrictor nerves and the release of
cotransmitters with norepinephrine.
In order to test this hypothesis, protocol 2 was performed to study the
occurrence of non-noradrenergic cutaneous vasoconstriction as a function of
mean skin temperature during more prolonged cold exposure. In agreement with
our hypothesis, non-noradrenergic vasoconstriction was absent during the first
half of the 3D minute cooling period and over the range of skin temperatures
likely induced during protocol 1. However, figure 7 shows a clear inflection at a
mean skin temperature of - 3D.5°C after which skin blood flow falls steadily in
sites where a-adrenergic receptors were blocked. These data provide strong
support for the idea that non-noradrenergic cutaneous vasoconstriction is absent
during mild cold exposure, but becomes activated as the increase in sympathetic
outflow is more pronounced (Le., at lower skin temperatures).
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There is some evidence to suggest that functional ~-adrenergic receptors
exist in the cutaneous microcirculation and playa small but potentially important
role in modulating vasoconstriction during whole body cooling (Crandall et al.,
1997; Stephens et al., 2001). For example, Stephens et al. (2001) demonstrated
that when a-adrenergic receptors were blocked with intradermal injection of
yohimbine, transient vasodilation was seen in a small percentage of subjects
(20%) during whole body cooling. When propranolol treatment was included with
yohimbine to block both a- and 13- adrenergic receptors the percentage of
subjects displaying transient vasodilation during cold stress was reduced to 14%,
but fewer total subjects were tested. Finally, when these investigators compared
the effect of propranolol treatment and saline on vasoconstrictor responses
during cold stress, no effect of propranolol was demonstrated on the magnitude
of cutaneous vasoconstriction. Taken together, these data suggest that sparsely
distributed ~-adrenergic receptors can be activated during whole body cooling,
but that any effects on cutaneous vasoconstrictor responses are likely to be small
and relatively uncommon in the population. Nevertheless, we tested the
possibility that non-noradrenergic cutaneous vasoconstriction was masked by
superimposed ~-adrenergic vasodilation in protocol 1. We found that the
inclusion of propranolol with yohimbine in protocol 2 did not profoundly alter the
timecourse or magnitude of non-noradrenergic cutaneous vasoconstriction during
prolonged whole body cooling. This suggests that the lack of non-noradrenergic
cutaneous vasoconstriction in protocol 1 was not due to f3-adrenergic
vasodilation overriding the cotransmitter-mediated vasoconstrictor signal.
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Perspectives
The current results support the notion that brief cold exposure activates
reflex cutaneous vasoconstriction that is entirely mediated by noradrenergic
pathways. Interestingly, the brief cold exposures in protocol 1 (10 minutes) were
similar to those used in our previous study of cutaneous vasoconstriction during
hypoxia (see chapter IV). One difference, however, was that water perfused suit
temperature was ramped down to 10·C in the current study whereas it was
decreased gradually (to 14·C) in our previous investigation. Therefore, the cold
exposure in the current study was in fact more aggressive, which further supports
the idea that reflex vasoconstrictor responses in our previous investigation were
mediated solely through noradrenergic pathways.
In summary, these studies provide strong evidence that non-noradrenergic
cutaneous vasoconstriction is selectively activated at lower skin temperatures
during more prolonged cold exposure. In addition, these data support the notion
that cutaneous vasoconstriction during a brief ten minute cold exposures is
mediated entirely through noradrenergic pathways.
---------_. --------
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The main findings from Chapter V entitled "Lack of non-noradrenergic
cutaneous vasoconstriction during short duration whole body cooling" were that
(1) blockade of a-adrenergic receptors with yohimbine completely abolished
reflex cutaneous vasoconstriction during a ten minute cold stress, and that (2)
during more prolonged cold exposure, non-noradrenergic cutaneous
vasoconstriction was absent at higher skin temperatures but was activated when
lower skin temperatures were reached (during more prolonged cooling). These
results suggest that cutaneous vasoconstriction during brief cold exposure is
mediated entirely through adrenergic pathways. Thus, inasmuch as Chapter VI
entitled "Increased contribution from non-noradrenergic cutaneous
vasoconstriction abolishes hypoxic vasodilation during prolonged cold stress"
was designed to investigate both noradrenergic and non-noradrenergic
cutaneous vasoconstrictor pathways during combined hypoxia and cold
exposure, a 30 minute cold exposure was used in this chapter. An additional
goal of Chapter VI was to test the contribution of blunted cutaneous
vasoconstriction to the decline in core body temperature during severe cold
exposure in hypoxia.
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CHAPTER VI
INCREASED CONTRIBUTION FROM NON-NORADRENERGIC CUTANEOUS
VASOCONSTRICTION ABOLISHES HYPOXIC VASODILATION DURING
PROLONGED COLD STRESS
Introduction
When humans undergo cold stress in low oxygen environments the
normal decline in skin temperature is upward shifted - even abolished -
suggesting less effective redistribution of blood away from the periphery
(Cipriano & Goldman, 1975; Blatteis & Lutherer, 1976). We have recently shown
that skin blood flow remains elevated in this setting, confirming the role of
cutaneous vasodilation in the associated redistribution of body temperature (see
Chapter IV). However, it is unclear how individual vasoconstrictor pathways are
affected to bring about this net shift in cutaneous perfusion during combined
hypoxia and cold stress.
The reduction in skin blood flow during whole body cooling is regulated by
cutaneous sympathetic adrenergic nerves, as demonstrated by the sensitivity of
this response to bretylium treatment (Kellogg et al., 1989; Thompson & Kenney,
2004). As ambient temperature decreases, the activity of cutaneous adrenergic
nerves increases causing the release of norepinephrine and sympathetic
cotransmitters. The binding of norepinephrine to post-junctional a-adrenergic
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receptors (predominantly Q2-receptors) causes vasoconstriction, and this
mechanism is responsible for approximately 60% of the reduction in skin blood
flow during cold stress (Stephens et a/., 2001; Thompson & Kenney, 2004). The
remaining -40% of the cold induced vasoconstriction is mediated by adrenergic
nerve cotransmission, and recent evidence has implicated neuropeptide Y acting
through post-junctional neuropeptide Y Y1-receptors in this response (Stephens
et a/., 2004).
When humans are exposed to cold temperatures at high altitude, the rate
of core cooling is accelerated, and lower core temperatures are reached
compared to sea level conditions (Cipriano & Goldman, 1975; Johnston et a/.,
1996). One mechanism suggested to account for this disparity is the increase in
respiratory heat loss associated with hypoxic hyperventilation. However,
Johnston et a/. (1996) calculated that the increase in heat loss due to hypoxic
hyperventilation (- 11.5 kcal/hr) would explain less than 40% of the increased
core cooling rate observed in their study. Furthermore, those data were collected
during a hypoxic exposure in which carbon dioxide was added to the breathing
mixture to prevent the development of hypocapnia. Therefore, total ventilation
and respiratory heat loss were likely greater in that study than would occur in the
high altitude setting (see Chapter IV).
Cipriano and Goldman (1975) suggested the maintenance of higher
peripheral blood flow could explain increased core cooling during hypoxia
through a blunted reduction in core-to-skin heat transfer. Our recent
demonstration that cutaneous vasodilation persists during whole body cooling in
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hypoxic conditions supports this idea (see Chapter IV). However, the cold
exposure in that study lasted only ten minutes and was not sufficient to alter core
body temperature. One difficulty in studying skin blood flow during induced core
cooling is that the shivering associated with such extreme cold exposure
obscures cutaneous vascular measurements. To overcome this problem, we
designed a two phase protocol to investigate the relationship between cutaneous
vascular responses to progressive cooling and core temperature responses to
extreme cooling during normoxic and hypoxic conditions.
This study was designed to accomplish two main goals. The first was to
test the effect of hypoxia on the noradrenergic and non-noradrenerg'ic
components of cutaneous vasoconstriction during progressive ,cold stress, and
the second was to assess whether persistent vasodilation during cold stress
contributes to more rapid core cooling in hypoxic conditions. We tested the
hypothesis that the increase in core cooling rate during hypoxia is directly related
to the upward shift in skin blood flow during whole body cooling.
Methods
This study was approved by the institutional review board of the University
of Oregon, and each subject gave written, informed consent before participation.
Subjects
Thirteen healthy, nonsmoking, normotensive subjects participated in this
study. However, one subject was unable to tolerate the entire experimental
procedure, and withdrew from the study voluntarily. Therefore, 12 subjects (6
men, 6 women), age22 ± 3 yr, completed the study. Subject anthropometric
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characteristics were as follows: height 172 ± 12 (SO) em, weight 63.4 ± 9.7 kg,
body mass index 21.4 ± 1.3 kg/m2, sLIm of 4 skin folds 46.6 ± 15.4 mm {Durnin &
Womersley, 1974). Subjects were taking no medications, except for women who
were taking oral contraceptives, and none had been to altitude (>1,500 m) within
5 months. Because non-noradrenergic cutaneous vasoconstriction occurs in
women during the high hormone phase of oral contraceptive use, but not the low
hormone (placebo) phase, women in this study were tested during the high
hormone phase of oral contraceptive use (Stephens et al., 2002). As an extra
precaution, all female subjects had a negative urine pregnancy test within 1 hour
of participation.
Experimental procedures
Experiments were performed in a temperature controlled laboratory with
the ambient temperature maintained at 25°C (average: 25.0 ±G.re). Subjects
visited the laboratory on three separate days, the first of which was an initial
interview. During this initial visit, anthropometric data were obtained and
subjects were familiarized with the laboratory and all experimental procedures.
The following two laboratory visits were identical except that one day involved
exposure to simulated high altitude and the other was a sham exposure in which
the subject breathed room air from the breathing circuit. The two experimental
days were performed in random order, and each took place at the same time of
day because cutaneous vasoconstrictor responses to whole body cooling are
altered by time of day (Aoki et al., 2003).
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The two experiments were performed at least 72 hours apart. Men were
instructed to wear swimming shorts, while women wore either soccer shorts with
a sports bra or a two piece swim suit. In addition, each subject was given two
ingestible pills for the measurement of core temperature (HQlnc, Palmetto, FL)
and instructed to take one the night before each study. When the subject arrived
on each study day, they immediately changed and lay in the supine position.
After the application of ice to the ventral forearm, three microdialysis fibers
(model MD 2000, Bioanalytical Systems, West Lafayette, IN) with a membrane
length of 10 mm and molecular mass cutoff of 20 kDa «5 ~l dead space) were
placed in the skin of the numbed area. Fibers were placed by inserting a 25-
gauge needle through the dermis of the skin while the subject lay in the supine
position. The fiber was then threaded through the internal lumen of the needle,
and the needle was withdrawn, leaving the membrane in place. The fiber was
taped in place and perfused with lactated Ringer's solution at a rate of 4 ~I/min
with a microinfusion pump (CMA/102, CMA Microdialysis, Stockholm, Sweden).
Sites were at least 5 em apart.
With microdialysis fiber secured in place, subjects rested in the supine
position while the local hyperemia subsided at each rnicrodialysis site and study
drugs were prepared. After 70 to 90 minutes, one microdialysis site was
perfused with 5mM yohimbine + 1mM propranolol (Sigma, St. Louis, MO) in
lactated Ringer's solution for the purpose of a- and 13- adrenergic blockade.
Although yohimbine has traditionally been thought of as an a2-adrenergic
receptor antagonist, numerous recent studies have demonstrated that at high
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concentrations yohimbine (5mM) produces non-specific blockade of both Q1- and
Q2-adrenergic receptors in human skin (Stephens et al., 2001; Thompson &
Kenney, 2004). Pilot work in our lab has confirmed this dose (see Chapter V),
and the time course of drug delivery in this protocol was based on pilot work with
propranolol performed in our laboratory. A second site was perfused with the
neuropeptide Y Y1-receptor antagonist BIBP-3226 (1 0.5~M) + 1mM propranolol
(Sigma, St. Louis, MO) in lactated Ringer's. This concentration of BIBP-3226
abolishes the non-noradrenergic component of reflex cutaneous vasoconstriction
during whole body cooling in humans (Stephens et al., 2004). The third
rnicrodialysis fiber received only 1rnM propranolol in lactated Ringer's solution
and was designated a control site. This study design aimed to produce one skin
site in which vasoconstrictor function was normal, one site in which only
noradrenergic vasoconstriction was functional, and one site which isolated non-
noradrenergic cutaneous vasoconstriction (presumably mediated through
neuropeptide Y Y1-receptors).
After 60 - 75 minutes of continuous study drug infusion, subjects were
allowed to use the restroom and were instrumented for the measurement of heart
rate via electrocardiography (Cardiocap/5, Datex-Ohmeda, Madison, WI) and
mean skin temperature via thermocouples placed on the head, chest, upper arm,
forearm, abdomen, thigh, and calf (Sawka & Wenger, 1988). Once EKG and
thermocouples were placed, subjects were helped into a custom modified jacuzzi
bathtub in which they sat semi-recumbent, and rested their arms on machine
fabricated arm rests positioned out of the water and at heart level. The water
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level in the tub was adjusted so that the subject was submerged to the level of
the sternum. Once in the tub and comfortable, subjects were instrumented for
the measurement of arterial pressure via brachial artery oscillometry
(Cardiocap/5) and arterial O2 saturation via pulse oximetry (Cardiocap/5).
Constant rate infusion of study drugs was continued as soon as the subject was
seated in the tub. To obtain an index of skin blood flow, cutaneous red blood cell
flux was measured on the ventral forearm by laser-Doppler flowmetry (MoorLAB,
Moor Instruments, Devon, UK) with integrated laser-Doppler probes placed over
the microdialysis sites. Skin blood flow was expressed as cutaneous vascular
conductance (red blood cell flux/mean arterial pressure) and normalized to
baseline values as described previously (Simmons ef a/., 2007). Laser-Doppler
flow probes were housed in local skin heaters (Moor Instruments, Devon, UK),
and these local heaters were set to maintain a constant skin temperature of 33°C
throughout the protocol.
When the subject was comfortable in the tub, head gear was donned
which secured a mouthpiece connected to inspiratory and expiratory tubes. The
mouthpiece apparatus incorporated a one-way, non-rebreathing valve system to
insure inspiration and expiration from separate tubes. A nose clip was placed to
prevent nasal breathing, and a gas sampling line connected to the mouthpiece
for monitoring of end-tidal P02 and PC02 (Cardiocap/5, Datex-Ohmeda, Madison,
WI). The inspiratory mixture provided at the mouthpiece originated from 2 gas
tanks - air (20.93% O2) and nitrogen (100% N2) -connected to the inspiratory
line by flow regulators. The fraction of inspired oxygen (FI02) was varied by
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adjusting the flowrate from each of the gas tanks, and the inspired air was first
humidified and then mixed as it filled a 6 liter tube which served as an inspiratory
reservoir. The 6 liter tube connected to the breathing circuit proximal to the
mouthpiece, and its distal end was open to room air. Total flowrate through the
breathing circuit was always greater than the subjects' minute ventilation, and
thus excess gas delivered through the inspiratory line escaped to the room
through the 6 liter tube. Expired gas was collected and the fraction of expired
oxygen (FE02), carbon dioxide (FEC02), and minute ventilation were measured
via a pneumotach and mixing chamber (Parvomedics, Sandy, UT) integrated with
a mass spectrometry system (Marquette MGA 1100, MA Tech Services, St.
Louis, MO). These data were combined with inspiratory values (FI02 and FIC02)
from the tidal O2and CO2tracing to calculate whole body O2uptake on a minute
by minute basis. Shivering onset was determined from the O2 uptake data as
described by others (Johnston et al., 1996).
Protocol
The purpose of this study was two fold. First, this study was designed to
probe the effects of simulated high altitude exposure on ,cutaneous reflex
vasoconstrictor mechanisms during progressive cooling. Second, the functional
importance of a previously observed upward shift in skin blood flow during
combined whole body cooling and hypoxia was investigated. Toward this end,
subjects underwent two identical study visits, one in which simulated high altitude
exposure was induced and one which simulated sea level conditions. The
experimental protocol is depicted in figure 8.
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Figure 8. Schematic representation of chapter VI experimental protocol. Experiments took
place on two study days, one in which normoxia was maintained (solid line at top) and one during
exposure to systemic hypoxia (dashed line at top). Alpha-adrenergic and neuropeptide Y (NPY)
receptor antagonists were infused continuously throughout the protocol.
The protocol began with 5 minutes of rest in a water temperature of 36°C,
during which baseline data values were recorded. Water temperature was
maintained by circulating the jacuzzi tub water through an extensive copper coil
(heat exchanger) submerged in a constant temperature water circulating bath
(Polyscience, Niles, IL). This system was used to heat the water above room
temperature (to 36°C), but was inactivated once cooling began because it lacked
the capacity to affect a change in water temperature over the desired time
course. Ice was added to the water bath in order to reduce the water
temperature during cooling. To maintain a homogeneous temperature within the
tub, water circulation continued during the cooling period, and the heat
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exchanger was simply removed from the constant temperature circulating bath.
Throughout the protocol, water temperature was measured by a thermocouple
placed 9 inches below the surface near the subject.
After baseline data were collected, subjects were exposed to either
poikilocapnic hypoxia (sImulated high altitude) or a sham gas mixture (normal air)
during a transition period lasting 5 minutes. Once the target level of hypoxia
(80% arterial 02 saturation) or sham (time control) was reached, steady state
data were recorded in this condition for 5 minutes. Immediately following steady
state data collection, the temperature of the water bath was progressively
reduced from 36°C to 23°C over a 30 minute period. This temperature and time
course was chosen because it typically produced maximal vasoconstriction in
pilot experiments without inducing uncontrollable shivering {obscuring vascular
measurements). All variables were recorded continuously during this period,
except core temperature and blood pressure which were recorded every 5
minutes. After 30 minutes of progressive cooling, water temperature was rapidly
reduced to 10°C by the addition of more ice to the water bath. This target water
temperature was reached within 7-10 minutes. Once water temperature was
steady at 10°C, a timer was started and subjects remained in the water bath until
either the timer reached 45 minutes or their internal temperature reached 35°C.
Core temperature was measured at 2 minute intervals during this period.
After termination of the cooling protocol, the subject was disconnected
from all measurement devices and helped out of the tub and into a climate
controlled environmental chamber (Tescor, Inc) maintained at 35°C and
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equipped with infrared radiant heat lamps. Subjects were immediately towel
dried, wrapped in a blanket, and laid in the supine position. Core temperature
was monitored and microdialysis fibers removed during this time. Once the
subject was comfortable and able to maintain a stable gait, they were given
access to a laboratory shower to finish the rewarming process.
Data acquisition and analysis
Data were digitized with signal-processing software (WinDaq, Dataq
Instruments, Akron, OH) and analyzed off-line. CutaneolJs vasodilator,
vasoconstrictor, and core temperature responses were first analyzed with a two
or three-way ANOVA (depending on whether drug site was a factor) to test the
effect of sex on these responses. There were no effects of sex in this protocol
(all P> 0.05). Thus data from men and women were pooled for all subsequent
analyses. Skin blood flow was not monitored during drug infusion in this protocol
because microdialysis instrumentation and initial drug infusions were not
performed in the jacuzzi bathtub, around which most of the necessary equipment
was built. However, we and others have shown that neither yohimbine nor BIBP-
3226 alters baseline skin blood flow at concentrations used in this study {see
chapter 5; (Stephens et al., 2004). Furthermore, each microdialysis fiber
received propranolol and thus any potential effect of propranolol on baseline skin
blood flow would be equally expressed in all skin sites. Statistical analyses were
performed with SAS statistical software using PROC MIXED (SAS v9.1.3, SAS
Institute, Cary, NC). Differences were considered significant when P < 0.05. All
values are presented as means ± SE, unless otherwise indicated.
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Results
Cardiorespiratory variables
Table 2 displays water bath temperature and cardiorespiratory responses
during the three thermal conditions on both experimental days. As planned,
water bath temperatures were not different between experimental days within
thermal condition. Heart rate was higher and oxyhemoglobin saturation was
lower at each timepoint on the hypoxia day (both P < 0.05 vs. normoxia day).
Mean arterial pressure was increased during progressive and severe cooling on
both experimental days (P < 0.05 vs. thermoneutral for both timepoints on both
days) while ventilation was only increased on the normoxic day (P < 0.05 vs.
thermoneutral for both timepoints). End-tidal PC02 fell slightly during severe
cooling on the hypoxia day (P =0.010 vs. thermoneutral) but was not different
from normoxia at any timepoint {all P> 0.05 vs. normoxia day).
Cutaneous vascular responses
Figure 9 displays cutaneous vascular conductance in propranolol only,
BIBP-3226 + propranolol, and yohimbine + propranolol treated sites measured
after 5 minutes of steady state hypoxia or sham exposure (control day).
Cutaneous vascular.conductance was increased in all sites during hypoxia
relative to air breathing (all P < 0.05), and this effect was greater i'n the site
treated with combined yohimbine + propranolol (P = 0.006 vs. control site).
BIBP-3226 had no effect on the cutaneous vascular response to hypoxia (P =
0.462 vs. control). During progressive cooling, cutaneous vascular conductance
in the control site was reduced to 54.2 ± 4.1 and 62.8 ± 5.9 % normoxic baseline
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Table 2. Cardiorespiratory responses to progressive and severe cold exposure during
normoxia and hypoxia. Values are means ± SE for 6 males and 6 females. * P < 0.05 vs.
thermoneutral, t P < 0.05 vs. progressive cooling, and :t: P < 0.05 vs. normoxia.
Thermoneutral Progressive cooling Severe cooling
Water temperature
(0G)
35.9 ± 0.2 23.4 ± 0.4* 9.9 ± 0.1*tNormoxia
Hypoxia 36.0 ± 0.1 23.4 ± 0.5* 10.2 ± 0.1*t
End-tidal Peo.
(mmHg)
35.7 ± 1.2Normoxia 36.0 ± 0.7 35.0 ± 0.9
Hypoxia 35.8 ± 0.7 35.2 ± 0.9 34.2 ± 0.7*
Oxyhemoglobin saturation
(%)
Normoxia 98.9 ± 0.2 98.8 ± 0.3 98.8 ±0.3
Hypoxia 81.3 ± 0.9:1: 83.3 ± 0.7*:1: 82.6 ± 0.5:1:
Ventilation
(Umin)
Normoxia 7.63 ± 0.41 8.78 ± 0.53* 8.75 ± 0.73*
Hypoxia 8.62 ± 0.50 8.91 ± 0.58 10.12 ± 1.19
Heart rate
(beats/min)
Normoxia 69.2 ± 3.8 61.1 ± 3.2* 62.9 ± 3.8*
Hypoxia 78.5 ±4.4:1: 72.2 ± 4.8:1: 73.4 ± 4.7:1:
Mean arterial pressure
(mmHg)
Normoxia 82.5± 1.4 92.2 ± 1.7* 93.5 ± 1.8*
Hypoxia 83.6 ± 2.7 93.2 ± 2.8* 95.2 ± 2.3*
on the normoxia and hypoxia days, respectively (P =0.177). In the BIBP-3226 +
propranolol treated site cutaneous vascular conductance was reduced to 55.1 ±
4.5 and 64.3 ± 8.1 % normoxic baseline on the normoxia and hypoxia days (P =
0.239), while cutaneous vascular conductance in the yohimbine + propranolol
site was reduced to 89.6 ± 6.6 and 114.9 ± 12.7 % normoxic baseline on the
normoxia and hypoxia days (P =0.034).
Figure 10 contrasts the magnitude of vasoconstriction in each skin site
during progressive cooling in normoxic and hypoxic conditions. Hypoxia caused
a similar increase in the magnitude of cutaneous vasoconstriction in control,
BIBP-3226 + propranolol, and yohimbine + propranolol treated sites (all P <
0.05). Neither normoxic nor hypoxic vasoconstrictor responses were affected by
BIBP 3226 + Propranolol Yohimbine + PropranololPropranolol only
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Figure 9. Cutaneous vascular responses to hypoxic exposure (experimental day) and
sham exposure (control day) during partial immersion in 36°C water (i.e., thermoneutral).
Values are means ± SE for 6 males and 6 females. * P < 0.05 VS. sham exposure; t P < 0.05 VS.
control site (propranolol only) within condition.
BIBP-3226 (P> 0.05 vs. control in both conditions). In contrast, yohimbine
treatment reduced the magnitude of vasoconstriction during both normoxic and
hypoxic conditions (P < 0.05 vs. control in both conditions).
Body temperature responses
Mean skin temperature (n =8) was not significantly altered by exposure to
hypoxia (34.9 ± 0.2 vs. 34.9 ± 0.2°C) or air breathing (34.5 ± 0.2 vs. 34.4 ± 0.2°C;
both- P > 0.05), but was reduce by progressive cooling to 29.7 ± 0.2 and 29.3 ±
0.2°C on hypoxia and sham days, respectively (both P> 0.05 vs. pre-cooling).
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Figure 10. Cutaneous vascular responses to 30 minutes of progressive water cooling in
normoxic (sham) and hypoxic conditions. Water temperature bathing the subject was
reduced from 36°C to 23°C with the addition of ice to the water bath. Values are means ± SE for
6 males and 6 females. * P < 0.05 YS. pre-cooling baseline; t P < 0.05 YS. sham exposure; t P <
0.05 YS. control site within condition.
There were no differences in mean skin temperature between hypoxia and
normoxia days at any time point (all P> 0.05 between conditions). Core body
temperature (n =12) also was not altered by exposure to hypoxia or air breathing
(both P> 0.05 vs. baseline). However, progressive cooling exerted differential
effects, increasing core body temperature from 37.29 ± 0.06 to 37.39 ± O.06°C
during normoxia (P = 0.004) but having no effect on the hypoxia day (37.35 ±
0.09 vs. 37.35 ± 0.11 °C; P =0.972, P:;: 0.009 for condition x time interaction).
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One of our study cessation criteria was a core temperature reading of
35·C during severe cold exposure (10·C water). This temperature was reached
in 3 of the 12 subjects who completed both study days, resulting in early
termination of the study. However, only one of these subjects reached this core
temperature on both study days, and the other two subjects only reached 35·C
on one of the study days. Therefore, core temperature data were analyzed by
calculating the core cooling rate, defined as the slope of the relation between
core temperature and time while the subject was immersed in 10·C water. In this
way, all 12 subjects were included in the analysis and differences between
hypoxic and normoxic cooling rates are not masked by similar final core
temperature readings in a subject who, for example, reached 35·C much faster
on one experimental day versus another. This analysis demonstrated that core
cooling rates during partial immersion were not different between normoxia and
hypoxia (P =0.511; see figure 11).
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Figure 11. Core temperature response during 45 minutes of partial immersion in water at
10°C. Cooling rates were determined from the slope of the core temperature - time relationship
beginning when water temperature reached 1DOC. Values are means ± SE for 6 men and 6
women.
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Figure 12 shows individual relationships between the effects of hypoxia on
cutaneous vasoconstriction and core cooling rate. Regression analysis of this
relationship yielded an ~ value of 0.163 (P =0.193; Le., - 16% of the change in
core cooling rate is explained by the effects of hypoxia vasoconstriction).
Therefore, it appears that changes in core cooling rate during hypoxia are not
related to the effects of hypoxia on cutaneous vasoconstriction.
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Figure 12. Scatter plot of individual data relating the effects of hypoxia on core cooling
rate and peak vasoconstriction. Positive values on x-axis represent an upward shift in peak
vasoconstriction during hypoxia. Positive values on y-axis represent slower core cooling during
hypoxia. Data are from 6 males and 6 females.
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Discussion
This study yielded several new findings. First, post-synaptic blockade of
a-adrenergic receptors increased the magnitude of cutaneous vasodilation during
hypoxia. Second, the magnitude of vasoconstriction during prolonged whole
body cooling was increased by hypoxia, and this was sufficient to abolish the
upward shift in skin blood flow that occurred in thermoneutral conditions. Third,
the increased vasoconstrictor response during hypoxia was present (and equal in
magnitude) when a-adrenergic vasoconstriction was blocked, suggesting a role
for non-noradrenergic cutaneous vasoconstriction in this response. And finally,
hypoxia did not affect resting core temperature or the rate of decline in core
temperature during 45 minutes of partial immersion in 10°C water. Furthermore,
analysis of individual responses demonstrated no relationship between the
effects of hypoxia on cutaneous vasoconstriction and core body cooling during
severe cold stress.
Traditionally the peripheral vascular response to systemic hypoxia has
been viewed as a competition between chemoreflex control, mediated primarily
through the sympathetic nervous system, and local vasodilator influences
(Heistad & Abboud, 1980; Rowell, 1986). Therefore, the net change in perfusion
observed during hypoxia represents the summation of two opposing vasoactive
processes: vasodilation mediated through locally produced and/or circulating
chemical mediators, and vasoconstriction mediated through the actions of
sympathetic vasoconstrictor nerves and/or circulating constrictor substances
(e.g., catecholamines, angiotensin II, etc). In forearm skin, previous work has
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shown that blockade of a-adrenergic receptors with phentolamine unmasks
greater vasodilation during acute hypoxia (Weisbrod et a/., 2001; Moradkhan et
a/., 2007). However, we have recently shown that pre-synaptic blockade of
sympathetic vasoconstrictor nerves does not affect the hypoxic response in the
same area of skin (Simmons et a/., 2007). From these combined observations, it
was suggested that a circulating catecholamine (epinephrine) may exert an
adrenergic vasoconstrictor influence in non-acral skin, and this was supported by
data showing elevated plasma epinephrine in previous studies which
documented the effects of post-synaptic a-adrenergic blockade (Weisbrod et a/.,
2001). Our current observations contribute further evidence to this concept, and
overcome previous concerns about the non-specific effects of phentolamine on
the cutaneous microcirculation (see discussion in Simmons et a/., 2007).
Importantly, the true test of this hypothesis awaits an investigation directed
specifically at this question in which the effects of pre- and post- synaptic
adrenergic blockade are tested in the same subjects, at the same time, and with
interstitial sampling of epinephrine during hypoxia.
We have previously shown that vasoconstrictor magnitude was
unchanged by hypoxia and that as a result skin blood flow was increased during
whole body cooling in the hypoxic setting (see Chapter IV). These results were
demonstrated during a ten minute cold stress, a response which our previous
data suggest is mediated entirely through noradrenergic mechanisms (see
Chapter V). However, hypoxic vasodilation was abolished in the current study
during a more prolonged cold exposure lasting 30 minutes. Moreover, the
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magnitude of increased vasoconstriction in the a-adrenergic blockade site was
sufficient to explain all of the net increase in vasoconstriction observed during
hypoxia. This conclusion is based on a comparison of vasoconstrictor responses
in control and a-adrenergic blocked sites. Importantly because these two sites
responded differently to hypoxia, it is possible that the difference in magnitude of
the hypoxic response limits our ability to draw conclusions through comparison of
response magnitudes. However, we feel that this comparison is justified for at
least three reasons. First, the cold responses are expressed in units measured
during normoxic baseline conditions. Therefore, the shift in cutaneous vascular
conductance during hypoxia - which was greater in the a-adrenergic blocked site
- did not influence the calculation of the magnitude of these responses. Second,
the difference in the responses between control and a-adrenergic blocked sites
was - 20% of baseline cutaneous vascular conductance, and we have previously
shown that a shift in baseline of this magnitude does not affect interpretation or
comparison of vasoconstrictor responses regardless of how they are calculated
(see Chapter IV). And third, we (see Chapter VII) and others (Stephens ef al.,
2004) have shown that yohimbine treatment does not alter baseline skin blood
flow in agreement with previous findings using other sympatholytic drugs
(Houghton ef al., 2006). Furthermore, any effect of propranolol on baseline
cutaneous vascular conductance would have been evenly distributed between
skin sites inasmuch as it was included in the control rnicrodialysis fiber as well.
Taken together, these factors suggest that comparison of the vasoconstrictor
responses between control and a-adrenergic blocked sites is warranted.
105
Therefore, we interpret these data as evidence that hypoxic vasodilation is
overcome by reflex vasoconstriction during prolonged cold stress such that no
upward shift in skin blood flow persists in this setting. The mechanism through
which this occurs is a selective increase in non-noradrenergic cutaneous
vasoconstriction.
The increase in non-noradrenergic cutaneous vasoconstriction during
hypoxia may be explained by central or peripheral mechanisms. For example, a
potentiation of the output from thermoregulatory centers would increase
sympathetic neural frequency leading to greater cotransmitter r€lease {Eckberg
et a/., 1988). Conversely, an increase in vascular responsiveness to sympathetic
cotransmitters could be stimulated by local hypoxia. Unfortunately, the present
data. can not distinguish between these potential mechanisms. However, we
believe that a local effect of hypoxia on non-noradrenergic cutaneous
vasoconstriction is the more likely explanation for these results for two r.easons.
First, a wide variety of species respond to low oxygen environments by
selectively regulating a lower body temperature, and this phenomenon appears
to be regulated centrally within the hypothalamus {Steiner & Branco, 2002).
Therefore, it is unlikely that subjects in this study would display the opposite
response and generate a larger efferent response to equivalent afferent input .(as
demonstrated by unchanged mean skin temperature in the two conditions). The
second reason which argues against a central mechanism regulating the
increased non-noradrenergic cutaneous vasoconstriction is that neuropeptide Y-
mediated vasoconstrictor responses in rats, stimulated peripherally by activation
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of the lumbar sympathetic chain (bypassing central integration), are robust to the
effects of hypoxia whereas a-adrenergic-mediated vasoconstriction is not (Coney
& Marshall, 2007). These data suggest that non-noradrenergic cutaneous
vasoconstriction is affected differently by hypoxia than noradrenergic
vasoconstriction, and support the idea that increased vasoconstriction during
cold stress in hypoxia is caused by a selective upregulation of vascular
responsiveness to sympathetic cotransmitters.
A main goal of this study was to evaluate the relationship between two
previously demonstrated phenomena which were thought to be related. One of
these phenomena was an upward shift in skin blood flow and the other was a
faster core cooling rate., both observed during acute hypoxia (see Chapter IV;
(Cipriano & Goldman, 1975; Johnston et al., 1996). Unexpectedly, neither of
these phenomena occurred on a consistent basis in this study as evidenced by
the group responses. However, we also analyzed individual relationships
between these two phenomena because a perfect correlation (~ = 1.00) could
exist between upward shifted skin blood flow and faster core cooling during cold
stress even if group means for both responses are not different between
normoxia and hypoxia. For example, if a straight line could be drawn through all
of the data points in figure 12, with half of the data points distributed in the upper
left quadrant and the other half in the bottom right quadrant, then this would
produce a scenario where a strong relationship exists but is masked by the
analysis of mean data. Nevertheless, analysis of the individual data, which
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represents the true test of our hypothesis, indicate that changes in core cooling
rate during hypoxia are not explained by persistent cutaneous vasodilation.
The lack of an effect of hypoxia on the core temperature response to
severe cold exposure disagrees with some but not all previous human studies in
this area. For example, Cipriano and Goldman (1975) found that core
temperature was shifted downward by hypoxia during cold stress while core
cooling rate increased early in the cooling period. In addition, Johnston at al.
(1996) found that core cooling rate during post-exercise water immersion was
increased by 33% n hypoxic conditions. However, Blatteis and Lutherer (1976)
found no evidence of altered core cooling during high altitude exposure in a field
study. Our results agree with those of Blatteis and Lutherer (1976) and suggest
that acute hypoxia does not increase the rate of core cooling during severe cold
exposure. The reason for conflicting results in this area is unclear, but may be
related to differences in methodology between studies. In the study of Cipriano
and Goldman (1975), hypoxia was superimposed on cold stress mid-way through
a 4 hour cold exposure. Therefore, it may be that the interaction between
hypoxia and cold is different depending on which environmental stress is initiated
first. Conversely, the more prolonged (hours) hypoxic and cold exposures in that
study may have resulted in less vasoconstriction, as evidenced by the
stabilization of mean skin temperature at higher values during cooling. An
important consideration in the study of Johnston at al. (1996) is that core cooling
responses were measured immediately after cessation of dynamic exercise.
This undoubtedly provided a greater range over which to study core temperature
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responses inasmuch as exercise increased esophageal temperature by - O.re.
However, thermoregulatory control is mechanistically different post-exercise, and
may be affected by relative work rate during the exercise period (Kenny et al.,
2003). Therefore, the possibility that the different relative work rate during
normoxia and hypoxia contributed to altered post-ex thermoregulatory control
can not be ruled out.
We did not include a site where sympathetic adrenergic nerves were
blocked in this study. Therefore, the assumption that increased non-
noradrenergic vasoconstrictor responses during hypoxia are mediated through
adrenergic nerve cotransmission relies on the observations of previous studies in
this area (Stephens et al., 2001; Thompson & Kenney, 2004). However, these
previous studies were performed in normoxic conditions, and so there may be
vasoconstrictor systems activated by combined hypoxia and cold stress that
were not addressed in the studies that identified adrenergic nerves as mediators
of sympathetic cotransmission. Therefore we can not rule out the 'contributions
of circulating vasoconstrictor substances to the increase in cutaneous
vasoconstriction observed during combined hypoxia and cold stress in the
current study.
The delivery of 10.5 IJM BIBP-3226 via microdialysis did not reduce
cutaneous vasoconstriction during whole body cooling, even though non-
noradrenergic cutaneous vasoconstriction was activated {see figure 10). This
observation is at odds with a previous investigation in which the same
concentration of BIBP-3226 blocked most of the non-noradrenergic cutaneous
I
I
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vasoconstrictor response during whole body cooling (Stephens et al., 2004). In
this case, both our laboratory and others (Lacy A. Holowatz, personal
communication) have been unable to reproduce these results. It is unclear
whether this is due to inaccurate reporting of the original concentration of BIBP-
3226 used by Stephens et al. (2004) or to some other methodological
differences. Regardless, this issue has proved difficult to resolve because of the
high cost of BIBP-3226 and the higher cost of research grade neuropeptide Y.
Finally, there is currently no selective neuropeptide Y-Y1 receptor agonist
approved for use in humans. Therefore, future studies will be necessary to
resolve this issue.
In summary, we show for the first time that the magnitude of cutaneous
vasoconstriction is increased during prolonged cold stress in a hypoxic
environment. This effect is sufficient to abolish hypoxic vasodilation present
during shorter cooling bouts, and it appears to be mechanistically linked to
increased non-noradrenergic cutaneous vasoconstriction. Acute hypoxia does
not alter the kinetics of core temperature measured during to severe cold
exposure, and individual responses demonstrated no evidence for a relationship
between the effects of hypoxia on cutaneous vasoconstriction and core body
cooling during severe cold stress.
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Chapter VI entitled "Increased contribution from non-noradrenergic
cutaneous vasoconstriction abolishes hypoxic vasodilation during prolonged cold
stress" yielded several novel findings. Most striking was the observation that
cutaneous vasoconstriction was greater in magnitude when cold exposure was
performed in hypoxic conditions. Moreover, the increase in vasoconstrictor
magnitude was mediated entirely through non-noradrenergic pathways. These
findings suggest that during acute hypoxia, either a central upregulation of
vasoconstrictor outflow during cold stress increases cotransmitter release from
sympathetic nerve terminals, or vascular responsiveness to sympathetic
cotransmitters is selectively increased. Therefore, Chapter VII entitled "Does
hypoxia affect post-junctional vasoconstrictor responsiveness in human skin?"
was designed to test cutaneous vascular responsiveness to locally released
sympathetic vasoconstrictor stimuli. Cutaneous sympathetic vasoconstriction
was stimulated peripherally so as to control for possible central effects of hypoxia
. on sensory integration (i.e., during cold exposure).
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CHAPTER VII
DOES HYPOXIA AFFECT POST-JUNCTIONAL VASOCONSTRICTOR
RESPONSIVENESS IN HUMAN SKIN?
Introduction
The reduction in skin blood flow during whole body cooling is regulated by
cutaneous sympathetic adrenergic nerves, as demonstrated by the sensitivity of
this response to bretylium treatment (Kellogg et a/., 1989; Thompson & Kenney,
2004). As ambient temperature decreases, the activity of cutaneous adrenergic
nerves increases causing the release of norepinephrine and sympathetic
cotransrnitters. The binding o'f norepinephrine to post-junctional a-receptors
(predominantly a2-receptors) causes vasoconstriction, and this mechanism is
responsible for approximately 60% of the reduction in skin blood flow during cold
stress (Stephens et a/., 2001; Thompson & Kenney, 2004). The remaining -40%
of the cold induced vasoconstriction is mediated by adrenergic nerve
cotransmission, and recent evidence has implicated neuropeptide Y acting
through post-junctional neuropeptide Y1-receptors in this response (Stephens et
a/., 2004).
Acute exposure to systemic hypoxia causes cutaneous vasodilation in
non-acral skin, and this response is not restrained by neurally-mediated
sympathetic vasoconstriction {Simmons et a/., 2007). We recently demonstrated
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that this hypoxic vasodilation persists during whole body cooling of short duration
(10 minutes; see Chapter IV). However, when cold exposure is more prolonged,
the upward shift in skin blood flow is abolished and cutaneous perfusion is not
different between hypoxic and normoxic conditions (see Chapter VI). Our
previous work suggests the mechanism mediating vasoconstriction during short
duration cold stress is entirely noradrenergic, while more prolonged cooling elicits
both noradrenergic and non-noradrenergic cutaneous vasoconstriction (see
Chapter V). During hypoxia, the increase in non-noradrenergic cutaneous
vasoconstriction accounts for all of the increase in net vasoconstriction in
response to whole body cooling. Therefore, it appears that non-noradrenergic
cutaneous vasoconstriction is selectively upregulated during hypoxia, and this
effect overcomes hypoxic cutaneous vasodilation during cold exposure (see
Chapter VI).
The mechanism by which non-noradrenergic cutaneous vasoconstriction
is upregulated during hypoxia is unclear. For example, a central effect of hypoxia
could alter the sensory integration within the pre-optic area of the hypothalamus
(POAH), thereby shifting the magnitude of sympathetic outnow for a given
combination of temperature inputs (Steiner & Branco, 2002). Conversely,
vascular responsiveness to sympathetic cotransmitters could be increased,
thereby eliciting greater vasoconstriction in response to equal neurotransmitter
release. In order to test this latter possibility, we stimulated cutaneous
vasoconstriction locally to eliminate a possible central influence of hypoxia on
sympathetic vasoconstrictor outflow.
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The original design of this study involved the selective stimulation of
separate cutaneous vasoconstrictor pathways by intradermal administration of
norepinephrine (a-receptor agonist) and [D-Arg25]-NPY (neuropeptide Y1-receptor
agonist). However, neither [D-Arg25]_NPY nor any other specific neuropeptide
Y1-receptor agonist is currently approved for use in humans. Therefore, because
both noradrenergic and non-noradrenergic cutaneous vasoconstriction are
stimulated by sympathetic adrenergic nerves, we stimulated vasoconstriction pre-
synaptically using tyramine. We reasoned that presynaptic stimulation of
sympathetic vasoconstrictor nerves would lead to both norepinephrine and
cotransmitter release, because previous studies have demonstrated that
neuropeptide Y is colocalized with norepinephrine in sympathetic perivascular
nerves (Ekblad ef a/., 1984; Pernow ef a/., 1987). Furthermore, we reasoned that
individual vasoconstrictor pathways could be isolated by selective post-synaptic
blockade of either pathway in discrete regions of the skin. This is supported by
our previous work (Chapter VI) and the work of others (Stephens et a/., 2004).
Therefore, the purpose of this study was to test post-junctional
vasoconstrictor responsiveness in non-acral skin during exposure to acute
hypoxia. We tested the hypothesis that non-noradrenergic cutaneous
vasoconstriction is selectively potentiated during hypoxia, while noradrenergic
vasoconstriction is unaffected.
Methods
This study was approved by the institutional review board of the University
of Oregon, and each subject gave written, informed consent before participation.
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Subjects
Twelve healthy, nonsmoking, normotensive subjects (6 men, 6 women),
age 23 ± 2 yr, participated in this study [height 176 ± 14 (SO) cm, weight 77.7 ±
18.6 kg, body mass index 24.7 ± 3.5 kg/m2]. Subjects were taking no
medications, except for oral contraceptives, and none had been to altitude
(>1,500 m) within 5 months. Women were studied either during the early
follicular phase of the menstrual cycle or during the placebo phase of oral
contraceptive use to minimize the potential effects of female hormones on these
responses. All female subjects had a negative urine pregnancy test within 1 hour
of participation.
Instrumentation and measurements
Experiments were performed in thermoneutral conditions inside of a
purpose built environmental chamber (Tescor, Inc) with ambient temperature
maintained at 24°C. When the subject arrived on the study day, three
microdialysis fibers (model MO 2000, Bioanalytical Systems, West Lafayette, IN)
with a membrane length of 10 mm and molecular mass cutoff of 20 kOa «5 \-II
dead space) were placed in the skin of the ventral forearm. Fibers were placed
by inserting a 25-gauge needle through the dermis of the skin while the subject
lay in the supine position. The fiber was then threaded through the internal
lumen of the needle, and the needle was withdrawn, leaving the membrane in
place. The fiber was taped in place and perfused with lactated Ringer's solution
at a rate of 4 \-II/min with a microinfusion pump (CMA/102, CMA Microdialysis,
Stockholm, Sweden). Sites were at least 5 cm apart.
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Immediately after microdialysis fiber insertion, subjects were moved to a
reclined chair and sat in the semi-recumbent position while the local hyperemia
subsided at each microdialysis site. Subjects were instrumented for the
measurement of heart rate via electrocardiography (Cardiocap/5, Datex-
Ohmeda, Madison, WI), ventilation via turbine pneumotach (VMM-400, Interface
Associates, Laguna Niguel, CA), arterial pressure via brachial artery oscillometry
(Cardiocap/5), arterial O2saturation via pulse oximetry (Cardiocap/5), and end-
tidal P02 and PC02 via mass spectrometry (Marquette MGA 1100, MA Tech
Services, S1. LOI~is, MO). Isocapnia/eucapnia was defined as the mean end-tidal
PC02 (nasal cannula) during a 5-min period of quiet breathing. To obtain an
index of skin blood flow, cutaneous red blood cell flux was measured on the
ventral forearm by laser-Doppler flowmetry (MoorLAB, Moor Instruments, Devon,
UK) with integrated laser-Doppler probes fixed to the skin with adhesive tape.
Skin blood flows were expressed as cutaneous vascular conductance (red blood
cell flux/mean" arterial pressure) and normalized to baseline values as described
previously (Simmons et a/., 2007).
After resolution of the local hyperemia (-1.5 h), one microdialysis site was
perfused with 5mM yohimbine (Sigma, S1. Louis, MO) in lactated Ringer's
solution for the purpose of a-adrenergic blockade. Although Yohimbine has
traditionally been thought of as an a2-adrenergic receptor antagonist, numerous
recent studies have demonstrated that at high concentrations yohimbine (5mM)
produces non-specific blockade of both a1- and a2-adrenergic receptors in human
skin (Stephens et a/., 2001; Thompson & Kenney, 2004). Pilot work in our lab
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has confirmed this dose (see Chapter V), and the time course of drug delivery in
this protocol was based on previous studies (Stephens et al., 2004; Hodges et
al., 2008). A second site was perfused with the neuropeptide Y Y1-receptor
antagonist BIBP-3226 (1 0.5I.1M; Sigma, St. Louis, MO) in lactated Ringer's. This
concentration of BIBP-3226 abolishes the non-noradrenergic component of reflex
cutaneous vasoconstriction during whole body cooling in humans (Stephens et
al.,2004). The third microdialysis fiber received only lactated Ringer's solution
and was designated a control site. This study design aimed to produce one skin
site in which vasoconstrictor function was normal, one site in which only
noradrenergic vasoconstriction was functional, and one site which isolated
cotransrnitter-mediated vasoconstriction (presumably mediated through
neuropeptide Y Y1-receptors). Study drugs were infused for 60-75 minutes prior
to beginning the protocol.
Protocol
After the initial drug infusion period, subjects were allowed to use the
restroom, and were moved from the semi-recumbent to the supine position. The
rest of the protocol was completed in the supine position.
To achieve control of tidal gases, subjects breathed from a custom built
breathing circuit using a scuba mouthpiece and nose clip. The inspiratory
mixture provided at the mouthpiece originated from 3 gas tanks - air (20.93%
O2), nitrogen (100% N2), and carbon dioxide (100% C02) - connected to the
inspiratory line by flow regulators. The fraction of inspired oxygen (FI02) and
carbon dioxide (FIC02) were varied by adjusting the flowrate from each of the gas
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tanks, and the inspired air was first humidified, and then mixed as it filled a 6 liter
tube which served as an inspiratory reservoir. The 6 liter tube connected to the
breathing circuit proximal to the mouthpiece, and its distal end was open to room
air. Total flowrate through the breathing circuit was always greater than the
subjects' minute ventilation, and thus excess gas delivered through the
. inspiratory line escaped to the room through the 6 liter tube. The mouthpiece
consisted of two one~way valves (Rudolph) to insure inspiration from the
breathing circuit and expiration to room air.
This study was designed to test the effect of hypoxia on post-junctional
vasoconstrictor resp'onsiveness in human skin. Toward this end, cutaneous
vasoconstrictor responses to intradermal Tyramine (Sigma, S1. Louis, MO)
administration were tested twice in random order: once during normoxia and
once during isocapnic hypoxia. Tyramine is selectively taken up by adrenergic
nerve terminals and displaces intraneuronal transmitters from their storage
vesicles, causing a transient release of neurotransmitter into the extracellular
space (Hoffman, 2001). In human skin, tyramine has recently been shown to
increase interstitial norepinephrine levels when administered through cutaneous
microdialysis (Leis ef al., 2004). However, we are aware of no published reports
of vascular responses to intradermal tyramine administration.
A schematic representation of the experimental protocol is shown in figure
13. Tyramine infusions were separated by 90 minutes. The timing of Tyramine
infusions was based on pilot studies in our lab. Extensive pHot work was
performed to determine a dose of Tyramine which elicits vasoconstriction similar
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in magnitude to that recorded during aggressive whole body cooling. A further
requirement was that skin blood flow return to baseline levels soon enough that
two doses of Tyramine could be delivered on the same study day. Finally, it was
essential that consecutive Tyramine infusions elicit quantitatively similar
vasoconstrictor responses. After experimenting with a variety of regimens, we
found that a 3.5 minute infusion of 30 jJg/ml Tyramine (173 jJM) at a rate of 4
jJl/min satisfied the necessary requirements. This infusion regimen delivers 420
ng of Tyramine through the microdialysis membrane over a short time course.
Before each Tyramine infusion, steady state data were recorded during
mouthpiece breathing in either normoxia or isocapnic hypoxia. Isocapnic hypoxia
was induced by decreasing the fraction of inspired oxygen (FI02) progressively
over a 10 minute period. The rate of decrease in FI02 was designed to produce
a fall in arterial O2 saturation of - 2% min-1 down to 80%. After the target level of
hypoxia was reached, 5 minutes of steady state data were recorded before the
infusion of Tyramine began. For each tyramine infusion, all three microdialysis
fibers were perfused with a solution of Tyramine at 30 jJg/ml (173 jJM) for 3.5
minutes (constant infusion rate: 4 jJl/min). Tyramine solutions included the drug
blockers that were already perfusing each microdialysis site, and solutions
containing only these blockers were reintroduced immediately after the Tyramine
infusion was stopped. The full extent of Tyramine-evoked vasoconstriction was
typically manifest around 20 minutes after cessation of the infusion. Therefore, in
addition to recording baseline data prior to Tyramine infusion, data were
recorded continuously for at least 20 minutes after the infusion was stopped.
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Care was taken to insure that a nadir in skin blood flow had been reached prior to
removing the subject from the breathing circuit.
Data acquisition and analysis
Data were digitized with signal-processing software (WihDaq, Dat~q
Instruments, Akron, OH) and analyzed off-line. Vasoconstrictor responses were
first analyzed with a three-way ANOVA (effects: sex, drug site, O2 levels) to test
the effect of sex on cutaneous vascular responses. There was no effect of sex
on cutaneous vasoconstrictor responses in this study (P = 0.985 for sex main
effect). Thus data from men and women were pooled for all subsequent
analyses. Baseline skin blood flow was recorded after the initial drug infusion
period of 60-75 minutes, prior to moving the subject to the supine position.
Cutaneous vascular conductance was calculated in arbitrary units (Keller et a/.,
2006), and these data were analyzed with a one-way repeated measures
ANOVA to test the effect of drug treatment on baseline skin blood flow.
Pretreatment with these study drugs did not significantly alter baseline cutaneous
vascular conductance (P =0.588 vs. control for yohimbine site, P =0.679 vs.
control for BIBP-3226) as shown previously by others (Stephens et a/., 2004).
Statistical analyses were performed with SAS statistical software using PROC
MIXED (SAS v9.1.3, SAS Institute, Cary, NC). Differences were considered
significant when P < 0.05. All values are presented as means ± SE, unless
otherwise indicated.
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Figure 13. Schematic representation of chapter VII experimental protocol. Alpha-
adrenergic and neuropeptide Y (NPY) receptor antagonists were infused continuously throughout
the protocol. Tyramine was infused at a dose of 30 IJg/ml (173 IJM) for 3.5 minutes (constant
infusion rate: 4 IJl/min).
Results
Cardiorespiratory variables
Table 3 displays the cardiorespiratory data collected during normoxia and
hypoxia. During hypoxia, heart rate was elevated while arterial oxygen saturation
was reduced (both P < 0.05). Neither end-tidal PCOz nor arterial pressure were
changed by hypoxia (both P> 0.05), while ventilation increased slightly (P =
0.065).
Cutaneous vascular responses
Cutaneous vascular responses to tyramine administration are displayed in
figure 14. During normoxia, tyramine reduced cutaneous vascular conductance
in both the control site and the site receiving BIBP-3226 by equal magnitudes
(both P < 0.05 vs. pre-tyramine; P =0.445 vs. between sites). However, vascular
conductance in the site receiving yohimbine did not change (P = 0.398 vs. pre-
tyramine). During hypoxia, responses to tyramine followed a similar trend as
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Table 3. Cardiorespiratory data during normoxia and isocapnic hypoxia. Values are means
± SE for 6 males and 6 females. * P <: 0.05 VS. normoxia.
Normoxia Hypoxia
End-tidal PC02 (mmHg) 35.7 ±0.6 36.0 ± 0.5
Oxyhemoglobin saturation (%) 98.4 ±0.2 82.5 ± 0.6*
Ventilation (Llmin) 6.01 ± 0040 7.51 ± 0.62
Heart rate (beats/min) 60.4 ± 1.7 68.8 ± 2.0*
Mean arterial pressure (mmHg) 86.1 ± 2.3 8804 ± 2.4
during normoxia, with vascular conductance decreased by equal magnitudes in
the control site and the site receiving BIBP-3226 {both P < 0.05 vs. pre-tyramine;
P = 0.814 between sites). Again, cutaneous vascular conductance was
unchanged in the site receiving yohimbine (P = 0.732 vs. pre-tyramine). There
was no effect of hypoxia on vasoconstrictor responses at any site (all P> 0.05
vs. normoxia).
Discussion
The major new findings of this study are that (1) sympathetic
vasoconstriction evoked by intradermal tyramine administration is mediated
entirely through a-adrenergic mechanisms, and (2) post-junctional a-adrenergic
vasoconstrictor responsiveness in non-acral skin is not affected by systemic
hypoxia.
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Figure 14. Cutaneous vasoconstrictor responses to intradermal tyramine administration
during normoxia and isocapnic hypoxia. Control site received only lactated ringers; BIBP-
3226 and yohimbine were infused at constant doses of 10.51..1M and 5mM, respectively. Values
are means ± SE for 6 males and 6 females. * P < 0.05 vs. baseline; t P < 0.05 vs. control
response.
Our laboratory has previously shown that systemic hypoxia selectively
increases the magnitude of non-noradrenergic cutaneous vasoconstriction during
prolonged cold exposure (see Chapter VI). However, it was unclear from those
findings whether increased non-noradrenergic cutaneous vasoconstriction was
due to central neural or peripheral vascular effects of hypoxia (Rowell &
Blackmon, 1987). Therefore, in the current study we stimulated vasoconstriction
peripherally using intradermal tyramine administration. Peripheral stimulation of
sympathetic vasoconstriction circumvents the central integration associated with
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reflex sympathetic activation and therefore eliminates the central nervous system
as a possible site for hypoxic-mediated effects. Because tyramine selectively
stimulates sympathetic adrenergic nerve endings, we reasoned that its
application to the cutaneous interstitium would liberate vasoconstrictor
substances from these nerves in a similar fashion to that observed during whole
body cooling. This reasoning is supported by the fact that sympathetic
cotransmitters, including neuropeptide Y, are co-stored with norepinephrine in
sympathetic perivascular nerves in both animals and humans (Lundberg ef al.,
1983; Ekblad ef al., 1984; Pernow ef al., 1987). However, the application of
tyramine caused no cutaneous vasoconstrictor response in the presence of Q-
adrenergic blockade. Therefore, these results suggest that tyramine does not
stimulate non-noradrenergic vasoconstriction in human skin.
The failure of tyramine to stimulate non-noradrenergic cutaneous
vasoconstriction could be explained by two possibilities. First, it may be that
tyramine does not induce the release of sympathetic cotransmitters (specifically
neuropeptide Y) upon uptake into adrenergic nerve endings. This possibility is
supported by some (Lundberg ef al., 1989b; Takiyyuddin ef al., 1994) but not all
(Cheng & Shen, 1987; Cheng ef al., 1987) previous studies in this area. For
example, Lund berg ef al. (1989b) showed that tyramine stimulation of the pig
spleen in vivo caused vasoconstriction that was associated with an increase in
norepinephrine outflow but no change in neuropeptide Y outflow in the venous
effluent draining the isolated organ. Later, Takiyyuddin ef al. (1994)
demonstrated that intravenous infusion of tyramine caused an increase in arterial
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pressure and plasma norepinephrine, while plasma neuropeptide Y was
unaltered. In contrast, Cheng et al. (1987) demonstrated that tyramine releases
both norepinephrine and neuropeptide Y from sympathetic terminals of the rabbit
jejunum, but that neuropeptide Y is only released at higher concentrations of
tyramine. In addition, tyramine was shown to cause a dose dependent rise in
neuropeptide Y release from sympathetic terminals of the rat vas deferens
(Cheng & Shen, 1987). Therefore, it appears that tyramine stimulates the
release of neuropeptide Y with norepinephrine in certain tissues, whereas
norepinephrine is released alone in others. Thus, one interpretation of our
results is that sympathetic cotransmitter release is not stimulated by tyramine in
human skin. A second possibility is that neuropeptide Y is present in cutaneous
adrenergic nerve terminals but at concentrations too low to exert vasoactive
effects. For example, separate analysis of the neuronal cell body (sympathetic
ganglia) and axon terminal (peripheral tissue) of sympathetic neurons displaying
neuropeptide Y-Iike immunoreactivity yielded norepinephrine:neuropeptide Y
ratios of 150:1 and 10:1 for axonal cell bodies and peripheral terminals,
respectively (Fried et al., 1985). These data indicate that NPY content is higher
in cell bodies, and lower in axon terminals of sympathetic neurons. Furthermore,
Fried et al. (1985) provided evidence that replenishment of neuropeptide Y to the
nerve terminal occurs via slower axonal transport mechanisms. Taken together,
these data suggest that neuropeptide Y is present (with norepinephrine) in the
terminal endings of sympathetic vasoconstrictor nerves, but at relatively lower
concentrations which may not exert vascular ·effects. However, during intense
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stimulation of sympathetic activity, axonal transport mechanisms are activated
which provide neuropeptide Y to the nerve terminal for subsequent release
(Lundberg et a/., 1990).
We have previously shown that the magnitude of cutaneous
vasoconstriction during ten minutes of whole body cooling is not altered by
systemic hypoxia (see Chapter IV). In a subsequent pilot study, we
demonstrated that vasoconstriction during ten minutes of whole body cooling is
mediated entirely through a-adrenergic mechanisms (see Chapter V). Taken
together, these data suggest that the noradrenergic component of cutaneous
vasoconstriction is not altered during whole body cooling in humans. However, a
limitation of this evidence is that opposing central neural (Farkas & Donhoffer,
1973) and peripheral vascular (Heistad & Wheeler, 1970) effects of hypoxia may
have masked one another, thereby producing no net change in cutaneous
vasoconstriction during cold stress. The current study overcomes this limitation
by stimulating cutaneous vasoconstriction locally and bypassing any central
effect of hypoxia. Furthermore, no non-noradrenergic cutaneous
vasoconstriction was stimulated by tyramine either during normoxia or hypoxia
(see above). Therefore, it appears that the vasoconstrictor responses presented
here are mediated entirely through noradrenergic mechanisms, and we conclude
that cutaneous vascular responsiveness to noradrenergic vasoconstrictor stimuli
is not altered by systemic hypoxia.
The maintenance of cutaneous vascular responsiveness to a-adrenergic
vasoconstriction agrees with some (Dinenno, 2003; Dinenno et al., 2003) but not
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all (Heistad & Wheeler, 1970, 1972) previous research in this area. Heistad and
Wheeler (1970) showed that both hand and forearm vasoconstrictor responses to
sympathetic stimulation were reduced during hypoxia. This effect was at least
partly explained by blunted vascular responsiveness, as indicated by reduced
vasoconstrictor responses to exogenous norepinephrine. However, Dinenno et
at. (2003) recently demonstrated that forearm vascular responses to intra-arterial
infusion of tyramine are not altered by hypoxia. The reason for discrepant
findings during norepinephrine and tyramine infusion is unclear. One possibility
is that forearm vascular responses to intraluminal and extralurninal
norepinephrine differ because the diffusion distance for norepinephrine to the
post-junctional receptors is shorter when released from sympathetic nerve
terminals. Therefore, decreased vasoconstrictor responses to intra-arterial
infusion of norepinephrine could be the result of increased norepinephrine
clearance during hypoxia (Leuenberger et a/., 1991) and a subsequent reduction
in the amount of catecholamine reaching post-junctional a-adrenergic receptors.
Future studies in which exogenous norepinephrine is introduced into the
interstitium by microdialysis (in both skin and muscle) during hypoxia may
resolve this issue.
Perspectives
As discussed above, the results of this study contribute further to a body
of evidence indicating that post-junctional a-adrenergic vasoconstrictor
responsiveness in human skin is not altered by hypoxia. When viewed in the
context of our previous work (see Chapter VI), these data support that notion that
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increased cutaneous vasoconstriction during combined hypoxia and co1d stress
is mediated through non-noradrenergic pathways, suggesting a role for
sympathetic cotransmission. Further evaluation of these hypotheses awaits the
approval for human use of pharmacological tools that selectively inhibit and
stimulate sympathetic cotransmitter-mediated vasoconstrictor pathways.
In summary, we have shown that sympathetic vasoconstriction evoked by
intradermal tyramine is mediated entirely through a-adrenergic mechanisms.
Furthermore, these noradrenergic vasoconstrictor mechanisms appear to be
unaltered by systemic hypoxia in the cutaneous vasculature.
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CHAPTER VIII
CONCLUSIONS
High altitude environments are characterized by reduced barometric
pressure and inadequate oxygen supply. In this setting, a variety of species
selectively regulate a lower body temperature, presumably favoring a protective
reduction in metabolism (Wood, 1991; Steiner & Branco, 2002). Some evidence
suggests that humans exhibit a similar response in hypoxic environments. For
example, some (Cipriano &Goldman, 1975) but not all (Blatteis &Lutherer,
1976) studies report a downward shift in resting core temperature in humans
exposed to cold temperatures in hypoxic environments. Conversely, numerous
studies report that skin blood flow (and presumably cutaneous heat loss) is
increased by hypoxia, although some report this response is masked by
sympathetic vasoconstriction (Schneider & Sisco, 1914; Kollai, 1983; Sagawa et
al., 1986; Anderson etal., 1991; Leuenberger et al., 1991; Weisbrod etal., 2001;
Simmons et al., 2007). In agreement with the blood flow data, mean skin
temp"erature - reflecting a balance between heat transfer from core to skin and
from skin to air - is increased both at rest and during cold exposure in hypoxic
environments (Cipriano & Goldman, 1975; Blatteis & Lutherer, 1976). Moreover,
one study found that the expected reduction in skin temperature (caused by
cutaneous vasoconstriction) during 4 hours of cold exposure was abolished at a
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simulated altitude of 5DOO meters (Cipriano & Goldman, 1975). Tak,en together,
these observations suggest that control of skin blood flow during thermoneutral
conditions and cold exposure is altered by systemic hypoxia. Furthermore, these
changes in thermoregulatory control of skin blood flow may adversely affect core
temperature regulation at high altitude. The focus of this review is the impact of
acute hypoxia on cutaneous vascular regulation in thermoneutral and cold
environments.
Cutaneous vascular control during hypoxia in thermoneutral conditions
In thermoneutral conditions, skin blood flow is increased by 25 - 30%
upon exposure to acute hypoxia. This response is present in both the upper and
lower limbs and occurs in the absence of changes in arterial pressure,
suggesting it is caused by vasodilation (Anderson et a/., 1991; Simmons et a/.,
2007). Furthermore, this response is not mediated by hyperventilation and
persists even if hypocapnia develops secondary to hypoxic hyperventilation (see
Chapter IV; Simmons et a/., 2007). Therefore, it appears that hypoxemia per se
elicits cutaneous vasodilation during exposure to systemic hypoxia, and this
response is not affected by secondary changes in ventilation or blood carbon
dioxide levels.
Traditionally, the peripheral vascular response to systemic hypoxia has
been viewed as a competition between chemoreflex control, mediated primarily
through the sympathetic nervous system, and local vasodilator influences
(Heistad & Abboud, 1980; Rowell, 1986). Therefore, the net change in perfusion
observed during hypoxia represents the summation of two opposing vasoactive
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processes: vasodilation mediated through locally produced and/or circulating
chemical mediators, and vasoconstriction mediated through the actions of
sympathetic vasoconstrictor nerves and/or circulating constrictor substances
(e.g., catecholamines, angiotensin II, etc). Weisbrod et a/. (2001) previously
dissected the components of this complex vascular control system in the skeletal
muscle vasculature. These authors showed that, during hypoxia, increases in
sympathetic vasoconstrictor nerve activity "mask" significant vasodilation, which
is mediated partly through local and partly through circulating chemical mediators
(Weisbrod et a/., 2001). Importantly, the control elements of the vascular
response to hypoxia may differ among peripheral vascular beds.
In the cutaneous circulation, the behavior of sympathetic vasoconstrictor
nerve activity is more difficult to document than in the skeletal muscle
vasculature (Vallbo et a/., 2004). The reason for this is that the cutaneous
circulation is innervated by two branches of the sympathetic nervous system: an
adrenergic vasoconstrictor system and a cholinergic vasodilator system (Roddie
et a/., 1957; Roddie, 1983; Johnson, 1986; Kellogg et a/., 1989; Kellogg et a/.,
1995). Owing to this dual sympathetic innervation, microneurographic recordings
of cutaneous sympathetic nerve activity can not adequately distinguish changes
in vasoconstrictor and vasodilator nerve activity. Thus, investigators are forced
to find pharmacological means to study the cutaneous vasculature under the
influence of varying degrees of adrenergic inhibition.
Our group has twice used pharmacological methods to study the
contribution of adrenergic vasoconstriction to the net cutaneous vascular
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response to hypoxia. The results from these two investigations initially
stimulated different conclusions regarding adrenergic vasoconstriction in the skin
during hypoxia. In 2001, Weisbrod et at. administered intra-arterial phentolamine
to produce post-synaptic blockade of alpha-adrenergic receptors in the forearm,
thus inhibiting sympathetic vasoconstriction. During hypoxia, the area of skin
pretreated with phentolamine displayed a greater vasodilation than the skin with
intact adrenergic control (Weisbrod et a/., 2001). Based on these results, the
authors concluded that sympathetic vasoconstriction masks a portion of hypoxic
vasodilation in the cutaneous circulation as is the case in the skeletal muscle
vasculature. However, Simmons et at. (2007) later showed that pretreatment of
the skin with bretylium tosylate (for presynaptic inhibition of adrenergic nerves)
did not affect the magnitude of hypoxic vasodilation, indicating that increases in
sympathetic vasoconstrictor nerve activity do not oppose hypoxic vasodilation in
the skin.
These seemingly disparate observations may be reconciled by
consideration of the different loci at which phentolamine and bretylium interfere
with sympathetic vasoconstriction. For instance, phentolamine blocks
postsynaptic 01- and 02- adrenergic receptors (Hoffman, 2001) while bretylium
tosylate blocks adrenergic nerve transmission presynaptically (Haeusler et a/.,
1969). Blockade of 01- and 02- adrenergic receptors interferes with both neural
and humoral adrenergic vasoconstriction, whereas only neural vasoconstriction is
blocked by inhibition of sympathetic adrenergic fibers. Thus the results indicating
that cutaneous vasodilation is unmasked by o-receptor blockade may indicate
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that humoral (adrenergic) vasoconstriction is present in the skin during hypoxia.
This vasoconstriction would be sensitive to a-receptor blockade but not to
presynaptic inhibition by bretylium. We have recently verified the resuUs
obtained during intra-arterial infusion of phentolamine using the same model in
which bretylium treatment was shown not to affect the hypoxic response (see
Chapter VI). The results of this study confirmed that hypoxic vasodilation is
augmented in the presence of a-adrenergic blockade, and provided further
evidence that humoral vasoconstriction opposes hypoxic vasodilation in the skin.
A likely candidate for such a circulating mediator of adrenergic vasoconstriction is
epinephrine, which is present in the blood at higher concentrations during acute
hypoxia (Weisbrod et al., 2001). Epinephrine has been shown to cause
cutaneous vasoconstriction (humoral) when administered intra-arterially,
intravenously, by sUbcutaneous injection, or by iontophoresis -(Barcroft et al.,
1955; Cooper et al., 1955; Roddie, 1983; Hoffman, 2001). Taken together, these
combined observations suggest that adrenergic vasoconstriction of humoral
origin (possibly epinephrine) masks some of the cutaneous vasodilation during
hypoxia, and adrenergic vasoconstriction of neural origin (Le., sympathetic
vasoconstrictor nerves) does not affect hypoxic vasodilation in human skin.
The regulatory mechanisms underlying hypoxic vasodilation in non-acral
skin are currently unknown. As mentioned above, the non-acral cutaneous
vasculature is innervated by two branches of the sympathetic nervous system: an
adrenergic vasoconstrictor system and a cholinergic vasodilator system (Roddie
et al., 1957; Roddie, 1983; Johnson, 1986; Kellogg et al., 1989; Kellogg et al.,
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1995). While current understanding indicates that the adrenergic vasoconstrictor
system is not involved in cutaneous vasodilation during hypoxia, the active
vasodilator system may playa role. For example, Weisbrod et al. (2001) showed
that blockade of nitric oxide production in the forearm reduces hypoxic
vasodilation in the skin, suggesting that nitric oxide plays a role in cutaneous
vasodilation during hypoxia. Nitric oxide contributes to cutaneous vasodilation
during thermal stress via direct actions on vascular smooth muscle and
synergistic activity with an unknown neurotransmitter associated with the active
vasodilator system (Wilkins et al., 2003). Thus the nitric oxide dependence of
cutaneous vasodilation during hypoxia may indicate a role for active vasodilation.
Conversely, nitric oxide may represent a pathway through which local vasodilator
mechanisms act, as has been suggested in skeletal muscle during hypoxia
(Blitzer et al., 1996; Halliwill, 2003).
Cutaneous vascular control during combined hypoxia and cold stress
When environmental temperature falls, skin blood flow is reduced in order
to decrease heat transfer from the core to the periphery, thereby promoting heat
conservation (Toner & McArdle, 1988). This thermoregulatory adjustment also
decreases skin temperature, which narrows the gradient for heat loss from the
skin and is vital to the prevention of hypothermia in cold environments. The
reduction in skin blood flow upon body cooling is regulated by cutaneous
sympathetic adrenergic nerves, which contain both norepinephrine and other
sympathetic cotransmitters including neuropeptide Y (Lundberg et al., 1983;
Ekblad etal., 1984; Fried etal., 1985; Pernowetal., 1987; Kellogg et al., 1989).
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As ambient temperature decreases, the activity of cutaneous adrenergic nerves
increases, releasing norepinephrine onto post junctional a-receptors
(predominantlya2-receptors). The binding of norepinephrine to post junctional a-
receptors causes vasoconstriction, and this mechanism is responsible for
approximately 60% of the reduction in skin blood flow during cold stress
(Thompson & Kenney, 2004). The remaining -40% of the cold induced
vasoconstriction is mediated by adrenergic nerve cotransmission (Stephens et
a/., 2001; Thompson & Kenney, 2004). The primary peptide thought to mediate
sympathetic cotransmission in this setting is neuropeptide Y, which causes
cutaneous vasoconstriction via post junctional neuropeptide Y y,-receptors
(Stephens et a/., 2004).
During hypoxemia, Heistad and Wheeler (1972) have shown that
vasoconstrictor responses to adrenergic stimulation (intra-arterial infusion of
norepinephrine) are blunted in the hand circulation. Cipriano and Goldman
(1975) and Blatteis and Lutherer (1976) later showed that mean skin temperature
is elevated by hypoxia during whole body cold stress. Taken together, these
data suggest that cutaneous vasoconstrictor responses during cold exposure
may be altered by systemic hypoxia.
Simmons et a/. (see Chapter IV) recently tested this idea by studying
cutaneous vascular responses during combined hypoxia and cold stress. When
cold exposure was induced gradually over a ten minute period, the final reduction
in skin blood flow was upward shifted during hypoxia compared to normoxia,
suggesting the maintenance of increased cutaneous heat loss. Furthermore, a
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subsequent protocol demonstrated that cutaneous vasoconstriction during ten
minutes of whole body cooling is mediated entirely through a-adrenergic
mechanisms, whereas more prolonged cold exposure evokes sympathetic non-
noradrenergic vasoconstriction (see Chapter V). These observations are likely to
be explained by increased sympathetic vasoconstrictor outflow during more
prolonged cold stress, inasmuch as the release of cotransmitters (e.g.,
neuropeptide Y) from sympathetic vasoconstrictor nerves is tightly linked to their
frequency of activation (Eckberg et al., 1988; Lundberg et al., 1989a; Pernow et
al., 1989b). Therefore, the combined results above suggest that a-adrenergic
vasoconstriction is functional during hypoxia, but that this system does not
effectively reduce skin blood flow to the same levels during hypoxia as seen
during normoxic cold stress.
As described above, when cold exposure is more prolonged, sympathetic
non-noradrenergic vasoconstriction contributes to the net reduction in skin blood
flow. In order to test the contribution of non-noradrenergic vasoconstriction to the
cutaneous vascular response during combined hypoxic and cold exposure,
Simmons et al. (see Chapter VI) exposed subjects to 30 minutes of progressive
cold stress while measuring cutaneous vascular responses in functionally intact
and a-adrenergic blocked sites on the forearm. These authors showed that the
magnitude of cutaneous vasoconstriction during cold exposure was increased by
hypoxia. This increase in vasoconstriction was su'fficient to abolish 'Cutaneous
vasodilation during hypoxia, and the proportion of the total vasoconstrictor
response accounted for by non-noradrenergic mechanisms increased from 30%
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to> 50% during hypoxia. Furthermore, comparison of responses in control and
a-adrenergic blocked sites indicated that increased vasoconstriction could be
explained entirely by a greater non-noradrenergic cutaneous vasoconstrictor
response (see figure 15). Therefore, it appears that non-noradrenergic
cutaneous vasoconstriction is increased by hypoxia during prolonged cold stress,
and this effect is sufficient to abolish hypoxic vasodilation observed in
thermoneutral conditions.
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Figure 15. Proposed model explaining the noradrenergic and non-noradrenergic
contributions to cutaneous vasoconstrictor responses during combined hypoxia and cold
stress. Responses observed during hypoxia are indicated by dashed lines.
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The effects of hypoxia on cutaneous vasoconstriction during prolonged
cooling could be explained by central or peripheral mechanisms (see figure 1'6).
However, the combined data thus far do not point to a clearly defined central
mechanism. For example, during brief cold stress, baseline skin blood flow is
increased by hypoxia but a-adrenergic vasoconstriction is unchanged, resulting
in an upward shift in the cutaneous vascular response to cold in this setting (see
Chapter IV). Interestingly, this effect is observed even if no hypoxic vasodilation
is present (e.g., in women). Taken together, this suggests a possible central
upregulation of cutaneous heat loss (Le., increased thermoregulatory set point).
However, during more prolonged cold exposure when both noradrenergic and
non-noradrenergic vasoconstrictor mechanisms are activated, non-noradrenergic
vasoconstriction is potentiated, resulting in a greater vasoconstrictor response
and the abolition of hypoxic vasodilation (see Chapter VI). The increased
vasoconstrictor response in this setting would suggest an opposite effect on
central regulation of cutaneous heat loss (Le., decreased thermoregulatory set
point). Moreover, recent measurements of core temperature at rest and during
aggressive cooling indicate no effect of hypoxia (see below). Therefore, data
currently do not support a central effect of hypoxia on cutaneous vasoconstriction
during cold exposure.
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Figure 16. Possible mechanisms through which hypoxia affects the cutaneous vascular
response to cold exposure. Tsk =Skin temperature; POAH =Pre-optic anterior hypothalamus;
NE = Norepinephrine; NPY = Neuropeptide Y.
In order to investigate whether increased non-noradrenergic cutaneous
vasoconstriction occurs through the peripheral effects of hypoxia, Simmons et al.
(see Chapter VII) stimulated cutaneous vasoconstriction locally using
microdialysis of tyramine. Tyramine has been shown to stimulate the release of
both norepinephrine and neuropeptide Y from adrenergic nerves in some (Cheng
& Shen, 1987; Cheng et al., 1987) but not all preparations (Lundberg et al.,
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1989b; Takiyyuddin et al., 1994). Apparently the effect of tyramine on
sympathetic cotransmitter release is dependent on the tissue examined as well
as the mode of drug delivery (intraluminal versus abluminal). Therefore, because
neuropeptide Y is colocalized with norepinephrine in perivascular nerve endings
(Lundberg et al., 1982; Lundberg et al., 1983; Ekblad et al., 1984; Pernow et al.,
1987) and post junctional neuropeptide Y receptors participate in reflex
cutaneous vasoconstriction during whole body cooling in humans (Stephens et
al., 2004), Simmons et al. reasoned that intradermal tyramine delivery via
microdialysis would stimulated both noradrenergic and non-noradrenergic
cutaneous vasoconstrictor responses. Cutaneous vascular responses to
tyramine were tested in control and a-adrenergic blocked sites during normoxia
and hypoxia. Contrary to their hypothesis, however, tyramine elicited no
vasoconstrictor response in the presence of a-adrenergic blockade. These data
suggest that intradermal tyramine administration, at least at concentrations near
those used by Simmons et al. (30 ~g/ml [173 ~M] x 3.5 minutes@ 4 ~I/min),
does not elicit vasoactive levels of sympathetic cotransmitter release in human
skin (see discussion in Chapter VII). In agreement with the findings during brief
cold stress, post-junctional a-adrenergic vasoconstrictor responses were not
altered by hypoxia.
Perspectives
Previous studies have shown that mean skin temperature is elevated in
humans exposed to cold stress during acute environmental hypoxia {Cipriano &
Goldman, 1975; Blatteis & Lutherer, 1976). In addition, some evidence suggests
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that increased skin temperature is associated with faster core heat loss in this
setting (Cipriano & Goldman, 1975). This line of research stimulated the
hypothesis that skin blood flow during cold exposure is upward shifted by hypoxia
(as occurs in thermoneutral conditions), and that this response ultimately
contributes to faster rates of core heat loss. Initial experiments conducted during
brief cold exposure lasting ten minutes supported this hypothesis {see Chapter
IV), demonstrating that hypoxic vasodilation persists through the end of cold
exposure (Le., skin blood flow was upward shifted). However, in a two phase
protocol during which cutaneous vascular responses to progressive cold
exposure and core cooling responses to severe cold exposure were tested back
to back, no correlation was detected between the cutaneous vascular effects and
core temperature effects of hypoxia in young healthy volunteers (Chapter VI).
Therefore, it appears that the mechanisms of cutaneous vascular regulation
during cold stress are altered by hypoxia, but these effects alone do not
predispose young healthy persons to hypothermia.
In contrast to young healthy individuals, the aged are not able to
adequately defend core temperature during prolonged mild cold stress. In the
aged, core temperature is reduced and cutaneous vasoconstriction blunted
during mild cold exposure compared to young volunteers (Degroot & Kenney,
2007). The effect of aging on the reduction in skin blood flow during cold
exposure occurs through a selective loss of cotransmitter-mediated (non-
noradrenergic) vasoconstriction (Thompson & Kenney, 2004). Therefore,
inasmuch non-noradrenergic cutaneous vasoconstriction is potentiated by
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hypoxia and eliminates the upward shift in skin blood flow during cold exposure
{see Chapter VI), the aged may be significantly impacted by combined hypoxic
and cold stress because they lack functional non-noradrenergic vasoconstrictor
pathways.
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APPENDIX A
INFORMED CONSENT FORM FOR CHAPTER IV
TITLE: Cutaneous vasodilation at high altitude: basic mechanisms and
impacts on human thermoregulation (Protocol 1)
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues
APPROVED BY INSTITUTIONAL REVIEW BOARD: July 27,2007
This is an important form. Please read it carefully. It tells you what you
need to know about this study. If you agree to take part in this research
study, you need to sign the form. Your signature means that you have
been told about the study and what the risks are. Your signature on this
form also means that you want to take part in this study.
Why is this research study being done?
When humans breathe, we take in oxygen from the air and expel carbon dioxide
that our bodies have made. When we travel to high altitudes, we fail to take in
enough oxygen and we expel excess amounts of carbon dioXide. Conversely,
some respiratory diseases are associated with failure to expel enough carbon
dioxide produced within the body. Too little oxygen and too much or too little
carbon dioxide may alter the distribution of blood in the limbs, increasing the
amount of blood circulating in the skin. Unfortunately, we do not understand how
these changes in blood distribution take place, or how they affect heat loss from
the body. The purpose of this study is to provide more information on what
causes the changes ;" blood flow when we take in too little oxygen or expel too
little or too much carbon dioxide.
What will happen in the study?
Study visit
1) You will arrive at Dr. Halliwill's laboratory in Esslinger Hall at the University of
Oregon on the study day. The study will last approximately 2 hours. You will
meet with one of the investigators of the study to discuss the project, to see
the laboratory, and to read this form. Your height and weight will be
measured. You will need to refrain from consuming caffeine (for example,
coffee, tea, red bull, coke, etc.) or medications (except oral contraceptives) for
12 hours prior to the study and abstain from alcohol or exercise for 24 hours
prior to the study. In addition, you will need to refrain from eating for at least
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2 hours prior to the study visit. If you use oral contraceptives, you should take
this when you normally do so.
2) If you are a woman who can still become pregnant, you will be asked to
undergo a pregnancy test. For this test, you will be asked to collect a sample
of urine in the women's restroom near the physiology lab. If the test is
"positive," indicating that you are pregnant, you will not be allowed to
participate and will be advised to see your physician or the University of
Oregon Health Center.
3) During the study visit, your heart rate will be monitored by electrocardiogram
electrodes placed on your skin. If you are a woman, the adhesive patches
used for this test will be placed on you by one of the women in the lab. Your
blood pressure will be measured at periodic intervals by the irrnation of a
blood pressure cuff around your arm or around your middle finger.
4) During the study visit, two small probes {laser-Doppler probes) will be placed
over your skin so that we can measure skin blood flow.
5) For a period of up to 10 minutes, your expired gas will be collected through a
nasal cannula to assess the resting carbon dioxide levels in your blood. After
removal of the nasal canulla, you will be asked to breathe air that has low
oxygen content either with or without high carbon dioxide content for up to 30
minutes. During this time, you will breathe through a scuba mouthpiece with
nasal breathing prevented by a nose clip. These procedures will increase
your rate of breathing and heart rate and are similar to what happens when
you travel to higher altitude. You will undergo several of these breathing
procedures during the study.
6) During the study, we will inflate a small cuff that is placed on your middle and
ring fingers of one of your hands to measure your blood pressure (Finometer
device). If the cuff becomes uncomfortable, let the investigator know and
they will turn it off for a few minutes.
7) You should notify the investigator immediately if you feel any significant
discomfort or concern about your well-being at any time during the initial visit
or the study visit. Some examples of discomfort include shortness of breath,
light-headedness, and nausea.
How long will I be in the study?
You will be in the study for two hours.
What are the risks of the study?
1. Breathing air with a low oxygen content with/without high carbon dioxide
content: During these procedures, it is possible you will feel distress, anxiety,
shortness of breath, or feellightheaded. These symptoms resolve rapidly
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when you return to breathing room air. In addition, these breathing
procedures have the potential to induce fainting. You should keep the
investigator informed of your feelings and you should not attempt to prolong
the breathing experiment if you do not feel well. You are free to stop at any
time.
2. Laser-Doppler Probes: These probes send a small light into your skin. You
will not feel anything except the probe touching your skin. The only risk
associated with this procedure is that you may have some slight skin irritation
(redness) to the adhesive tape used to hold the probe on your skin. There
are no major risks associated with this device.
3. Finger blood pressure: In some people, this blood pressure cuff causes their
finger to become red and uncomfortable after a long period (over 40 minutes).
We will not inflate the cuff for longer than 40 minutes during the study. If your
finger becomes uncomfortable during the study, let the investigator know and
they will turn it off for a few minutes. There are no major risks associated with
this device.
May I participate if I am pregnant or breast-feeding?
This study may be harmful to an unborn or breast-fed child. There is not enough
medical information to know what the risks might be to a breast-fed infant or to
an unborn child in a woman who takes part in this study. Breast-feeding mothers
are not able to take part in this study. Women who can still become pregnant
must have a negative pregnancy test no more than 24 hours before taking part in
the study. If the pregnancy test is positive (meaning that you are pregnant), you
will not be able to take part in the study. There is no cost for the pregnancy test.
Are there benefits to taking part in this study?
This study will not make your health better.
What other choices do I have if I don't take part in this study?
This study is only being done to gather information. You may choose not to take
part in this study.
What are the costs of tests and procedures?
You will not need to pay for any tests or procedures that are done just for this
research study. You will get $20 for participating in this study. This money is for
the inconvenience and time you spent in this study. If you start the study but
stop before the study has ended, the amount of money you receive will be pro-
rated at a rate of $10 per hour of the study you complete.
Who can answer my questions?
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You may talk to Dr. John Halliwill at any time about any question you have on
this study. You may contact Dr. Halliwill by calling the Department of Human
Physiology at {541 ) 346-5425.
What are my rights if I take part in this study?
Taking part in this research study is your decision. You do not have to take part
in this study, but if you do, you can stop at any time. Your decision whether or not
to participate will not affect your relationship with the University of Oregon.
You do not waive any liability rights for personal injury by signing this form. All
forms of medical diagnosis and treatment whether routine or experimental,
involve some risk of injury. In spite of all precautions, you might develop medical
complications from participating in this study.
The investigators may stop you from taking part in this study at any time if it is in
your best interest, if you do not follow the study rules, or if the study is stopped.
If you are physically injured because of the project, you and your insurance
company will have to pay your doctor bills. If you are a UO student or employee
and are covered by a UO medical plan, that plan might have terms that apply to
your injury.
If you experience harm because of the project, you can ask the State of Oregon
to pay you. If you have been harmed, there are two University representatives
you need to contact. Here are their addresses and phone numbers:
General Counsel Office of Human Subjects Compliance
Office of the President University of Oregon
University of Oregon Eugene, OR 97403
Eugene, OR 97403 (541) 346-2510
(541 ) 346-3082
A law called the Oregon Tort Claims Act limits the amount of money you can
receive from the State of Oregon if you are harmed. The most you could receive
would be $100,000, no matter how badly you are harmed. If other people are
also harmed by the project, all of you together could only receive $500,000.
What about confidentiality?
Any information that is obtained in connection with this study and that can be
identified with you will remain confidential and will be disclosed only with your
permission. Subject identities will be kept confidential by assigning you a "subject
identification number". The names associated with each subject identification
number will be kept in a locked file cabinet in Dr. Halliwill's office area.
The Office for Responsible Conduct of Research and/or authorized
representatives of the Food and Drug Administration (FDA) or National Institute
of Health (NIH) may need to review records of individual subjects. As a result,
they may see your name, but they are bound by rules of confidentiality not to
reveal your identity to others.
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The list of names will be destroyed when study results are published or 24
months after your participation, whichever comes first. Other information may be
stored by the researchers indefinitely.
I have had an opportunity to have my questions answered. I have been
given a copy of this form. I agree to take part in this study.
If you have questions regarding your rights as a research subject, contact Office
for Protection of Human Subjects, 5237 University of Oregon, Eugene, OR
97403, (541) 346-2510.
Your signature indicates that you have read and understand the information
provided above, that you willingly agree to participate, that you may withdraw
your consent at any time and discontinue participation without penalty, that you
will receive a copy of this form, and that you are not waiving any legal claims,
rights or remedies.
(Date)
(Date)
(Signature of Participant)
(Signature of Individual Obtaining Consent)
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APPENDIX B
INFORMED CONSENT FORM FOR CHAPTERS V & VII
TITLE: Cutaneous vasodilation at high altitude: basic mechanisms and
impacts on human thermoregulation (Protocol 2)
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues
APPROVED BY INSTITUTIONAL REVIEW BOARD: December 10, 2007
This is an important form. Please read it carefully. It tells you what you
need to know about this study. If you agree to take part in this research
study, you need to sign the form. Your signature means that you have
been told about the study and what the risks are. Your signature on this
form also means that you want to take part in this study.
Why is this research study being done?
When humans breathe, we take in oxygen from the air and expel carbon dioxide
that our bodies have made. When we travel to high altitudes, we fail to take in
enough oxygen and we expel excess amounts of carbon dioxide. Conversely,
some respiratory diseases are associated with failure to expel enough carbon
dioxide produced within the body. Too little oxygen and too much or too little
carbon dioxide may alter the distribution of blood in the limbs, increasing the
amount of blood circulating in the skin. Unfortunately, we do not understand how
these changes in blood distribution take place, or how they affect heat loss from
the body. The purpose of this study is to provide more information on what
causes the changes in blood flow when we take in too little oxygen or expel too
little or too much carbon dioxide.
What will happen in the study?
1) You will arrive at Dr. Halliwill's laboratory in Esslinger Hall at the University of
Oregon on the study day. The study will last approximately 4 hours. You will
meet with one of the investigators of the study to discuss the project, to see
the laboratory, and to read this form. Your height and weight will be
measured, and you will be asked to put on a black woven suit covered with
small tubes through which water will be circulated (a "water' perfused suit").
You will need to refrain from consuming caffeine (for example, coffee, tea, red
bull, coke, etc.) or medications (except oral contraceptives) for 12 hours prior
to the study and abstain from alcohol or exercise for 24 hours prior to the
study. In addition, you will need to refrain from eating for at least 2 hours
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prior to the study visit. If you use oral contraceptives, you should take this
when you normally do so.
2) If you are a woman who can still become pregnant, you will be asked to
undergo a pregnancy test. For this test, you will be asked to collect a sample
of urine in the women's restroom near the physiology lab. If the test is
"positive," indicating that you are pregnant, you will not be allowed to
participate and will be advised to see your physician or the University of
Oregon Health Center.
3) During the visit, your heart rate will be monitored by electrocardiogram
electrodes placed on your skin. If you are a woman, the adhesive patches
used for this test will be placed on you by one of the women in the lab. Your
blood pressure will be measured at periodic intervals by the inflation of a
blood pressure cuff around your arm or around your middle finger..
4) You will have 4 small tubes {these are called "microdialysis fibers", and are
smaller than the lead of a pencil) placed in the skin of your forearm. First we
will numb the area of skin by placing a bag of ice over the area for 5 minutes.
Then a small needle will be placed just under the surface of your skin and will
exit back out about 11'2 inches from where it entered your skin. The small
tubes will be placed inside the needle, and the needle will be withdrawn,
leaving the small tubes under your skin. These will remain in your skin
throughout the rest of the study.
5) We need to wait about 1-2 hours after the small tubes are placed in your skin
to let the insertion trauma (redness of your skin around the small tubes) to go
away. During this time, a small probe (laser-Doppler probe) will be placed
over each area of skin where the small tubes are so that we can measure
skin blood flow over the small tube.
6) Microdialysis infusions: We will put small doses of several drugs through the
small probes in your skin. The drugs you may receive include the following:
a. L-NAME: this stops nitric oxide from being produced and causes the
skin vessels to narrow
b. Bretylium Tosylate: this substance inhibits the release of transmitters
from the nerves in your skin and causes vessels in the skin to open
c. Yohimbine: this substance blocks the effect of transmitters in your skin
and causes vessels to open
d. Propranolol: this substance blocks the effect of transmitters in your
skin and causes vessels to narrow
e. BIBP-3226: this substance blocks the effect of transmitters in your skin
and causes vessels to open
f. Tyramine: this substance stimulates the release of transmitters from
the nerves in your skin and causes vessels in the skin to narrow
7) For a period of up to 10 minutes, your expired gas will be collected through a
nasal cannula to assess the resting carbon dioxide levels in your blood. After
removal of the nasal canulla, you will be asked to breathe air that has low
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oxygen content either with or without high carbon dioxide content for up to 30
minutes. During this time, you will breathe through a scuba mouthpiece with
nasal breathing prevented by a nose clip. These procedures will increase
your rate of breathing and heart rate and are similar to what happens when
you travel to higher altitude. You will undergo several of these breathing
procedures during the study.
8) During the study, we will inflate a small cuff that is placed on your middle and
ring fingers of one of your hands to measure your blood pressure (Finometer
device). If the cuff becomes uncomfortable, let the investigator know and
they will turn it off for a few minutes.
9) For a period of up to 5 minutes, cold water will be circulated through the water
perfused suit in order to decrease your skin temperature. After this simulated
cold exposure, warm water will be circulated through the suit immediately in
order to rewarm your skin. During the cold exposure, your breathing may
become rapid and you may shiver brielly, and this is similar to what happens
when you enter a cold environment. You will undergo several of these cold
exposures during the study.
1O)After the study, we will remove the small tubes in your skin and a bandage
will be placed over the area of skin where the tubes were placed. You will
then be sent home.
11 )You should notify the investigator immediately if you feel any significant
discomfort or concern about your well-being at any time during the initial visit
or the study visit. Some examples of discomfort include shortness of breath,
light-headedness, and nausea.
How long will I be in the study?
You will be in the study for four hours.
What are the risks of the study?
1. Skin Microdialysis: There may be some discomfort during the insertion of the
small tubes in your skin. Once the needle is in place, the pain should
subside. Infusions through the fibers should not be painful, and there shou~d
only be minor swelling at the site. At the end of the study, the fibers will be
withdrawn and a sterile dressing will be applied. Any swelling or redness
after the study should be gone a few hours after completion of the study.
Although the small tubes are sterile, there is a slight risk of infection at the
sites where the small tubes were placed in your skin. You will be instructed
how to keep the area clean for a day or two following the study.
2. Study drugs administered to the skin: We will be infusing very small doses of
each drug, and only into a very small area of your skin. The drugs are only
infused into the small area of skin where the microdialysis tubes are placed.
Therefore, these drugs will not directly cause any systemic (whole body)
changes in blood pressure. However, as with any infusions or medications,
there is the possibility that you are allergic to the drug and may have an
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allergic reaction to the drug including changes in blood pressure and difficulty
breathing.
3. Breathing air with a low oxygen content with/without high carbon dioxide
content: During these procedures, it is possible you will feel distress, anxiety,
shortness of breath, or feellightheaded. These symptoms resolve rapidly
when you return to breathing room air. In addition, these breathing
procedures have the potential to induce fainting. You should keep the
investigator informed of your feelings and you should not attempt to prolong
the breathing experiment if you do not feel well. You are free to stop at any
time.
4. Laser-Doppler Probes: These probes send a small light into your skin. You
will not feel anything except the probe touching your skin. The only risk
associated with this procedure is that you may have some slight skin irritation
(redness) to the adhesive tape used to hold the probe on your skin. There
are no major risks associated with this device.
5. Finger blood pressure: In some people, this blood pressure cuff causes their
finger to become red and uncomfortable after a long period (over 40 minutes).
We will not inflate the cuff for longer than 40 minutes during the study. If your
finger becomes uncomfortable during the study, let the investigator know and
they will turn it off for a few minutes. There are no major risks associated with
this device.
6. Cold exposure: The duration and magnitude of cold exposure in the current
study do not have the potential to alter internal temperature. Therefore, you
will not become hypothermic during this procedure. However, cooling of the
skin does have the potential to be discomforting. There are no major risks
associated with this procedure.
May I participate if I am pregnant or breast-feeding?
This study may be harmful toan unborn or breast-fed child. There is not enough
medical information to know what the risks might be to a breast-fed infant or to
an unborn child in a woman who takes part in this study. Breast-feeding mothers
are not able to take part in this study. Women who can still become pregnant
must have a negative pregnancy test no more than 24 hours before taking part in
the study. If the pregnancy test is positive (meaning that you are pregnant), you
will not be able to take part in the study. There is no cost for the pregnancy test.
Are there benefits to taking part in this study?
This study will not make your health better.
What other choices do I have if I don't take part in this study?
This study is only being done to gather information. You may choose not to take
part in this study.
What are the costs of tests and procedures?
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You will not need to pay for any tests or procedures that are done just for this
research study. You will get $40 for participating in this study. This money is for
the inconvenience and time you spent in this study. If you start the study but
stop before the study has ended, the amount of money you receive will be pro-
rated at a rate of $10 per hour of the study you complete.
Who can answer my questions?
You may talk to Dr. John Halliwill at any time about any question you have on
this study. You may contact Dr. Halliwill by calling the Department of Human
Physiology at (541) 346-5425.
What are my rights if I take part in this study?
Taking part in this research study is your decision. You do not have to take part
in this study, but if you do, you can stop at any time. Your decision whether or not
to participate will not affect your relationship with the University of Oregon.
You do not waive any liability rights for personal injury by signing this form. All
forms of medical diagnosis and treatment whether routine or experimental,
involve some risk of injury. In spite of all precautions, you might develop medical
complications from participating in this study.
The investigators may stop you from taking part in this study at any time if it is in
your best interest, if you do not follow the study rules, or if the study is stopped.
If you are physically injured because of the project, you and your insurance
company will have to pay your doctor bills. If you are a UO student or employee
and are covered by a UO medical plan, that plan might have terms that apply to
your injury.
If you experience harm because of the project, you can ask the State of Oregon
to pay you. If you have been harmed, there are two University representatives
you need to contact. Here are their addresses and phone numbers:
General Counsel Office of Human Subjects Compliance
Office of the President University of Oregon
University of Oregon Eugene, OR 97403
Eugene, OR 97403 (541) 346-2510
(541 ) 346-3082
A law called the Oregon Tort Claims Act limits the amount of money you can
receive from the State of Oregon if you are harmed. The most you could receive
would be $100,000, no matter how badly you are harmed. If other people are
also harmed by the project, all of you together could only receive $500,000.
What about con'fidentiality?
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Any information that is obtained in connection with this study and that can be
identified with you will remain confidential and will be disclosed only with your
permission. Subject identities will be kept confidential by assigning you a "subject
identification number". The names associated with each subject identification
number will be kept in a locked file cabinet in Dr. Halliwill's office area.
The Office for Responsible Conduct of Research and/or authorized
representatives of the Food and Drug Administration (FDA) or National Institute
of Health (NIH) may need to review records of individual subjects. As a result,
they may see your name, but they are bound by rules of confidentiality not to
reveal your identity to others.
The list of names will be destroyed when study results are published or 24
months after your participation, whichever comes first. Other information may be
stored by the researchers indefinitely.
I have had an opportunity to have my questions answered. I have been
given a copy of this form. I agree to take part in this study.
If you have questions regarding your rights as a research subject, contact Office
for Protection of Human Subjects, 5237 University of Oregon, Eugene, OR
97403, (541) 346-2510.
Your signature indicates that you have read and understand the information
provided above, that you willingly agree to participate, that you may withdraw
your consent at any time and discontinue participation without penalty, that you
will receive a copy of this form, and that you are not waiving any legal claims,
rights or remedies.
(Date)
(Date)
(Signature of Participant)
(Signature of Individual Obtaining Consent)
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APPENDIX C
INFORMED CONSENT FORM FOR CHAPTER VI
TITLE: Cutaneous vasodilation at high altitude: basic mechanisms and
impacts on human thermoregulation (Protocol 2)
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues
APPROVED BY INSTITUTIONAL REVIEW BOARD: August 5, 2008
This is an important form. Please read it carefully. It tells you what you
need to know about this study. If you agree to take part in this research
study, you need to sign the form. Your signature means that you have
been told about the study and what the risks are. Your signature on this
form also means that you want to take part in this study.
Why is this research study being done?
When humans breathe, we take in oxygen from the air and expel carbon dioxide
that our bodies have made. When we travel to high altitudes, we fail to take in
enough oxygen and we expel excess amounts of carbon dioxide. Conversely,
some respiratory diseases are associated with failure to expel enough carbon
dioxide produced within the body. Too little oxygen and too much or too little
carbon dioxide may alter the distribution of blood in the limbs, increasing the
amount of blood circulating in the skin. Unfortunately, we do not understand how
these changes in blood distribution take place, or how they affect heat loss from
the body. The purpose of this study is to provide more information on what
causes the changes in blood flow when we take in too little oxygen or expel too
little or too much carbon dioxide, and how these changes affect responses to
cold temperature.
What will happen in the study?
1) You will have an initial meeting with the study investigator prior to any
experimentation. During this meeting, you will discuss the project, see the
laboratory, and to read this form. In addition, you will be given two
temperature pills and instructed to ingest one of these pills the night before
each study day. Lastly, your height, weight, and skin fold thickness will be
measured. Following this initial meeting, you will arrive at Dr. Halliwill's
laboratory in Esslinger Hall at the University of Oregon on 2 separate study
days. Each study will last approximately 5 hours. During each of these study
days, you will need to refrain from consuming caffeine (for example, coffee,
154
tea, red bull, coke, etc.) or medications (except oral contraceptives) for 12
hours prior to the study and abstain from alcohol or exercise for 24 hours prior
to the study. In addition, you will need to refrain from eating for at least 2
hours prior to the study visit. If you use oral contraceptives, you should take
this when you normally do so.
2) You will be asked to bring water approved apparel with you on each study
day. If you· are a man, you will be asked to bring shorts or a swim suit to the
experiment so that you can wear these during the partial immersion in a bath
tub of water. If you are a woman, you will be asked to bring either shorts or a
swim suit bottom, and additionally you will need to bring either a swim suit top
or a sports bra. You will be allowed to change into these items in the privacy
of a personal bathroom.
3) If you are a woman who can still become pregnant, you will be asked to
undergo a pregnancy test. For this test, you will be asked to collect a sample
of urine in the women's restroom near the physiology lab. If the test is
"positive," indicating that you are pregnant, you will not be allowed to
participate and will be advised to see your physician or the University of
Oregon Health Center.
4) During the visit, your heart rate will be monitored by electrocardiogram
electrodes placed on your skin. If you are a woman, the adhesive patches
used for this test will be placed on you by one of the women in the lab. Your
blood pressure will be measured at periodic intervals by the inflation of a
blood pressure cuff around your arm or around your middle finger.
5) You will have 4 small tubes (these are called "microdialysis fibers", and are
smaller than the lead of a pencil) placed in the skin of your forearm. First we
will numb the area of skin by placing a bag of ice over the area for 5 minutes.
Then a small needle will be placed just under the surface of your skin and will
exit back out about 1'Y2 inches from where it entered your skin. The small
tubes will be placed inside the needle, and the needle will be withdrawn,
leaving the small tubes under your skin. These will remain in your skin
throughout the rest of the study.
6) We need to wait about 1-2 hours after the small tubes are placed in your skin
to let the insertion trauma (redness of your skin around the small tubes) to go
away. During tl"lis time, a small probe {laser-Doppler probe) will be placed
over each area of skin where the small tUbes are so that we can measure
skin blood flow over the small tube. In addition, you will be placed in a bath
tub with platforms on which you can rest your arms out of the water. The
water will be lukewarm at this time.
7) While you are being moved into the bathtub, you will have additional
electrodes place on your back and upper arm for the measurement of muscle
activity. You will also have 9 thermocouples placed over your skin to
m~asure your skin temperature.
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8) Microdialysis infusions: We will put small doses of several drugs through the
small probes in your skin. The drugs you may receive include the following:
a. L-NAME: this stops nitric oxide from being produced and causes the
skin vessels to narrow
b. Bretylium Tosylate: this substance inhibits the release of transmitters
from the nerves in your skin and causes vessels in the skin to open
c. Yohimbine: this substance blocks the effect of transmitters in your skin
and causes vessels to open
d. Propranolol: this substance blocks the effect of transmitters in your
skin and causes vessels to narrow
e. BIBP-3226: this substance blocks the effect of transmitters in your skin
and causes vessels to open
f. Tyramine: this substance stimulates the release of transmitters from
the nerves in your skin and causes vessels in the skin to narrow
9) For a period of up to 10 minutes, your expired gas will be collected through a
nasal cannula to assess the resting carbon dioxide levels in your blood. After
removal of the nasal canulla, you will be asked to breathe air that has low
oxygen content either with or without high carbon dioxide content for up to
100 minutes. Du ring this time, you will breathe through a scuba mouthpiece
with nasal breathing prevented by a nose clip. These procedures will
increase your rate of breathing and heart rate and are similar to what
happens when you travel to higher altitude. You will undergo several of these
breathing procedures during the study.
1O)During the study, we will inflate a small cuff that is placed on your middle and
ring fingers of one of your hands to measure your blood pressure {Finometer
device). If the cuff becomes uncomfortable, let the investigator know and
they will turn it off for a few minutes.
11 )For a period of up to 90 minutes, the water in the bath tub will be cooled in
order to decrease your body temperature. This cooling will be slow at first,
targeting a water temperature of 86 degrees Fahrenheit (30°C) at the end of
the first 30 minutes. Then, water temperature will be decreased to 50
degrees Fahrenheit (10°C) over the course of 15 minutes. This temperature
will be held for the final 45 minutes of the study. After this cold exposure, you
will be removed from the bath tub, towel dried, and placed in a slightly warm
environmental chamber with a blanket. During the cold exposure, your
breathing may become rapid and you may begin to shiver, and this is similar
to what happens when you enter a cold environment. You will undergo a cold
exposure on each of the 2 experimental days.
12)After the study, we will remove the small tubes in your skin and a bandage
will be placed over the area of skin where the tubes were placed. You will
then be sent home.
13)You should notify the investigator immediately if you feel any significant
discomfort or concern about your well-being at any time during the initial visit
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or the study visit. Some examples of discomfort include shortness of breath,
light-headedness, and nausea.
How long willi be in the study?
You will be in the study for 5 hours on each study day, and 1 to 2 hours for the
initial lab visit.
What are the risks of the study?
1. Skin Microdialysis: There may be some discomfort during the insertion of
the small tubes in your skin. Once the needle is in place, the pain should
subside. Infusions through the fibers should not be painful, and there
should only be minor swelling at the site. At the end of the study, the
fibers will be withdrawn and a sterile dressing will be applied. Any
swelling or redness after the study should be gone a few hours after
completion of the study. Although the small tubes are sterile, there is a
slight risk of infection at the sites where the small tubes were placed in
your skin. You will be instructed how to keep the area clean for a day or
two following the study.
2. Study drugs administered to the skin: We will be infusing very small doses
of each drug, and only into a very small area of your skin. The drugs are
only infused into the small area of skin where the microdialysis tubes are
placed. Therefore, these drugs will not directly cause any systemic (whole
body) changes in blood pressure. However, as with any infusions or
medications, there is the possibility that you are allergic to the drug and
may have an allergic reaction to the drug including changes in blood
pressure and difficulty breathing.
3. Breathing air with a low oxygen content with/without high carbon dioxide
content: During these procedures, it is possible you will feel distress,
anxiety, shortness of breath, or feellightheaded. These symptoms
resolve rapidly when you return to breathing room air. In addition, these
breathing procedures have the potential to induce fainting. You should
keep the investigator informed of your feelings and you should not attempt
to prolong the breathing experiment if you do not feel well. You are free to
stop at any time.
4. Laser-Doppler Probes: These probes send a small light into your skin.
You will not feel anything except the probe touching your skin. The only
risk associated with this procedure is that you may have some slight skin
irritation (redness) to the adhesive tape used to hold the probe on your
skin. There are no major risks associated with this device.
5. Finger blood pressure: In some people, this blood pressure cuff causes
their finger to become red and uncomfortable after a long period (over 40
minutes). We will not inflate the cuff for longer than 40 minutes during the
study. If your finger becomes uncomfortable during the study, let the
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investigator know and they will turn it off for a few minutes. There are no
major risks associated with this device.
6. Cold exposure: The duration and magnitude of cold exposure in the
current study are designed to slightly decrease internal body temperature.
However, you will not become hypothermic during this procedure (defined
by the US Center for Disease Control and Prevention as a core body
temperature below 35°C [95°F]). Nevertheless, whole body cooling does
have the potential to be discomforting. Common responses to whole body
cold exposure include an initial increase in breathing rate and depth, an
increased heart rate (initially), and the occurrence of shivering. You will
not be discouraged from shivering as needed during this study. You will
be monitored closely by a trained physiologist throughout the cold
exposure, and rewarming will occur inside of a temperature controlled
room immediately after the study ends.
7. Core temperature: Core temperature is measured by an ingestible pill that
is designed for human use (approved by the FDA). You will ingest the pill
at least 6 hours before the study, or the night before if the study begins
early in the morning. This pill will harmlessly pass through your intestinal
tract. The pill is not recovered and is disposable. There are no major risks
associated with this device.
8. Skin temperature: Skin temperature will be measured at multiple sites on
the surface of your skin. The temperature sensors (thermocouples) are
passive sensing devices consisting of small wires with a rubber tip. These
sensors will be taped to your skin and relay the temperature of the skin
surface to a data acquisition computer. There are no major risks
associated with this device.
May I participate if I am pregnant or breast~feeding?
This study may be harmful to an unborn or breast-fed child. There is not enough
medical information to know what the risks might be to a breast-fed infant or to
an unborn child in a woman who takes part in this study. Breast-feeding mothers
are not able to take part in this study. Women who can still become pregnant
must have a negative pregnancy test no more than 24 hours before taking part in
the study. If the pregnancy test is positive (meaning that you are pregnant), you
will not be able to take part in the study. There is no cost for the pregnancy test.
Are there benefits to taking part in this study?
This study will not make your health better.
What other choices do I have if I don't take part in this study?
This study is only being done to gather information. You may choose not to take
part in this study.
What are the costs of tests and procedures?
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You will not need to pay for any tests or procedures that are done just for this
research study. You will get $120 for participating in this study. This money is
for the inconvenience and time you spent in this study. If you start the study but
stop before the study has ended, the amount of money you receive will be pro-
rated at a rate of $10 per hour of the study you complete.
Who can answer my questions?
You may talk to Dr. John Halliwill at any time about any question you have on
this study. You may contact Dr. Halliwill by calling the Department of Human
Physiology at (541) 346-5425.
What are my rights if I take part in this study?
Taking part in this research study is your decision. You do not have to take part
in this study, but if you do, you can stop at any time. Your decision whether or not
to participate will not affect your relationship with the University of Oregon.
You do not waive any liability rights for personal injury by signing this form. All
forms of medical diagnosis and treatment whether routine or experimental,
involve some risk of injury. In spite of all precautions, you mightdevelop medical
complications from participating in this study.
The investigators may stop you from taking part in this study at any time if it is in
your best interest, if you do not follow the study rules, or if the study is stopped.
If you are physically injured because of the project, you and your insurance
company will have to pay your doctor bills. If you are a UO student or employee
and are covered by a UO medical plan, that plan might have terms that apply to
your injury.
If you experience harm because of the project, you can ask the State of Oregon
to pay you. If you have been harmed, there are two University representatives
you need to contact. Here are their addresses and phone numbers:
General Counsel Office of Human Subjects Compliance
Office of the President University of Oregon
University of Oregon Eugene, OR 97403
Eugene, OR 97403 (541) 346-2510
(541) 346-3082
A law called the Oregon Tort Claims Act limits the amount of money you can
receive from the State of Oregon if you are harmed. The most you could receive
would be $100,000, no matter how badly you are harmed. If other people are
also harmed by the project, all of you together could only receive $500,000.
What about confidentiality?
Any information that is obtained in connection with this study and that can be
identified with you will remain confidential and will be disclosed only with your
permission. Subject identities will be kept confidential by assigning you a "subject
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identification number". The names associated with each subject identification
number will be kept in a locked file cabinet in Dr. Halliwill's office area.
The Office for Responsible Conduct of Research and/or authorized
representatives of the Food and Drug Administration (FDA) or National Institute
of Health (NIH) may need to review records of individual subjects. As a result,
they may see your name, but they are bound by rules of confidentiality not to
reveal your identity to others.
The list of names will be destroyed when study results are published or 24
months after your participation, whichever comes first. Other information may be
stored by the researchers indefinitely.
I have had an opportunity to have my questions answered. I have been
given a copy of this form. I agree to take partin this study.
If you have questions regarding your rights as a research subject, contact Office
for Protection of Human Subjects, 5237 University of Oregon, Eugene, OR
97403, (541) 346-2510.
Your signature indicates that you have read and understand the information
provided above, that you willingly agree to participate, that you may withdraw
your consent at any time and discontinue participation without penalty, that you
will receive a copy of this form, and that you are not waiving any legal claims,
rights or remedies.
(Date)
(Date)
(Signature of Participant)
(Signature of Individual Obtaining Consent)
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APPENDIX D
MIXING PROCEDURE FOR STUDY DRUGS IN CHAPTER V
Lactated Ringers (before subject arrives)
• Fill four 1ml syringes with Lactated Ringers and label R
Yohimbine, BIBP-3226 (after fibers are placed)
1. Mass out 19.5 mg Yohimbine in sterilized vial and label Y
2. Fill a 10 ml syringe with 10 ml Lactated Ringers and another 10 ml syringe
with 1ml Lactated Ringers (eject from a 10 ml syringe)
3. Label the syringe with 10 ml "Y" and the other "10.5 B"
4. Empty Y syringe and tiny stir bar into Yohimbine vial; place on hot plate
5. Place 19 gage needle in thawed BIBP vial and draw contents into clean 10
rnl syringe (label B)
6. Eject contents of B syringe until plunger lines up with the 9 ml mark
7. Eject remaining 9 ml from B syringe into lactated ringers syringe labeled
10.5 B
8. Shake well and place red needle on syringe tip
9. Fill a 1 ml syringe with contents of 10.5 B syringe, label 10.5 B
10.Suck heated Yohimbine solution back into Y syringe and align plunger at
10 ml
11. Use fresh 10 ml syringe (red needle) to fill rest of Y syringe with Lactated
Ringers
12. Shake Y syringe well
13. Place sterilization filter and red needle on Y syringe and fill a 1 ml syringe
with contents of Y syringe (label this syringe Y)
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APPENDIX E
MIXING PROCEDURE FOR STUDY DRUGS IN CHAPTER VI
Yohimbine + Propranolol and BIBP-3226 + Propranolol
1. Mass out 19.5 mg Yohimbine, tare scale, and add3 mg of Propranolol
(Y+P)
2. In a separate vial, mass out 3 mg Propranolol alone (label P)
3. Fill two 10 ml syringes with EXACTLY 10 ml Lactated Ringers
4. Label "Y+P" and "P"
5. Empty 10 ml syringes into vials and place on hot plate for 20-30 minutes
6. Place 19 gage needle in thawed BIBP vial and draw contents into clean 10
ml syringe
7. Shake well and fill two 1 ml B+P syringes
8. Suck heated solutions back into both syringes and align plunger at 10 ml
9. Use two fresh 10 rnl syringes to fill rest of these syringes w/Lactated
Ringers
10. Shake well and fill two 1 ml Y+P syringes and two 1 ml P syringes
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APPENDIX F
MIXING PROCEDURE FOR STUDY DRUGS IN CHAPTER VII
15 minutes before study begins:
1. Take BIBP-3226 out of freezer to thaw
2. Turn on hot plate
3. Fill three 1 ml syringes with Lactated Ringers
To mix the Yohimbine. BIBP-3226. and Tyramine
1. Fill two 1 ml syringes with Lactated Ringers and label R
2. Fill two 1 ml syringes with 0.6 ml Lactated Ringers, then eject the contents
through needle until plunger is aligned with the 0.5 ml mark (label R)
3. Mass out 21.7 mg Yohimbine in sterilized vial and label Y
4. Mass out 3 mg Tyramine in sterilized vial and label T
5. Fill 2 10 ml syringes with 10 ml Lactated Ringers (eject from a 10 ml
syringe)
6. Label one 10 ml syringe "Y" and another "300 Til
7. Fill a third 10 ml syringe with 9 ml lactated ringers and label it "30 T" (red
needle)
8. Empty Y syringe and tiny stir bar into Yohimbine vial and place on hot
plate
9. UNDER HOOD, empty 300 T syringe in Tyramine vial and dissolve drug
10. Suck 10 ml Tyramine solution back into 300 T syringe and attach red
needle
11. Eject Tyramine from 300 T syringe until plunger lines Lip at 9 ml, then
transfer 1 ml from this syringe into the 30 T syringe
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12. Shake 30 T syringe and transfer -0.5 ml into a 1 ml syringe and label 30 T
13.Align plunger in two 1 ml syringes at .6 ml and fill with contents of 300 T
syringe
14. Eject - 0.1 ml from both 1 ml syringes so plunger rests at 0.5 ml (label
both ''1'')
15. Place 19 gage needle in 81BP vial and draw contents into 10 ml syringe
(label 8)
16. Replace gray needle on 8 syringe with red needle
17.Align plunger in two 1 ml syringes at 0.6 ml and fill with contents of 8
syringe
18. Eject - 0.1 ml from both 1 ml syringes so plunger rests at 0.5 ml (label
both "8")
19. Reattach grey needle, and eject contents of 10 ml 8 syringe until plunger
lines up with the 8 ml mark
20. Obtain two 6 ml syringes and label one "10.5 8" and the other "10.5 8 + 1"
21.lnto 10.58 syringe, eject 4 ml from 10 ml 8 syringe and the contents of a
1 ml 8 syringe and a 1 ml R syringe (filled with 0.5 ml Lactated Ringers)
22. Shake well and fill two 1 ml syringes, label them "10.5 8"
23. Into 10.58 + T syringe, eject 4 ml from 10 ml 8 syringe and the contents
of a 1 ml 8 syringe and a 1 ml T syringe
24. Shake well and transfer 0.5 ml to a 1 ml syringe, label it "10.58 + T"
25. Suck heated Yohimbine solution back into Y syringe and align plunger at
10 ml
26. Use fresh 6 ml syringe (red needle) to fill rest of Y syringe with lactated
Ringers
27. Shake Y syringe well
28. Replace gray needle on Y syringe with red needle
29.Align plunger in two 1 ml syringes at 0.6 ml and fill with contents of Y
syringe
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30. Eject - 0.1 ml from both 1 ml syringes so plunger rests at 0.5 ml (label
both "y")
31. Replace red needle on 10 ml Y syringe with gray needle
32. Eject contents of 10 rnl Y syringe until plunger lines up with the 8 ml mark
33. Obtain two 6 ml syringes (wI red needle) and label 1 "5 Y" and the other "5
Y + 1"
34. Into 5 Y syringe, eject 4 ml from 10 rnl Y syringe and the contents of a 1
ml Y syringe and a 1 ml R syringe (filled with 0.5 ml Lactated Ringers)
35. Shake well and fill two 1 ml syringes (use sterilization filter), label them "5
Y"
36. Into 5 Y + T syringe, eject 4 ml from 10 Y syringe and the contents of a 1
ml Y syringe and a 1 ml T syringe
37. Shake well and push a few milliliters through the sterilization filter to clear
it out
38. Transfer 0.5 ml to a 1 ml syringe and label it "5 Y + 1"
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